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General introduction and outline of this thesis 
 
Therese Heller was a 43 year old woman and mother of 8 children. Since 6 weeks she experienced 
symptoms of vomiting, weight loss and tachycardia. Clinical exam revealed a palpable mass 
in the epigastric region. After the gastrointestinal tract was irrigated with 14 liters of water, 
a partial gastrectomy was performed through an 11 centimeter oblique incision. The tumor 
was resected with a 2 centimeter margin and a gastrojejunostomy was performed with 54 silk 
stiches.1 
 
Ever since Theodor Billroth (figure 1) performed the first 
partial gastrectomy in 1881, the treatment of gastric cancer 
has significantly evolved.1 In the last decades, important 
advances in the understanding of the epidemiology, pathology 
and therapeutic options in gastric cancer treatment have been 
made.2 
Incidence rates in the Netherlands have been declining, 
but survival of gastric cancer still remains generally dismal 
with approximately one third of patients surviving 5-year 
when diagnosed with stage I-III gastric cancer. The number of 
patients diagnosed with metastatic (stage IV) disease (being 
42 per cent of all patients) surviving more than 5 years is 
virtually negligible.3 
On a global level, gastric cancer is the third largest 
contributor to the burden of disability-adjusted life-years 
from cancer in men and accounts for 20 per cent of the total 
worldwide.4 The burden of gastric cancer remains very high 
in Asia, whereas in the Netherlands it is not a very common 
cancer. 2, 5 
 
Classification and Pathology 
 
 
 
Figure 1 Theodor Billroth 
(1829-1894) 
 
The most commonly used histopathological classifications on gastric cancer are the Laurén 
and WHO classification.2 In this thesis we predominantly used the Lauren classification which 
was first described by Pekka Laurén in 1965.6 According to this classification, gastric cancer is 
separated into two main histological types: diffuse and intestinal type.2 Both types of gastric 
cancer have different biological features and clinical behaviour.7 The intestinal type of gastric 
cancer is a well to moderately differentiated tumour type and in general characterized by a 
more favourable prognosis compared to patients with the poorly differentiated diffuse type 
of gastric cancer.8 
In the 1974 the Tumour Node Metastasis (TNM) classification system was established by 
the Union for International Cancer Control (UICC).9 Various improvements have been made 
throughout the years, which resulted in consecutive versions of the TNM-classification system 
(figure 2). T-stage describes the size of the tumour. According to the seventh version of the 
1 
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TNM-classification, T1a corresponds to a tumour invading the mucosa of the stomach wall. A 
gastric tumour stage T1b infiltrates the submucosa and T2 penetrates the muscular layer of 
the stomach. In the more advaced stages of gastric cancer, T3 invades the subserosal and T4a 
the serosal layer. If the tumour grows into adjacent organs or structures it corresponds to a 
T4b stage. N describes the regional lymph nodes that are affected by the gastric tumour. When 
the gastric malignancy has spread to 1 or 2 lymph nodes it corresponds to N1 disease. Worst 
stage is when the gastric tumour is found in more than 15 lymph nodes, which is defined as 
N3b stage. M defines the absence (M0) or presence (M1) of distant metastases, metastases 
most often occur in the liver and the peritoneum (figure 2). In December 2016, the 8th version 
of the TNM-classification on gastric cancer has been published.10 
 
 
 
Figure 2 7th version of the UICC TNM-classification 
 
In 1982 it was discovered that gastric cancer often is an infection-related type of cancer.11 
It is thought that the discovery and subsequent eradication of helicobacter pylori gastritis led 
to a decreasing incidence of gastric cancer in recent years.3 Also increased consumption of 
fruit and vegetables, and lower salt consumption have reduced the risk of gastric cancer.3, 12 
A high prevalence of these and other risk factors such as poor food preservation and tobacco 
smoking may have contributed to the high risk of gastric cancer in Asia.5 
Around 1991 it became more clear that there are two distinct types of gastric cancer: cardia 
and non-cardia cancer.13 These two types of gastric cancer show different epidemiological 
and biological behaviour.3 Most importantly, the prognosis of patients with gastric cardia 
carcinoma is worse compared to patients with non-cardia carcinoma and it often needs a 
different surgical approach (i.e. (partial) oesophagectomy with partial gastrectomy).14 This 
thesis is mostly about non-cardia gastric cancer. 
Diagnosis and staging 
 
Diagnosing gastric cancer can be challenging, since patients with early stage gastric cancer 
are most often asymptomatic.2 Once gastric cancer becomes symptomatic (e.g. anorexia, 
dyspepsia, weight loss and abdominal pain) it often is at an advanced stage.2 Due to its rarity 
screening for gastric cancer in the Dutch population does not seem to be effective.15 
After its introduction in 1957, gastroscopy has taken a crucial role in the diagnosis of 
gastric cancer. 2, 16, 17 Once the diagnosis is confirmed by histopathology, accurate assessment 
of the stage of disease is of utmost importance. In the Netherlands staging is most often done 
by computed tomography (CT).4 Alternatively, T and N-stage can be evaluated by endoscopic 
ultrasound. This can be done with a similar sensitivy and specificity compared to CT.18, 19 
Difficulty with endoscopic ultrasound lies within the potential interobserver variability.20 
Especially for M-staging, there is a growing interest in the staging laparoscopy. The 
sensitivity to detect peritoneal metastases or other distant metastases on CT is low (ie. 22%- 
69%), which could lead to understaging.21-24 Understaging gastric cancer can potentially lead 
to futile treatment, since there is no curative treatment for patients with extensive peritoneal 
and/or distant metastases. Pre-treatment staging laparoscopy can avoid unneccessary 
treatment in up to 38% of patients.25, 26 Another evolving diagnostic M-stage modality in 
gastric cancer is the Positron Emission Tomography Computed Tomography (PET-CT). PET- 
CT proved to be able to avoid futile treatment up to 10% by detecting distant metastases.26 In 
the Netherlands, the clinical guideline suggests only to use PET-CT and staging laparoscopy 
in advaced gastric cancer (T3-4).15 
Currently a Dutch prospective observational cohort study analyses the potential diagnostic 
benefits of both PET and diagnostic laparoscopy in advaced gastric cancer.21 
 
Multimodal treatment 
 
The most recent version of the Dutch clinical guideline on treatment of gastric cancer was 
published in 2016.15 Nowadays, treatment of gastric cancer is a multidisciplinary team 
effort. Within this multidisciplinary team many medical specialists such as surgical and 
medical oncologists, radiologists, radiotherapists, nuclear medicine specialists and gastro- 
enterologists are represented. Patients are discussed in Multidisciplinary Team meetings, in 
order to initiate the optimal multimodal treatment for each patient. 
In recent years very early stage gastric cancer, without lymph node involvement can be 
treated safely with endoscopic resection.2, 16, 17 Although no randomized controlled trial has 
evaluated the best treatment for mucosal gastric cancer (i.e. endoscopic or surgical resection), 
all European guidelines consider endoscopic resection sufficient for node negative very early 
gastric cancer.16, 17 
For all higher staged gastric cancer patients, surgical resection is the only curative option 
for gastric cancer. Surgical treatment should consist out of a resection of the tumour with a 
wide margin and an adequate lymphadenectomy.15 For a tumour located in the upper third of 
the stomach this leads in most cases to a total gastrectomy. In case of a tumour in the lower 
two-thirds of the stomach a subtotal gastrectomy can usually be performed (figure 3).2, 15 
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Figure 3 A. Partial gastrectomy. B. Total gastrectomy, Roux-Y reconstruction. 
 
The most recent Dutch clinical guideline suggests that the lymphadenectomy should consist 
out of at least 15 lymph nodes to enable adequate tumour staging and predict prognosis.15 The 
lymphadenectomy illustrates one of the differences in treatment between Asian and Caucasian 
gastric cancer patients. Until 1995 Caucasian patients without evidence of metastases were 
treated with resection of the perigastric lymph nodes (D1 dissection, figure 4), while the 
treatment for Asian patients also included a resection of the regional lymph nodes along the 
coeliac artery. The latter type of lymph node dissection could include a partial pancreatectomy 
and/or splenectomy (D2 dissection, figure 4). In 1995 a Dutch randomized controlled trial 
compared these two types of surgical treatment for gastric cancer.27 This trial concluded that 
after a D2 lymphadenectomy (peri-gastric lymph nodes and N2 lymph nodes (station 7-11)) 
there was a significant higher post-operative mortality and morbidity and no increase in 
short term survival.27,28 Nonetheless, after 15 years of follow-up of the abovementioned trial, 
a spleen and pancreas preserving D2 resection showed lower locoregional recurrence and 
gastric-cancer related death rates and is currently advocated as the recommended approach 
for patients with resectable gastric cancer. 29 
 
 
 
Figure 4 Lymph node stations. D1 resection: removal of the N1 lymph nodes. D2 resection: removal of 
the N1 and N2 lymph nodes. 
 
Nowadays, surgical treatment is more often performed using minimal invasive procedures. 
Laparoscopic gatrectomy was first described by Kitano et. al. in 1994. So far laparoscopic 
surgery has shown to improve short term morbidity and mortality and has an equal 
oncological outcome compared to open gastrectomy.30 This is however based on Asian 
literature, and there is a marked difference between Asian and Caucasian gastric cancer 
patients. For instance, Caucasian gastric cancer patients are usually older, have a higher BMI 
and are diagnosed at an advanced stage of disease.30 A Dutch retrospective study showed no 
difference in oncological results (i.e. lymph node yield and R0 resection) and 1-year overall 
survival between laparoscopic and open surgery. 31 Randomized controlled trials are currently 
including patients to study the differences between open and laparoscopic gastric surgery in 
a Caucasian patient population.30, 32 
N1 lymph node stations: 
1. Right cardiac nodes 
2. Left cardiac nodes 
3. Nodes along the lesser curvature 
4. D. Lymph nodes along the short gastric and the left 
gastroepiploic vessels 
5. S. Lymph nodes along the right gastroepiploic vessels 
6. Suprapyloric nodes 
7. Infrapyloric nodes 
N2 lymph node stations: 
8. Nodes along root left gastric artery 
9. Nodes along common hepatic artery 
10. Nodes around coeliac axis 
11. Nodes at splenic hilum 
12. Nodes along splenic artery 
N3 lymph node stations: 
13. Nodes at the hepatoduodenal ligament 
14. Retropancreatic (periduodenal) nodes 
15. Nodes at the root of the mesentery 
N4 lymph node stations: 
16. Nodes along the middle colic vein 
17. Para-aortic nodes 
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In the last decade, (neo)-adjuvant chemotherapy of gastric cancer was introduced as     
a treatment modality. In 2006 Cunningham et. al. showed that peri-operative epirubicin, 
cisplatin and fluorouracil increased 5-year survival from 23 per cent to 36 per cent.33 From 
that time on patients who are candidates for curative surgery and fit enough with a more 
advanced stage of disease (i.e. stage II and III) receive peri-operative chemotherapy to improve 
disease-free and overall survival.2, 15 
When curative treatment is not possible, palliative chemotherapy should be offered to 
patients who are fit enough and are willing to undergo chemotherapy in order to improve 
survival and disease-related symptoms.2, 15 According to the Dutch clinical guidelines, 
palliative gastrectomy can be performed in patients younger than 70 years of age and with 
a limited amount of incurable factors (i.e. T4b tumour, peritoneal , liver or distant lymph 
node metastasis).15 Apart from chemotherapy and surgery, palliative patients who have an 
overexpression of human epidermal growth factor receptor 2 (HER2) can be treated with 
Trastuzumab. Trastuzumab is a monoclonal antibody that targets HER2 and has been shown 
to be able to improve overall survival.34 
Since 2012 gastric cancer care has been standardized at a nationwide level (SONCOS 
standardisation report).35 As part of this agreement, a minimum amount of gastrectomies per 
hospital per year has been established. Several studies have shown a strong and consistent 
inverse relationship between the hospital volume of high-risk surgical procedures and 
postoperative mortality.36-40 In order to improve survival and decrease morbidity for gastric 
cancer patients, centralisation has been initiated in the Netherlands. Since 2012, hospitals 
should perform a minimum of 10 gastrectomies per year, and since 2013 the minimum annual 
hospital volume of gastrectomies for cancer was increased to 20. 
 
Thesis on surgical and epidemiological aspects in gastric cancer 
patients 
 
This thesis particularly evaluates different aspects of the surgical treatment of gastric cancer 
and based on the available evidence, various questions arose that formed the basis of this 
thesis. In the past, several clinical trials resulted in changes of treatment regimens. The overall 
impact of these changes on day to day quality of gastric cancer care remains unclear. The 
current quality of care for Dutch gastric cancer patients in terms of morbidity, mortality and 
survival is not wel known. 
A recent nationwide change in the surgical treatment of gastric cancer is the centralisation 
of gastric cancer surgery. A study from Denmark has shown improved outcomes of gastric 
cancer after centralisation of surgery, including less anastomotic leakages, a decreased 30- 
day mortality and an improved lymph node harvesting.40 In the Netherlands the benefit of 
centralisation in terms of morbidity, mortality and survival has not yet been proven. 
In Chapter 2 and Chapter 3 we study the possible effects of centralizing gastric cancer 
surgery on both a regional and national level. 
Many patients with gastric cancer are diagnosed at an advaced age and stage of disease. 
Although this is the vast majority of all gastric cancer patients, there is a lack of knowledge 
about these specific groups of patients. Moreover, one of the important reasons for the 
 
generally poor prognosis for gastric cancer patients is that a considerable proportion of 
patients (45 per cent) are diagnosed with metastatic disease.3, 41 With a median overall 
survival of less than 4 months for patients with metastatic gastric cancer, their survival rate 
is amongst the lowest in gastrointestinal oncology.42, 43 In addition, over 60 per cent of all 
newly diagnosed patients is over 70 years of age in 2016.44 Since elderly patients are often not 
included in clinical trials, evidence based guidelines are mainly based on results of treatment 
in young patients. Therefore, the best treatment in the fit or frail elderly with gastric cancer, 
and the distinction with young patients remains unclear.45 
In Chapter 4 we aim to elucidate the short-term surgical outcome differences between 
young and elderly patients. Chapter 5 focuses on age-related differences in survival and 
treatment trends of patients with potentially curable gastric cancer in the past two decades. 
The number of metastatic lymph nodes is considered to be the most reliable prognostic 
indicator for patients with radically resected gastric cancer.46 However, the difficulty of the 
TNM-classification is that for adequate N-staging at least 15 lymph nodes should be retrieved. 
Literature expresses that in some Western countries including the Netherlands, this amount 
of lymph nodes is not met by surgeons or pathologists, which can lead to under staging.47 
Apart from the TNM system, another N-staging system was developed, which would not need 
the required 15 lymph nodes for adequate staging, the so-called metastatic lymph node ratio 
(LNR). In Chapter 6 we compare the different versions of TNM staging system (ie. 5th/6th/7th 
version) with the lymph node ratio and determine which system has the best prognostic value 
for surgically treated gastric cancer patients between 2000 and 2009. 
In the last two chapters palliative treatment of gastric cancer patients is studied. Chapter 7 
presents age-related differences between young and elderly palliative gastric cancer patients 
in terms of treatment and survival. Based on this study we propose a study protocol in 
Chapter 8. This phase 2 study will evaluate the overall survival for palliative gastric cancer 
patients treated with surgical resection and chemotherapy. Chapter 9 forms the discussion 
of this thesis. It reviews the various epidemiological aspects in gastric cancer surgery and 
puts results from this thesis in a broader clinical context. 
 
Presumably Theodor Billroth would have experienced rough times if he was a Dutch surgeon 
in modern times. Possibly, clinical auditing would point him out as underperforming since 
Therese had to stay in the hospital for at least 26 days and unfortunately died of tumour 
recurrence only 4 months later. On the other hand, he could set the example for the rest. 
Therese’s post-operative course was favourable, she started eating on the first day post- 
operative and in the 14 years as a (gastric) surgeon, Billroth performed almost 20 gastrectomies 
per year only by himself.1 Evaluating the abovementioned is exactly what this thesis is all 
about. Performing studies on the quality of gastric cancer care in order to evaluate the past 
and learn for the future. 
1 1 
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Abstract 
 
Introduction: 
Centralization of gastric cancer surgery is thought to improve outcome and has been imposed 
in the Netherlands since 2012. This study analyses the effect of centralization in terms of 
treatment outcome and survival in the Eastern part of the Netherlands. 
 
Methods: 
All gastric cancer patients without distant metastases who underwent a gastrectomy in 6 
hospitals in the Eastern part of the Netherlands between 2008-2011 (pre-centralization) 
and 2013-2016 (post-centralization) were selected from the Netherlands Cancer Registry. 
Patient and tumour characteristics and treatment outcomes (duration of surgery, blood loss, 
resection margin, lymphadenectomy, chemotherapy, postoperative complications and hospital 
stay, overall and disease free survival) were analysed and compared between pre- and post- 
centralization. 
 
Results: 
144 patients were included pre-centralization and 106 patients post-centralization. Patient 
and tumour characteristics were almost similar in the two periods. After centralization more 
patients were treated with perioperative chemotherapy (25 per cent vs. 42 per cent P<0.01). 
The proportion of patients treated with an adequate lymphadenectomy (21 per cent vs. 93 
per cent P<0.01) and laparoscopic surgery (6 per cent vs. 40 per cent P<0.01) increased 
significantly (P<0.01). The amount of cardiac complications (16 per cent vs. 7.5 per cent 
P<0.05) decreased, however complications needing a re-intervention were comparable (42 
per cent vs. 40 per cent P=0.79). Median hospital stay decreased from 10 to 8 days (P<0.01). 
30-day mortality did not differ significantly (4.2 per cent vs. 1.9 per cent). 1-year overall (78 
per cent vs. 80 per cent P=0.17) and disease free survival (73 per cent vs. 74 per cent P=0.66) 
remained stable. 
 
Discussion: 
Centralizing gastric cancer treatment in the Eastern part of the Netherlands resulted in 
improved lymph node harvesting and a successful introduction of laparoscopic gastrectomies. 
Centralization has not translated into improved mortality, and other variables may also have 
led to these improved outcomes. Further research using a nationwide population based study 
population will be needed to confirm these data. 
Introduction 
 
Centralization of gastric cancer treatment is believed to improve outcome. Performing 
more gastrectomies per year in one centre should lead to better surgical training and more 
specialized oncological (perioperative) care. A study from Denmark has shown improved 
outcomes of gastric cancer after centralization of gastric cancer surgery, including less 
anastomotic leakages, a decreased 30-day mortality and an improved lymph node harvesting.1 
In the Netherlands centralization of gastric cancer surgery has been imposed in 2012 by 
mandating a minimum of 10 gastrectomies per hospital per year and as of 2013 to a minimum 
of 20 per year. In the Netherlands the benefit of centralization of gastric cancer treatment 
has not yet been proven. 
Previous Dutch studies that were conducted have researched the influence of surgical 
training and hospital volume on survival in gastric cancer.2,3 Data from the West of the 
Netherlands have already showed in 2009 that after standardization and surgical training, 
relative 5-year survival rates increased for resected gastric cancer patients (41 per cent vs. 
52 per cent P=0.06).2 Other data from the Netherlands Cancer Registry (NCR) showed that 
high hospital volume was associated with a higher amount of harvested lymph nodes during 
surgery and pathology, but a difference in survival after gastrectomy was not demonstrated. 
This was probably caused by the limited amount of gastric cancer patients that were treated 
before 2009 in high volume hospitals (i.e. ≥ 20 patients per year).3 
The aim of the present study was to examine the effects of centralization in terms of 
morbidity and mortality by comparing a cohort of surgical gastric cancer patients before 
(2008-2011) and after (2013-2016) centralization in the Eastern part of the Netherlands. 
 
Methods 
 
Primary data were obtained from the population-based Netherlands Cancer Registry (NCR). 
This registry serves the total Dutch population of almost 17 million inhabitants. The NCR is 
based on notification of all newly diagnosed malignancies in the Netherlands by the national 
automated pathological archive (PALGA). Additional sources are the national registry of 
hospital discharge and radiotherapy institutions. Specially trained data managers of the 
NCR routinely extract information on diagnosis, staging and treatment from the medical 
records. The information on vital status is obtained by an annual linkage with the Municipal 
Administrative Databases, which registers all deceased and emigrated persons in the 
Netherlands. Tumour staging was performed according to the 6th & 7th UICC TNM classification. 
In order to reduce the influence of differences between the different TNM versions, the 7th UICC 
TNM classification was recoded into the 6th UICC TNM classification. Due to the fact that the 7th 
version of the UICC TNM classification is more specific than the 6th version, it was impossible 
to recode the 6th version into the 7th version of the UICC TNM classification. Tumour site within 
the stomach was coded based on the International Classification of Diseases for Oncology: 
proximal / middle (cardia, fundus, corpus and lesser and greater curvature (C16.0, C16.1, 
C16.2, C16.5, C16.6)), pyloric and antrum (C16.3, C16.4), and overlapping or not otherwise 
specified (C16.8, C16.9).4 Tumour histology was coded according the Lauren classification.5 
2 2 
28 | Chapter 2 Impact of centralizing gastric cancer surgery on treatment, morbidity and mortality | 29 
 
 
 
Additional data on comorbidity and complications were retrospectively registered by   
a data manager. Patient history, comorbidities and American Society of Anaesthesiologists 
(ASA)-classification were extracted from the pre-operative anaesthesiology report. Seven 
different comorbidities were registered: diabetes mellitus, immune compromising diseases, 
pulmonary disease, kidney failure, liver failure, cardiovascular disease and/or gastrointestinal 
disease. Time between diagnosis and treatment was defined as the time between the diagnostic 
biopsy result and the first treatment (neoadjuvant chemotherapy or surgery). 
The occurrence of postoperative complications and reinterventions were extracted from 
medical records. Complications were defined as any unwanted effect of primary treatment 
leading to reintervention within 30 days after surgery. Postoperative complications consist 
of anastomotic leakage, intra-abdominal abscess, wound infection, post-operative bleeding, 
pneumonia, urinary tract infection and cardiac complications and were ranked according to 
the Clavien-Dindo classification6. Postoperative reinterventions were defined as surgical-, 
radiological, endoscopic measures or antibiotic therapy within 30 days after surgery. Tumour 
recurrence was registered when patients had histological proven recurrent gastric cancer or 
a strong suggestion on computed tomography and/or gastroscopy. 
Before 2012 gastric cancer surgery in the Eastern part of the Netherlands was performed 
in six hospitals by 16 gastrointestinal surgeons of which only one surgeon performed 
laparoscopic surgery. After 2012 the gastric cancer surgery was centralized into one hospital 
(Rijnstate hospital) and was done by 2 teams of 2 gastrointestinal surgeons each. These 4 
surgeons all performed laparoscopic gastrectomy. 2012 was a transitional year in which 
centralization was partly adopted and was therefore excluded from further analysis. For 
this study we selected all patients with gastric cancer without distant metastases operated 
in the Eastern part of the Netherlands between January 2008 and December 2011 (pre- 
centralization) and patients who underwent gastrectomy in the Rijnstate hospital between 
January 2013 and June 2016 (post-centralization). In both pre- and post-centralization period, 
surgeons were well trained in laparoscopic surgery, and in the entire study period all patients 
were discussed in a multidisciplinary team meeting. 
 
Statistical analysis 
Descriptive statistics were used to characterize the patients before and after centralization, 
significance was calculated by means of Chi-Square or Mann-Whitney Test. Treatment 
modalities and outcome of treatment in terms of post-operative complications and hospital 
stay were compared by Chi-Square or Mann-Whitney Test. 
Survival time was defined as time from surgery to death or until January 1st 2016 for 
patients who were still alive. With exception for patients who underwent surgery in 2016; 
for these patients, survival time was defined as time from surgery to death or until the last 
hospital visit registered in the medical file in December 2016. Disease free survival was 
defined as time from surgery to tumour recurrence(regardless of the location of recurrence) 
or until the last hospital visit registered in the medical file in December 2016 in which there 
was no evidence on tumour recurrence. Kaplan Meier curves were generated to examine the 
overall and disease free survival and compared by log-rank test. Multivariable Cox regression 
analyses were performed to investigate the prognostic impact of centralization on overall 
 
survival after adjustment for patient and tumour characteristics. To prevent over fitting due 
to limited amount of events in our study population, multivariable analysis was limited to 
5 variables. Results from survival analyses using Cox regression analyses were reported as 
hazard ratios (HR) and 95 per cent confidence interval (c.i.). Reported P values of <0.050 were 
considered statistically significant. All analyses were conducted using IBM SPSS Statistics 
Version 23 (International Business Machines Statistical Package for the Social Sciences). 
 
Results 
 
A total of 250 gastric cancer patients without distant metastasis who underwent gastric 
surgery were included. Before centralization 144 patients (median follow-up time 43 months) 
were treated, 106 patients were treated post-centralization (median follow-up time 15 
months, P<0.01). Apart from variation in ASA-classification (P<0.01), all other patient- and 
tumour characteristics were comparable between both study populations (Table 1). 
 
Table 1 Patient and tumour characteristics according to centralization status; pre-centralization 2008- 
2011 and post-centralization 2013-2016. 
 
 Pre- centralization 
N=144 
% Post-centralization 
N=106 
% P value 
Follow-up (months) Median: 43 
IQR:48 (15-63) 
 Median: 15 
IQR:17 (7-24) 
 <0.01* 
Age in years     0.90^ 
<70 65 45 47 44  
≥70 79 55 59 56  
Gender     0.35^ 
Male 90 63 60 57  
Female 54 38 46 43  
BMI Mean: 25.1 
(SD 4.0) 
 Mean: 25.4 
(SD 4.0) 
 0.27* 
ASA-classification     <0.02^ 
I 17 12 7 6.6  
II 81 56 74 70  
III 35 24 21 20  
IV 2 1.4 4 3.8  
Unknown 9 6.3 0 0  
Comorbidity     0.79^ 
0 44 31 31 29  
1 63 44 45 43  
≥2 36 25 30 28  
Unknown 1 0.7 0 0  
Previous abdominal surgery     0.38^ 
Yes 54 38 33 31  
No 89 62 73 69  
Unknown 1 0.7 0 0  
Table 1 continues on next page 
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Continuation of table 1 
After centralization there was a significant increase in the use of perioperative 
chemotherapy (25 per cent vs. 42 per cent, P<0.01), patients receiving no chemotherapy 
remained almost equal (47 per cent vs. 44 per cent P=0.65) and the amount of patients 
receiving only neo-adjuvant treatment decreased significantly (26 per cent vs. 13 per cent 
P=0.02). More patients were treated laparoscopically, respectively 5.6 per cent and 40 per 
cent of all patients received a laparoscopic gastrectomy before and after centralization 
(P<0.01). Median duration of surgery increased (147 minutes vs. 180 minutes (P<0.01) and 
the median amount of peroperative blood loss decreased (300ml vs. 200ml (P<0.01). There 
was a significant increase of patients who had an adequate amount of more than 15 lymph 
nodes harvested during surgery from 21 per cent towards 93 per cent after centralization 
(P<0.01). The median hospital stay decreased with two days after centralization (10 vs. 8 
days P<0.01) (Table 2.) 
Table 2 Surgery and hospital stay according to centralization status; pre-centralization 2008-2011 and 
post-centralization 2013-2016. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^ Pearson Chi Square * Mann-Whitney Test 
 
Treatment 
Centralization did not significantly affect time between diagnosis and start of treatment (Table 
2). The amount of partial gastrectomies increased non-significantly, 68 per cent between 2008- 
2011 and 74 per cent between 2013-2016 (P=0.34) and there was no significant increase in 
the number of microscopically radical resections (R0); 79 per cent before centralization and 
87 per cent after centralization (P=0.16) (Table 2). 
 
^ Pearson Chi Square, * Mann-Whitney Test 
2 2 
Previous gastric surgery    0.49^ 
Yes 12 8.3 6 5.7 
No 131 91 100 94 
Unknown 1 0.7 0 0 
Previous malignancy    0.40^ 
Yes 20 14 20 19 
No 123 85 86 81 
Unknown 1 0.7 0 0 
pT-stage    0.36^ 
0/X 10 6.9 9 9 
1 29 20 23 22 
2A 17 12 20 19 
2B 55 38 38 36 
3 27 19 15 14 
4 6 4.2 1 0.9 
pN-stage    0.11^ 
Nx 9 6.3 2 1.9 
0 78 54 51 48 
1 43 30 34 32 
2 13 9 15 14 
3 1 0.7 4 3.8 
Tumour topography    0.30^ 
Proximal/middle 43 30 33 31 
Pyloric/antrum 62 43 53 50 
Overlapping/not specified 39 27 20 19 
Tumour grade    0.12^ 
Well differentiated 8 5.6 4 3.8 
Moderately differentiated 16 11 22 21 
Poorly/Undifferentiated 68 47 39 37 
Unknown 52 36 41 39 
Type (Lauren classification)    0.05^ 
Intestinal type 92 64 52 49 
Diffuse type 45 31 49 46 
Indeterminate type 7 4.9 5 4.7 
 
 Pre-centralization 
N=144 
% Post-centralization 
N=106 
% P value 
Time between diagnosis and 
treatment (days) 
Median: 35.50 
IQR: 23 (27-50) 
 Median: 34.00 
IQR: 17 (28-45) 
 0.94* 
Type of chemotherapy      
None 68 47 47 44 0.65^ 
Only neoadjuvant 37 26 14 13 0.02^ 
Only adjuvant 3 2.1 1 0.9 0.44^ 
Peri-operative 36 25 44 42 <0.01^ 
Type of resection     0.34^ 
Partial gastrectomy 98 68 78 74  
Total gastrectomy 46 32 28 26  
Resection method     <0.01^ 
Laparotomy 133 92 62 59  
Laparoscopic 8 5.6 42 40  
Unknown 3 2.1 2 1.9  
Duration surgery (minutes) Median: 147 
IQR: 69 (116-185) 
 Median: 180 
IQR: 74 (154-228) 
 <0.01* 
Blood loss (ml) Median: 300 
IQR: 488 (200-688) 
 Median: 200 
IQR: 313 (100-413) 
 <0.01* 
Lymph nodes harvested     <0.01^ 
<15 114 79 8 8  
≥15 30 21 98 92  
Tumour residue     0.16^ 
R0 115 79 92 87  
R1 22 15 13 12  
Unknown 7 4.9 1 0.9  
Hospital stay (days) Median: 10 
IQR: 7 (7-14) 
 Median: 8 
IQR: 4 (7-11) 
 <0.01* 
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Complications 
No significant difference was seen in the amount and grade of post-operative complications 
(Table 3). The amount of anastomotic leakages did not decrease significantly; 9.0 per cent 
between 2008-2011 and 6.6 per cent between 2012-2016 (P=0.49). The occurrence of an 
intra-abdominal abscess did not decrease after centralization (2.8 per cent vs. 6.6 per cent 
P=0.15). However the amount of patients with cardiac complications (16 per cent vs. 7.5 per 
cent P<0.05) decreased significantly after centralization (Table 4). 
Additional analysis on the influence of type of surgery (i.e. laparoscopy vs laparotomy), 
showed no significant difference in the amount of post-operative morbidity (39 per cent vs. 
42 per cent P=0.76). 
 
Table 3 Postoperative complications according the Clavien Dindo classification of surgical complications. 
Table 5 Postoperative re-interventions in 30 days after surgery according to centralization status; pre- 
centralization 2008-2011 and post-centralization 2013-2016. 
 
Pre-centralization 
N=144 
Post-centralization 
N=106 
P-value 
 N %  N %  
Surgical intervention 17 12  13 12 0.91 
Radiological intervention 11 7.6  3 2.8 0.10 
Endoscopic intervention 2 1.4  3 2.8 0.42 
Antibiotic therapy 48 33  36 34 0.92 
 
 
Recurrence and survival 
There were no statistically significant differences in disease free and overall survival between 
patients treated before and after centralization in univariable and multivariable analysis. 
Pre-centralization 
N=144 
Post-centralization 
N=106 
P-value 
Kaplan Meier survival analyses showed that 1-year disease free survival was 73 per cent 
 
  
  N % N %  
<II 84 58 65 61 0.51 
II 32 22 23 22  
III 10 7 11 10  
IV 11 8 5 5  
V 7 5 2 2  
 
Table 4 Postoperative complications in 30 days after surgery according to centralization status; pre- 
centralization 2008-2011 and post-centralization 2013-2016. 
Pre-centralization 
N=144 
Post-centralization 
N=106 
P-value 
 N %  N %  
Post-operative complications 60 42  42 40 0.75 
Anastomotic leakage 13 9.0  7 6.6 0.49 
Intra-abdominal abscess 4 2.8  7 6.6 0.15 
Wound infection 5 3.5  2 1.9 0.45 
Post-operative bleeding 6 4.2  3 2.8 0.58 
Pneumonia 29 20  19 18 0.66 
Urinary tract infection 5 3.5  0 0 0.05 
Cardiac complications 23 16  8 7.5 <0.05 
 
 
There were no statistically significant differences in the amount of re-interventions 
between both study populations (Table 5). In both study periods, 12 per cent of all patients 
underwent a post-operative surgical re-intervention. This was mainly caused by (a suspicion 
of) a failure of the gastrojejunostomy (pre-centralization 6.9 per cent and post-centralization 
6.6 per cent). 30-day mortality was 4.2 per cent and 1.9 per cent respectively (P=0.17) before 
and after centralization. No statistically significant difference was seen in 30-day mortality for 
both types of surgery (i.e. laparoscopy vs. laparotomy (2.0 per cent vs. 3.6 per cent P=0.56). 
before and 74 per cent after centralization (figure 1, P=0.66). 1-year overall survival of all 
patients treated before centralization was 78 per cent and after centralization 80 per cent; 
2-year overall survival was 62 per cent versus 70 per cent (figure 2, P=0.17). Additional Kaplan 
Meier survival analysis to examine the 2-year overall survival for both types of surgery (i.e. 
laparoscopy vs laparotomy), showed no significant difference (Figure not shown, P=0.35). 
Multivariable cox regression analysis showed no significant effect of centralization on 
overall survival (Table 6, HR 0.6, 95 per cent c.i. 0.4 to 1.1 P=0.08). However, an impact was 
seen of tumour stage on overall survival (Table 6, HR 9.6, 95 per cent c.i. 4.6 to 19.7 P<0.01). 
 
Table 6 Cox regression analyses. The influence of different clinicopathological factors on survival. 
 
 Hazard ratio 95.0 per cent c.i. P value 
Centralization status    
Post-centralization 
(Reference: Pre-centralization) 
0.6 0.4-1.1 0.08 
Age 
≥70 (Reference <70) 1.8 1.1-2.8 0.02 
Comorbidity 
0 (Reference) 
1 1.0 0.6-1.6 1.0 
≥2 1.2 0.7-2.1 0.51 
Unknown 1.7 0.2-13.8 0.62 
Tumour Stage 
Stage 1 (Reference) 
Stage 2/3 2.8 1.8-4.3 <0.01 
Stage 4 9.6 4.6-19.7 <0.01 
Unknown 1.5 0.7-3.1 0.26 
Chemotherapy 
Yes (Reference: No) 0.8 0.5-1.3 0.42 
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Discussion 
 
This is the first study showing improved treatment outcome after centralization of gastric 
cancer treatment in the Netherlands since centralization had been effectuated in 2012. 
Gastric cancer patients significantly more often received peri-operative chemotherapy and 
laparoscopic gastrectomy, the amount of peroperative blood loss significantly decreased and 
more patients received an adequate lymphadenectomy. After surgery, patients remained 
hospitalized for a significantly shorter period of time. Also after centralization patients had 
significantly less post-operative cardiac complications, which might be caused by improved 
pre-operative optimization and peri-operative monitoring.3,7 On the other hand, 30 day 
mortality, disease free and overall survival did not improve significantly after centralization 
of gastric cancer treatment in the Eastern part of the Netherlands. 
The introduction of laparoscopic gastrectomy in this region of the Netherlands, makes 
this study more difficult to interpret. It is suggested that laparoscopic gastrectomy causes 
less perioperative blood loss, fewer post-operative complications, shorter hospital stay, 
but equal surgical oncological results (i.e. tumour residue, lymph nodes harvest) and post- 
operative mortality.8-10 The abovementioned improved results of gastric cancer treatment 
Figure 1 Kaplan Meier 2- year disease free survival curve. Patients grouped by centralization status. 
P=0.66 (Log Rank test). 
after centralization could thus also be due to the introduction of laparoscopic surgery. 
However, introduction and performance of laparoscopic gastrectomy requires a certain 
number of resection per surgeon per time period. Therefore, it is safer and easier to perform 
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laparoscopic gastric surgery in one high volume hospital than in six low volume centres. 
Various studies suggest that the learning curve of a laparoscopic gastrectomy is considered 
complete after more than 50 gastrectomies.11,12 this study showed that in our region less than 
40 gastrectomies are being performed per year. Dividing these cases over several hospitals, 
would have extended the surgeons learning curve for laparoscopic gastrectomy over several 
years. 
The importance of centralizing low frequent and complex cancer care into high volume 
hospitals is endorsed globally. 1,3,13-15 Nevertheless, for gastric cancer the benefit of centralizing 
treatment has not been proven beyond doubt; studies on centralization of gastric cancer care 
are often heterogeneous and occasionally conflicting.16-19 In recent years several studies on 
centralization of gastric cancer care in the UK have been published.17-19 In those studies, both 
oesophagus and gastric cancer are combined despite well-known differences in treatment, 
survival and impact of centralization.20 Chan et al. reported decreased morbidity, mortality 
and length of hospital stay after centralization.17 Next to that, the rate of patients treated 
with curative intent increased from 21 per cent to 36 per cent. However, another UK study in 
which survival was shown separately for gastric and oesophagus cancer, showed no significant 
improvement of median survival after centralization for gastric cancer 18. Recently a study 
Figure 2 Kaplan Meier 2-year overall survival curve. Patients grouped by centralization status. P=0.17 
(Log Rank test). 
by Mamidanna et al. demonstrated that mortality after gastrectomy was lower for surgeons 
with higher volumes15. This study, done in over twelve thousand patients showed that for each 
additional gastrectomy per year 30-day mortality decreased significantly.15 
After centralization of gastric cancer in the Eastern part of the Netherlands, there was a 
decrease in the incidence of surgically treated gastric cancer patients (N = 144 patients vs. 
N= 106 patients). Apart from the difference in the length of both study periods, this could 
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be caused by the decreasing incidence of curative treatable gastric cancer.21 Furthermore, it 
could be possible that centralized hospitals perform a more critical pre-operative selection, 
causing more patients to be excluded from surgical intervention. 
Also an increased use of perioperative chemotherapy was shown in this study. One possible 
explanation for the increased use perioperative chemotherapy could be that centralization 
has led to stricter compliance of the Dutch Guidelines for Gastric Cancer treatment which is 
introduced in May 2009. This guideline recommends perioperative chemotherapy with an 
epirubicin, cisplatin and/or fluorouracil based regime in patients with stage II and III gastric 
cancer. The guidelines were recently further expanded but recommendations considering 
perioperative chemotherapy remained similar22. Besides that, the increased hospital volume 
after centralization has probably led to more experience in treating (high-risk) patients with 
perioperative chemotherapy and thereby better awareness of the possibilities, risks and 
benefits of perioperative chemotherapy. 
In this study the increased use of perioperative chemotherapy was mainly due to 
increased use of adjuvant chemotherapy. A possible explanation for this is that patients    
in the post-centralization group had a shorter and/or better recovery after surgery (i.e. 
decreased hospital stay, less blood loss and less postoperative complications). Postoperative 
complications are one of the main reasons for not starting postoperative chemotherapy. 16 
Completion of perioperative chemotherapy is able to improve 5-year overall and disease free 
survival with more than 10 per cent.23,24 However in this retrospective study the increased 
use of perioperative chemotherapy post-centralization did not result into an increased 
survival benefit. This is in line with the suggestion that adjuvant chemotherapy offers limited 
additional survival benefit for patients with curatively resected gastric cancer.25,26 
The increased amount of harvested lymph nodes might be the effect of more experienced 
and trained surgeons in performing an adequate lymphadenectomy, but also due to the 
diligence and effort put in these time-consuming examinations by pathology departments.27 
An adequate lymphadenectomy is especially relevant in order to predict prognosis, by 
assessing an adequate and reliable UICC TNM N-stage.28 But evidence also suggests that 
resection of 15 or more lymph nodes resulted in an improvement of 10-year disease specific 
survival with more than 15 per cent.29-31 In the present study a survival benefit due to the 
improved lymphadenectomy could not be demonstrated. This might be caused due to the 
suggestion that surgical lymphadenectomy before and after centralization remained equal, 
but harvesting of lymph nodes by pathology department improved after centralization. 
Variation in evaluated lymph nodes between pathology departments has been studied before 
in the Netherlands.27 Lemmens et. al. investigated the median evaluated lymph nodes in 6 
different pathology departments between 1999 and 2007 and showed a variation between 
5 to 9 median evaluated nodes27. Another explanation for the lack of survival benefit after 
centralization might be the low number of patients. 
This study showed no significant improvement in 30-day mortality and 1-year overall 
survival. Before centralization 30-day mortality (4,2 per cent) was already lower than the 
nationwide average of 6,9 per cent.32 Mortality rates after gastric surgery in the Eastern part 
of the Netherlands were also among the lowest compared to various European countries, 
ranging from 3.5 per cent to 6.9 per cent 32 and only slightly higher than in the Danish study 
 
after their national centralization (2,4 per cent) 1. This relatively good outcome would be 
difficult to improve significantly after centralization. Moreover, producing a statistically 
significant difference in overall survival before and after centralization will probably require 
a larger study population and a longer follow-up. Possibly with a lager study population, 
the 40 per cent risk reduction in multivariate analysis of the current study could result in 
statistical significance. Nevertheless, a postoperative mortality after centralization of 1,8 per 
cent is a very satisfying outcome. 
To conclude, this is the first retrospective cohort study to show a positive effect of 
centralizing gastric cancer treatment in the Netherlands. More peri-operative chemotherapy, 
more harvested lymph nodes during surgery and/or pathology, less peroperative blood loss 
and less post-operative cardiac complications, have however not yet led to a significant 
improvement of overall or disease free survival. This is probably due to the small study 
population. A nationwide population based study will be needed to show a significant 
improvement in overall survival. 
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Abstract 
 
Background:                                                                                                                           
Centralization of surgery has been shown to improve outcomes for oesophageal and pancreatic 
cancer, and has been implemented for gastric cancer since 2012 in the Netherlands. This study 
evaluated the impact of centralizing gastric cancer surgery on outcomes for all patients with 
gastric cancer. 
 
Methods: 
Patients diagnosed with non-cardia gastric adenocarcinoma in the intervals 2009–2011 
and 2013–2015 were selected from the Netherlands Cancer Registry. Clinicopathological, 
treatment characteristics and mortality were assessed for the periods before (2009–2011) 
and after (2013–2015) centralization. Cox regression analyses were used to assess differences 
in overall survival between these intervals. 
 
Results: 
A total of 7204 patients were included. Resection rates increased slightly from 37.6 per cent 
before to 39.6 per cent after centralization (P=0.023). Before centralization, 50.1 per cent of 
surgically treated patients underwent gastrectomy in hospitals that performed fewer than 
ten procedures annually, compared with 9.2 per cent after centralization. Patients who had 
gastrectomy in the second interval were younger and more often underwent total gastrectomy 
(29.3 per cent before versus 41.2 per cent after centralization). Thirty-day postoperative 
mortality rates dropped from 6.5 to 4.1 per cent (P=0.004), and 90-day mortality rates 
decreased from 10.6 to 7.2 per cent (P=0.002). Two-year overall survival rates increased 
from 55.4 to 58.5 per cent among patients who had gastrectomy (P=0.031) and from 27.1 
to 29.6 per cent for all patients (P=0.003). Improvements remained after adjustment for 
case mix; however, adjustment for hospital volume attenuated this association for surgically 
treated patients. 
 
Conclusion: 
Centralization of gastric cancer surgery was associated with reduced postoperative mortality 
and improved survival. 
Introduction 
 
Gastric cancer is the fifth most common cancer and the third leading cause of cancer death 
worldwide.1 Although the incidence has decreased over recent decades in the Netherlands, 
prognosis remains poor. The 5-year overall survival rate for patients with gastric cancer is 
approximately 25 per cent in Western countries.2–4 Survival has remained dismal during the 
past two decades, although a minor improvement has been observed in recent years in the 
Netherlands.3,5 
Surgery is the cornerstone of curative treatment for gastric cancer. However, gastric 
cancer surgery is considered to be an operation with relatively high morbidity and mortality 
rates.6–8 Owing to a low incidence of gastric cancer in the Netherlands, most hospitals used 
to undertake only a limited number of gastrectomies per year.9 
Several studies10–15 have shown an inverse relationship between hospital volume of high- 
risk upper gastrointestinal surgical procedures and postoperative mortality. To improve 
survival and decrease morbidity for patients with gastric cancer, centralization has been 
initiated in the Netherlands. Since 2012, hospitals that undertake gastric cancer surgery 
should perform a minimum of ten gastrectomies per year, and since 2013 this has increased 
to 20. 
The results from previous studies investigating the effects of centralization of gastric 
cancer surgery on outcome are ambiguous.10,11,14–17 Studies from the UK10 and Denmark11 
showed that patients who underwent gastrectomy in the period after centralization had a 
lower postoperative mortality rate and better overall survival than patients treated before 
centralization. Other studies14,15 showed that increased hospital volume was associated with 
lower postoperative mortality rates and improved survival after gastric cancer surgery. 
However, a Dutch study16, which included patients treated surgically in the eastern part of 
the country, did not find an improvement in overall survival after gastrectomy following 
centralization; this was probably related to the small number of patients investigated. Another 
study17 also reported no association between hospital volume and long-term survival. 
The improvement in survival after gastrectomy may be explained by patient selection 
rather than better care; only fit patients are referred for surgery and less fit patients are 
not offered curative treatment. As a result, survival may improve only for a selected group 
of patients and may be worse for all patients.18 The present study evaluated the impact of 
centralization of gastric cancer surgery on survival for all patients with gastric cancer in a 
population-based setting. 
 
Methods 
 
Data were obtained from the population-based Netherlands Cancer Registry (NCR). This 
registry serves the total Dutch population of 16.9 million inhabitants. The NCR is based on 
notification of all newly diagnosed malignancies in the Netherlands by the national automated 
pathological archive. Additional sources are the national registry of hospital discharge and 
radiotherapy institutions. Specially trained data managers of the NCR routinely extract 
information on diagnosis, tumour stage and treatment from the medical records. Information 
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on vital status was obtained through annual linkage with the Municipal Administration 
Database, in which all people who have died or emigrated from the Netherlands are registered. 
This study was approved by the Privacy Review Board of the NCR and did not require approval 
from an ethics committee in the Netherlands. 
 
Patient selection criteria 
The reporting of this study followed the STROBE guidelines.19 Patients diagnosed with non- 
cardia gastric adenocarcinoma in the intervals 2009–2011 and 2013–2015 in the Netherlands 
were identified from the NCR. This study compared overall survival for all patients between 
the period preceding centralization (2009–2011) and the period after centralization (2013– 
2015), and for those treated surgically in the same intervals. The authors considered 2012 
as a transition year, as the first initiatives to centralize gastric cancer surgery started in the 
first months of 2012 and the current minimum hospital volume of 20 resections per year was 
introduced in 2013. Survival of all patients with gastric cancer, regardless of treatment, was 
evaluated to rule out the possible confounding effect of patient selection. 
 
Tumour location and stage 
Topography and morphology were coded according to the ICD-O-3.20 Location in the stomach 
was divided as follows: proximal/middle (fundus, corpus, and lesser and greater curvature 
(C16.1, C16.2, C16.5 and C16.6), antrum (C16.3), pyloric (C16.4) and overlapping or unknown 
(C16.8, C16.9). 
Tumour staging was carried according to the UICC TNM classification that was valid at 
the time of diagnosis. Patients diagnosed in 2009 were staged according to the sixth edition 
(TNM-6), whereas those diagnosed between 2010 and 2015 were staged according to the 
seventh edition (TNM-7).21,22 For analyses including all patients regardless of treatment, the 
pathological stage of the resection specimen was used where available; if not, clinical tumour 
stage was noted. For analyses among patients who underwent gastrectomy, the pathological 
tumour stage was used. A pT0 N0 M0 or pT0 NX M0 stage was classified as a pathological 
complete response. TNM-7 tumour staging was recoded according to TNM-6, which means 
that patients with a cT4A tumour according to TNM-7 were recoded as having a cT3 tumour 
according to TNM-6. Patients with cN1 or cN2 disease according to TNM-7 were recoded as 
having a cN1 tumour according to TNM-6. Tumour grade was classified as moderate or well 
differentiated, poorly differentiated or anaplastic, or unknown. 
 
Treatment definitions 
Surgery for gastric cancer was classified according to the NCR as subtotal gastrectomy, 
total gastrectomy or multiple organ resection, which was defined as a gastrectomy and 
surgical removal of other organs. Perioperative treatment was defined as preoperative 
chemotherapy followed by surgical resection and postoperative chemo(radio)therapy. 
Preoperative chemotherapy was defined as preoperative chemotherapy followed by surgical 
resection without postoperative treatment. Postoperative treatment included postoperative 
chemotherapy and postoperative chemoradiotherapy. Patients in the latter group were mainly 
those included in the CRITICS trial.23 Patients who underwent postoperative treatment also 
 
had preoperative chemotherapy. Surgery alone was defined as surgery without preoperative 
or postoperative treatment. 
 
Hospital Volume 
The experience of hospitals performing gastrectomies was defined in categories. For example, 
if a patient underwent gastrectomy in a hospital that performed 20 or more gastrectomies, the 
patient was included in the group of hospitals with an annual volume of at least 20 procedures. 
As gastrectomy could also be performed for tumours of the cardia, both cardia and non-cardia 
gastric cancers were included when defining hospital volume. Data from cardia tumours 
were used only to define the annual number of gastrectomies per hospital and were not used 
included in the study groups analysed here. 
 
Statistical analysis 
Descriptive statistics were used to characterize the patients before and after centralization of 
surgery. Period of diagnosis was used for analysis among all patients and period of resection 
was used for analysis among surgically treated patients. So some patients diagnosed in 2008 
who underwent gastrectomy in 2009 were included in table 2 but not in table 1. Differences 
in characteristics were analysed by means of Chi-Square tests for nominal data and ANOVA 
for continuous data. 
Kaplan–Meier curves were generated to examine overall survival before and after 
centralization for all patients and for those who had surgical treatment. Survival curves were 
compared by means of the log rank test. Cox proportional hazards regression analyses were 
used to investigate the effect of time interval of treatment on overall survival for all patients 
and those treated surgically after adjustment for potential confounding factors. For survival 
analyses based on patients who underwent gastrectomy, survival time was defined as the 
interval from gastrectomy to death or until 1 February 2017 for patients who were still alive. 
For survival analyses based on all patients irrespective of treatment, survival time was defined 
as time from diagnosis to death or until 1 February 2017 for patients who were still alive. 
Hazard ratios (HRs) were calculated with 95 per cent confidence intervals. P<0.050 was 
considered statistically significant. All analyses were carried out using SAS® version 9.4 (SAS 
Institute, Cary, North Carolina, USA). 
 
Results 
 
A total of 7214 patients were included in the study, 3777 diagnosed with gastric cancer 
between 2009 and 2011, and 3427 between 2013 and 2015 (Table 1). More patients in the 
interval before centralization had unknown tumour stage and the proportion of patients who 
underwent gastrectomy was higher in later period (1421 of 3777 (37.6 per cent) before and 
1358 of 3427 (39.6 per cent) after centralization; P=0.023). 
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Table 1 Characteristics of patients with non-cardia gastric cancer by period of diagnosis in the 
Netherlands, 2009-2011 and 2013-2015 (n=7204). 
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Figure 1 Percentage of patients treated with a gastrectomy for cancer per hospital volume category. 
In the first interval, 711 of 1418 surgically treated patients (50.1 per cent) underwent 
gastrectomy in hospitals that performed fewer than ten procedures per year, compared with 
129 of 1401 patients (9.2 per cent) in the second interval (Figure 1). After centralization, 
761 of 1401 patients (54.3 per cent) underwent gastrectomy in a high-volume hospital 
(performing 20 or more procedures each year). In the second interval, the proportion of 
patients who underwent gastrectomy in high-volume hospitals increased from 187 of 479 
(39.0 per cent) in 2013 to 246 of 405 (60.7 per cent) in 2015. Furthermore, the proportion 
of patients referred by the hospital of diagnosis to another hospital for preoperative 
chemotherapy slightly increased from 107 of 642 (16.7 per cent) before to 192 of 778 (24.7 
per cent) after centralization. 
Patients who underwent gastrectomy after centralization were younger, more often had 
a proximal gastric cancer or a stage III tumour, and more often received preoperative and/ 
or postoperative chemotherapy (Table 2). The proportion of patients who underwent total 
gastrectomy was higher after centralization. 
 
Table 2 Characteristics of 2819 patients with non-cardia gastric cancer who underwent gastrectomy 
by period of resection. 
 2009-2011 
N=1418 
  2013-2015 
N=1401 
P-value ‡ 
 N %  N % 
Gender     0.220 
Male 867 61.1  888 63.4 
Female 551 38.9  513 36.6 
Age (years)     <0.001 
< 60 290 20.5  304 21.7 
60- 74 580 40.9  654 46.7 
≥ 75 548 38.6  443 31.6 
*Preoperative chemotherapy followed by surgical resection and postoperative chemo(radio)therapy; †preoperative  
chemotherapy followed by surgery without postoperative chemo(radio)therapy. Table 2 continues on next page 
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2009-2011 
N=3777 
2013-2015 
N=3427 
  N  %   N  %  
Gender     
Male 2256 59.7  2080 60.7 
Female 1521 40.4  1347 39.3 
Age (yrs.)      
< 60 646 17.1  619 18.1 
60- 74 1440 38.1  1351 39.4 
≥ 75 1691 44.8  1457 42.5 
Tumour location      
Proximal/ middle 1101 29.2  1057 30.8 
Antrum 1102 29.2  949 27.7 
Pyloric 269 7.1  217 6.3 
Overlapping, unknown 1305 34.6  1204 35.1 
Clinical tumour stage      
I 354 9.4  582 17.0 
II 312 8.3  452 13.2 
III 277 7.3  238 6.9 
IV 1485 39.3  1333 38.9 
Unknown 1349 35.7  822 24.0 
Tumour stage      
0 (Complete response) 49 1.3  79 2.3 
I 496 13.1  431 12.6 
II 549 14.5  509 14.9 
III 595 15.8  617 18.0 
IV 1575 41.7  1389 40.5 
Unknown 513 13.6  402 11.7 
Tumour grade      
Moderate/ well differentiated 546 14.5  538 15.7 
Poorly differentiated or anaplastic 1608 42.6  1459 42.6 
Unknown 1623 43.0  1430 41.7 
Gastrectomy      
Yes 2356 62.4  2069 60.3 
No 1421 37.6  1358 39.6 
Treatment      
Perioperative chemo(radio)therapy + surgery* 375 9.9  447 13.0 
Preoperative chemotherapy + surgery† 310 8.2  303 8.8 
Surgery alone 736 19.5  608 17.7 
Chemotherapy alone 699 18.5  619 18.1 
Other 350 9.3  304 8.9 
None 1307 34.6  1146 33.4 
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Continuation of table 2 
Table 3 Outcomes after gastrectomy by period of resection 
*values are median (i.q.r.). †Chi-Square test, except ‡ANOVA. 
 
Two-year overall survival among patients who underwent gastrectomy was higher after 
centralization (58.5 per cent versus 55.4 per cent before centralization; P=0.031) (Figure 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*These  patients  underwent  preoperative  chemotherapy  followed  by  surgery  with  or  without  postoperative 
chemo(radio)therapy; †these patients also underwent preoperative chemotherapy followed by surgery. ‡Chi-Square 
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Postoperative 30- and 90-day mortality rates were significantly lower after centralization 
Figure 2 Overall survival among patients who underwent gastrectomy for gastric cancer in 2009–2011 
versus 2013–2015. 
Survival time was defined as the interval from gastrectomy to death or until 1 February 2017 for patients 
who were still alive. P =0.031 (log rank test) 
(4.1 and 7.2 per cent respectively) than before (6.5 and 10.6 per cent) (Table 3). The proportion 
of patients who had a radical resection with tumour-free resection margins increased from 
76.8 per cent before to 80.6 per cent after centralization. The proportion of patients with 
more than 15 lymph nodes resected was also higher after centralization. 
2009-2011 
N=1418 
2013-2015 
N=1401 
P value† 
 N %  N %  
Radicality of resection      0.009 
R0 1089 76.8  1129 80.6  
R+ 274 19.3  210 15.0  
Unknown 55 3.9  62 4.4  
Number of investigated lymph nodes      <0.001 
< 15 868 61.2  425 30.3  
≥ 15 544 38.4  961 68.6  
Unknown 6 <1.0  15 1.1  
Duration of hospital stay (days)* 10 8-15  9 7-13 <0.001‡ 
Postoperative mortality       
30-days 92 6.5  57 4.1 0.004 
60-days 124 8.7  81 5.8 0.003 
90-days 150 10.6  101 7.2 0.002 
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Tumour location    0.012 
Proximal/ middle a 419 29.5 492 35.1 
Antrum 506 35.7 468 33.4 
Pyloric 147 10.4 119 8.5 
Overlapping, unknown 346 24.4 322 23.0 
Clinical tumour stage    <0.001 
I 243 17.1 439 31.3 
II 197 13.9 329 23.5 
III 87 6.1 127 9.1 
IV 93 6.6 60 4.3 
Unknown 798 56.3 446 31.8 
Pathological tumour stage    <0.001 
Complete response 44 3.1 67 4.8 
I 429 30.3 338 24.1 
II 410 28.9 396 28.3 
III 397 28.0 496 35.5 
IV 137 9.7 96 6.9 
Unknown 1 <1.0 8 <1.0 
Tumour grade    0.896 
Moderate/ well differentiated 287 20.2 285 20.3 
Poorly differentiated or anaplastic 713 50.3 693 49.5 
Unknown 418 29.5 423 30.2 
Preoperative chemotherapy    <0.001 
No 776 54.7 623 44.5 
Yes* 642 45.3 778 55.5 
Postoperative chemo(radio)therapy    <0.001 
No 1015 71.6 906 64.7 
Yes† 403 28.4 495 35.3 
Type of gastrectomy    <0.001 
Total 415 29.3 577 41.2 
Subtotal 962 67.8 792 56.5 
Multi-organ /unknown 41 2.9 32 2.3 
Hospital volume    <0.001 
1-9 711 50.1 129 9.2 
10-19 523 36.9 511 36.5 
≥ 20 184 13.0 761 54.3 
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model 1† 
model 1† 
 
 
Univariable Cox regression analysis showed that survival was better in later period 
Continuation of table 4 
 
 
Hazard ratio 
(HR 0.89, 95 per cent c.i. 0.80 to 0.99) (Table 4). Multivariable Cox regression models were 
performed stepwise to investigate which variable explained the difference in overall survival 
between the intervals before and after centralization. After adjustment for age, sex, tumour 
 
 
Type of gastrectomy 
Univariable Multivariable Multivariable 
model 2‡ 
Multivariable 
model 3§ 
location and pathological tumour stage, survival was still better after centralization (HR Total 1.00 (reference) 1.00 (reference) 1.00 (reference) 
0.88, 0.79 to 0.97) (model 1). After additional adjustment for neoadjuvant chemotherapy and Subtotal 0.75 (0.68 - 0.84) 0.77 (0.69 - 0.87) 0.77 (0.68 - 0.86) 
type of surgery, survival was still better in the later period (HR 0.88, 0.79 to 0.98) (model 
2). However,  additional adjustment for annual hospital volume attenuated this association 
Multiple organs/ 
unknown 
1.11 (0.82 - 1.51) 0.86 (0.63 - 1.17) 0.86 (0.63 - 1.17) 
(HR 0.91, 0.80 to 1.03) (model 3), suggesting that increasing procedure volume through 
centralization contributed to the improved survival over time. 
Hospital volume (annual volume of gastrectomies) 
1–9 1.00 (reference) 1.00 (reference) 
Table 4 Univariable and multivariable Cox regression analyses of survival in 2819 patients with gastric 
cancer who underwent gastrectomy in the periods 2009–2011 and 2013–2015. 
10–19 0.95 (0.84 - 1.07) 
≥ 20 0.89 (0.79 - 1.01) 
0.96 (0.85 - 1.08) 
0.92 (0.79 - 1.06) 
 
 
  Hazard ratio  
Values in parentheses are 95 per cent confidence intervals. *Including nine patients with unknown pathological tumour 
stage. †Adjusted for age, sex tumour location and pathological tumour stage; ‡additionally adjusted for preoperative 
 
 
Period of resection 
Univariable Multivariable Multivariable 
model 2‡ 
Multivariable 
model 3§ 
chemotherapy and type of gastrectomy; §additionally adjusted for hospital volume. No adjustment was made for 
receiving postoperative chemotherapy as adjustment for this would result in immortal time bias for patients who 
underwent such treatment. 
2009–2011 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
2013–2015 0.89 (0.80 - 0.99) 0.88 (0.79 - 0.97) 0.88 (0.79 - 0.98) 0.91 (0.80 - 1.03) 
Age (years) 
< 60 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
60–74 1.11 (0.97 - 1.27) 1.15 (1.01 - 1.33) 1.11 (0.96 - 1.28) 1.11 (0.96 - 1.27) 
The 2-year overall survival rate for patients who did not receive surgical treatment was 
7.8 per cent in the interval before and 7.4 per cent in the interval after centralization. Median 
survival for non-surgically treated patients remained stable, at 17 weeks in the period before 
centralization and 18 weeks in the later period (P=0.463). 
≥ 75 1.57 (1.36 - 1.80) 1.59 (1.38 - 1.82) 1.38 (1.18 - 1.61) 1.38 (1.18 - 1.62) 
Gender 
male 1.00 (reference) 1.00 (reference) 1.00 (reference) 
female 0.96 (0.87 - 1.06) 0.98 (0.88 - 1.08) 0.98 (0.89 - 1.08) 0.98 (0.89 - 1.09) 
Tumour location 
Proximal/middle 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Antrum 1.04 (0.92 - 1.18) 1.02 (0.90 - 1.15) 1.10 (0.96 - 1.26) 1.10 (0.96 - 1.26) 
Pyloric 1.20 (0.99 - 1.43) 1.13 (0.94 - 1.36) 1.18 (0.98 - 1.43) 1.18 (0.97 - 1.42) 
Overlapping, unknown 1.47 (1.29 - 1.67)  1.32 (1.16 - 1.50) 1.31 (1.15 - 1.50) 
Pathological tumour stage 
Complete response 0.31 (0.20 - 0.48)     0.33 (0.21 - 0.52)     0.36 (0.23 - 0.57)     0.36 (0.23 - 0.57) 
I 0.48 (0.41 - 0.56)     0.48 (0.41 - 0.56)     0.47 (0.40 - 0.56)     0.47 (0.40 - 0.55) 
II* 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference) 
III 2.48 (2.19 - 2.81)     2.48 (2.19 - 2.81)     2.41 (2.13 - 2.72)     2.40 (2.12 - 2.71) 
IV 4.55 (3.82 - 5.38)     4.61 (3.90 - 5.45)     4.49 (3.79 - 5.32)     4.47 (3.77 - 5.29) 
Preoperative chemotherapy 
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21 24 
Centralization period 
2013-2015 
2009-2011 
No 1.00 (reference) 1.00 (reference) 1.00 (reference) 
Yes 0.66 (0.60 - 0.73) 0.74 (0.66 - 0.84) 0.74 (0.66 - 0.84) 
 
Table 4 continues on next page 
Follow-up (months) 
Figure 3 Overall survival among all patients with gastric cancer in 2009–2011 versus 2013–2015. 
Survival time was defined as the interval from diagnosis to death or until 1 February 2017 for patients 
who were still alive. P =0.003 (log rank test) 
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The 2-year overall survival rate for the whole cohort was 27.1 per cent in the period before 
and 29.6 per cent in the period after centralization (P=0.003) (Figure 3). 
Multivariable Cox regression analysis confirmed that survival was better in the interval 
after centralization, even after adjustment for age, sex, tumour stage, tumour location and 
tumour grade (HR 0.95, 0.90 to 0.99) (Table 5). 
Table 5 Multivariable Cox regression analysis of survival in patients with gastric cancer diagnosed in 
the period 2009-2011 and 2013-2015 (n=7204) 
  Univariable HR  Multivariable HR  
Period of diagnosis 
2009-2011 ref ref 
2013-2015 0.92 (0.87 - 0.97) 0.95 (0.90 - 0.99) 
Gender   
Male ref ref 
Female 1.05 (0.99 - 1.11) 1.03 (0.97 - 1.08) 
Age (yrs.)   
< 60 ref ref 
60- 74 1.14 (1.06 - 1.24) 1.27 (1.17 - 1.37) 
≥ 75 1.65 (1.53 - 1.78) 2.04 (1.89 - 2.21) 
Tumour location   
Proximal/ middle ref ref 
Antrum 0.97 (0.90 - 1.04) 1.05 (0.97 - 1.12) 
Pyloric 0.97 (0.87 - 1.09) 1.02 (0.91 - 1.15) 
Overlapping, unknown 1.54 (1.45 - 1.64) 1.26 (1.18 - 1.34) 
Pathological, or if not available clinical tumour stage 
I * 0.65 (0.58 - 0.74) 0.65 (0.57 - 0.74) 
II ref ref 
III 2.12 (1.91 - 2.35) 2.09 (1.89 - 2.32) 
IV 5.76 (5.25 - 6.32) 5.73 (5.22 - 6.30) 
Unknown 4.98 (4.47 - 5.55) 4.05 (3.62 - 4.52) 
Tumour grade   
Moderate/ well differentiated ref ref 
Poorly differentiated or anaplastic 1.48 (1.36 - 1.60) 1.28 (1.18 - 1.40) 
Unknown 1.57 (1.45 - 1.70) 1.25 (1.15 - 1.36) 
Survival time was defined as time from diagnosis to death or until February 1st 2017 for patients who were still 
alive. *Including patients with a complete response as only a few patients of all patients with gastric cancer have a 
complete response. 
 
Discussion 
 
This population-based study of the effect of centralization of surgery for gastric cancer 
demonstrated an improvement in surgical outcome parameters (lymph  node  retrieval 
and radical resection rate), a reduction in postoperative mortality and an improvement in 
overall survival for all patients after centralization. Survival improved both for surgically 
 
treated patients and for all patients, irrespective of treatment, but not for patients who did 
not undergo gastrectomy. This suggests that advances in (peri)operative treatment and 
possibly other factors related to surgical treatment may play a role. Moreover, the interval in 
which treatment was undertaken was associated with hospital volume among patients who 
underwent surgery. 
Although centralization of oesophageal and pancreatic cancer surgery improves overall 
survival, the benefits of centralizing gastric cancer surgery seem ambiguous according to 
previous studies.11,17,24 Some studies reported reduced postoperative mortality and better 
overall survival for patients who underwent gastrectomy after centralization, but others 
found no improvement in overall survival, probably related to the small number of patients 
included.10,11,16 These studies included only patients who underwent surgical treatment. The 
effect of centralization for surgically as well as non-surgically treated patients with gastric 
cancer has not been studied before. The present study tried to minimize the effect of possible 
confounding by selective referral. The data showed an improvement in overall survival for 
all patients with gastric cancer, which is consistent with results from previous studies in 
oesophageal and pancreatic cancer.13,25 
An explanation for the improved survival after centralization could be that ‘practice makes 
perfect’. Treating a greater number of patients with gastric cancer in a hospital could lead to 
improvements in the patient management across the whole treatment pathway.18 For example, 
further specialization of a surgeon in gastric cancer surgery may lead to a higher proportion 
of radical resections and a more extensive lymph node dissection.26,27 It is also possible that 
greater exposure of other specialists and nurses to patients who have had gastric cancer 
surgery increases their ability to recognize and treat complications at an earlier stage. This 
could lower the failure-to-rescue rate and postoperative mortality.28,29 Moreover, better patient 
selection by improved preoperative staging using endoscopic ultrasonography and PET by 
experienced specialists is also likely to play a role.30,31 In another study32, medical specialists 
working in a high-volume hospital also used a wider range of diagnostic investigations, which 
was not only explained by better access to these facilities. The present data also point to a 
decrease in the proportion of patients with unknown clinical tumour stage after centralization, 
suggesting stage migration owing to improved staging. 
The present study demonstrated an 11.9 per cent increase in the number of total 
gastrectomies and a decrease of 11.3 per cent in the number of subtotal gastrectomies 
after centralization. Although total gastrectomy is associated with a higher postoperative 
complication rate33,34, postoperative mortality and survival still improved among surgically 
treated patients in the present study. Furthermore, patients who underwent gastrectomy more 
often had a stage III tumour in the interval after centralization than in the earlier period, which 
may be explained by stage migration resulting from more extensive lymph node dissection. 
The improvement in overall survival after centralization of gastric cancer surgery can 
also be explained by the increased use of perioperative chemotherapy since 2006.7 The use 
of postoperative chemotherapy may have increased because of the lower postoperative 
complication rate after centralization.7 Even though adjustment for preoperative chemotherapy 
was made in the multivariable analysis, survival was still better after centralization for 
surgically treated patients. 
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References A reduction in postoperative mortality and improved overall survival among patients 
 
who have undergone surgery is sometimes challenged owing to the selection of patients 
who already have a higher chance of superior outcomes.18 In the present study, however, the 
resection rate increased, which does not point towards selection bias. On the other hand, 
patients were slightly younger in the interval after centralization. Nevertheless, overall 
survival improved for all patients in the period after centralization. Therefore, selective 
referral may have slightly influenced the improved outcome in surgically treated patients. 
The use of laparoscopic gastrectomy increased during the study period. It has been 
suggested that laparoscopic gastrectomy is associated with less perioperative blood loss, 
fewer postoperative complications and shorter hospital stay, with surgicopathological 
outcomes (radicality and lymph node harvest) and postoperative mortality equivalent to those 
of open surgery.35,36 Furthermore, a previous Dutch study37, also based on the NCR, reported 
comparable 1-year overall survival for patients who underwent open versus laparoscopic 
gastrectomy between 2010 and 2014. Therefore, improved survival for surgically treated 
patients after centralization cannot be explained by the increased use of laparoscopic 
gastrectomy. 
It is important to mention that in 2015, 39.3 per cent of the surgically treated patients 
still did not undergo surgery in a hospital that performed 20 or more resections per year. The 
surgical outcomes may have been better if all patients underwent surgery in a high-volume 
hospital. Moreover, a small proportion of the patients may have had surgery with palliative 
intent. Based on a previous study, this percentage would be approximately 4.3 per cent.38 
However, excluding these patients from the analysis was impossible as no information about 
the intention of surgery was available in the NCR. Excluding these patients from the analysis 
based on their clinical tumour stage may be inaccurate. 
A major strength of the present study is its population-based nature, which enabled  
the authors to capture all patients with gastric cancer in the Netherlands and compare the 
outcomes for the entire group of patients before and after centralization. This study also 
has some limitations. First, the impact of centralization on other important outcomes was 
not examined, such as postoperative complications, healthcare costs and quality of life, as 
these data were not available. Second, it was not possible to adjust for performance status 
and co-morbidity as this information was lacking nationwide. Differences in performance 
status and co-morbidity before and after centralization may have influenced the survival 
analysis for surgically treated patients because patient age (a proxy for performance status 
and co-morbidity) was different before and after centralization. However, it is unlikely that 
performance status and co-morbidity will have changed substantially for all patients during 
the study period. Third, no information was available about regimens used for chemotherapy. 
However, the authors believe that the chemotherapy regimens did not change considerably 
as MAGIC (Medical Research Council Adjuvant Gastric Infusional Chemotherapy)-based 
regimens (epirubicin, cisplatin, fluorouracil (ECF)/epirubicin, cisplatin, capecitabine (ECX)) 
were the recommended and standard regimens for perioperative chemotherapy during the 
whole study period. 
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Abstract 
 
Introduction: 
This study investigated age-related differences in surgically treated patients with gastric 
cancer, and aimed to identify factors associated with outcome. 
 
Methods: 
Data from the Dutch Upper Gastrointestinal Cancer Audit were used. All patients with non- 
cardia gastric cancer registered between 2011 and 2015 who underwent surgery were 
selected. Patients were analysed by age group (less 70 years versus 70 years or more). 
Multivariable logistic regression was used to assess the influence of clinicopathological factors 
on morbidity and mortality. 
 
Results: 
A total of 1109 patients younger than 70 years and 1206 aged 70 years or more were included. 
Patients aged at least 70 years had more perioperative or postoperative complications (41.2 
versus 32.5 per cent; P<0.001) and a higher 30-day mortality rate (7.9 versus 3.2 per cent; 
P<0.001) than those younger than 70 years. In multivariable analysis, age 70 years or more 
was associated with a higher risk of complications (odds ratio 1.29, 95 per cent c.i. 1.05 to 
1.59). Postoperative mortality was not significantly associated with age. In the entire cohort, 
morbidity and mortality were most influenced by ASA grade, neoadjuvant chemotherapy 
and type of resection. 
 
Conclusion: 
ASA grade, neoadjuvant chemotherapy and type of resection are independent predictors of 
morbidity and death in patients with gastric cancer, irrespective of age. 
Introduction 
 
In Western countries, gastric cancer surgery is associated with high postoperative mortality 
rates.1 Recent studies have demonstrated that 30-day mortality rates range from 3.7 to 12.8 
per cent among patients with gastric cancer. This is almost twice as high as the postoperative 
mortality rate in patients with rectal cancer, which ranges from 0.9 to 7.5 per cent.1,2 In a 
Dutch nationwide study1, a significant influence of age was seen on 30-day mortality following 
surgery for gastrointestinal cancers. Patients aged over 75 years had a significantly higher 
risk of 30-day mortality (odds ratio (OR) 2.94, 95 per cent c.i. 1.06 to 8.19) compared with 
patients under 65 years of age. It was suggested that mortality is influenced by the growing 
prevalence of co-morbidities in older patients. Mortality after gastrectomy is also affected 
by patient age.1,3,4 
In recent years, postoperative morbidity and mortality for gastric surgery has declined. 
The introduction of minimally invasive techniques and better perioperative care may be 
reasons for this.3,5,6 Because of better outcomes, more (fragile) elderly patients could benefit 
from surgery as this is still considered the only curative treatment. However, because co- 
morbidity is increased in the elderly and the overall population is ageing, selection of elderly 
patients for gastric surgery is of increased importance.7 
It has been shown that gastric cancer surgery in elderly patients can be done with a low 
30-day mortality rate of 8 per cent, and with morbidity and survival rates equivalent to those 
in younger patients.8,9 These studies also suggested that age alone is not the main factor 
predicting postoperative outcome. However, previous studies1,4,10–17 of age-related differences 
in gastric cancer surgery were mainly small cohort studies and failed to identify adequate 
alternative predictors. 
The aim of the present study was to assess age-related differences in morbidity and 
mortality, and to identify factors associated with outcome in patients who underwent surgery 
for gastric cancer. 
 
Methods 
 
Data from the Dutch Upper Gastrointestinal Cancer Audit (DUCA) were used. The DUCA is 
web-based, nationwide registry, founded in 2011. It includes details on patient, tumour and 
treatment characteristics for all patients scheduled for resection of oesophageal or gastric 
cancer in the Netherlands. 
To secure data quality, hospitals receive quality reports on inconsistent or unusual data 
combinations. In addition, an independent team of data managers evaluated a random data 
sample for an in-depth quality investigation in 2013 and 2017. The completeness of the 
registry was estimated at approximately 96 per cent in 2013 based on comparison with 
numbers of the Netherlands Cancer Registry. Details of data collection and methodology of 
the DUCA have been published previously.3 
4 4 
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Patients 
All patients with primary non-cardia gastric cancer registered between 2011 and 2015, who 
were scheduled to undergo (partial) gastrectomy in the Netherlands, were selected. Patients 
with non-epithelial tumours (such as sarcoma, melanoma, and gastrointestinal stromal 
tumour) and patients who received only non-surgical treatments (such as chemotherapy 
alone) are not registered in the DUCA. Two patients of unknown age were excluded. Patients 
were analysed in two age groups according to guidelines of the European Society of Medical 
Oncology and the Dutch clinical guideline.18,19 These guidelines and the international 
literature20 report that, when chronological age is used, the most clinically relevant cut-off 
point for defining elderly patients is around 70 years of age. 
 
Definitions 
Preoperative screening of patients was done by an anaesthesiologist, and fitness was classified 
according to the ASA grade.21 The intention of treatment (curative or palliative) was registered 
by the treating surgeon at the end of the procedure. Topography was coded according to 
ICD-O-3.22 Tumour location in the stomach was grouped as follows: proximal/ middle (fundus, 
corpus, lesser and greater curvature; C16.1, C16.2); pylorus and antrum (C16.3, C16.4); and 
diffuse when the tumour was located in the entire stomach. Tumour histology was registered 
according to the Laurén classification.23 Complications were defined as any unwanted effect of 
treatment during surgery, within 30 days after surgery or during the hospital stay. Severity of 
complications and reinterventions was graded according to the Clavien–Dindo classification 
(grades I–V).24 Postoperative mortality was defined as death during the same hospital 
admission as surgical resection or within 30 days after resection. 
 
Statistical analysis 
Characteristics of patients younger than 70 years and those aged 70 years or older were 
compared using Chi-Square test for categorical data and t test for continuous data. Outcomes 
of surgery in terms of morbidity and mortality were calculated for both age groups, and 
compared by Chi-Square test. Only patients who underwent gastric resection were included 
in the analyses of postoperative pathological tumour characteristics (such as radicality of 
surgery, pathological tumour stage). Univariable logistic regression analyses were performed 
for each age groups to assess the influence of clinicopathological factors on morbidity    
and mortality. Factors that had a statistically significant association were included in a 
multivariable model. To prevent overfitting owing to a limited number of events in the study 
population, the number of variables included in the multivariable analysis was limited to 
one variable per ten events. The multivariable analyses were performed for both age groups 
together. In the event of multiple highly correlated significant variables in the univariable 
analysis, the single variable with the highest predictive value in the univariable analysis was 
used in the multivariable model. P<0.050 was considered statistically significant. All analyses 
were conducted using SPSS® version 23 (IBM, Armonk, New York, USA). 
Results 
 
Some 2315 patients were scheduled to undergo (partial) gastrectomy for a primary non- 
cardia gastric tumour, including 1109 (47.9 per cent) younger than 70 years and 1206 (52.1 
per cent) aged 70 years or over. Baseline characteristics of two age groups are shown in 
Table 1. Patients aged 70 years or more had a higher ASA grade. Those younger than 70 
years more often underwent total gastrectomy and were more likely to be treated in a high- 
volume hospital. A significantly higher proportion of patients in the younger group received 
perioperative chemotherapy: 529 of 1109 (47.7 per cent) versus 214 of 1206 (17.7 per cent) 
(P<0.001). 
Table 1 Characteristics of patients younger than 70 years and those aged 70 years or more who were 
scheduled undergo surgical resection between 2011 and 2015 
 
 < 70 years 
(n = 1109) 
> 70 years 
(n = 1206) 
Total 
(n = 2315) 
P† 
Age (years)* 61 (22–69) 77 (70–100) 70 (22–100) < 0.001‡ 
Sex ratio (M : F) 692 : 417 755 : 451 1447 : 868 0.919 
BMI (kg/m2)    0.258 
< 18.5 46 (4.1) 33 (2.7) 79 (3.4)  
18.5–25.0 526 (47.4) 573 (47.5) 1099 (47.5)  
25.1–30.0 358 (32.3) 394 (32.7) 752 (32.5)  
> 30.0 133 (12.0) 141 (11.7) 274 (11.8)  
Unknown 46 (4.1) 65 (5.4) 111 (4.8)  
ASA grade    < 0.001 
I 250 (22.5) 71 (5.9) 321 (13.9)  
II 627 (56.5) 640 (53.1) 1267 (54.7)  
III 213 (19.2) 458 (38.0) 671 (29.0)  
IV–V 7 (0.6) 22 (1.8) 29 (1.3)  
Unknown 12 (1.1) 15 (1.2) 27 (1.2)  
Tumour location    0.032 
Fundus and corpus 432 (39.0) 432 (35.8) 864 (37.3)  
Antrum and pylorus 510 (46.0) 603 (50.0) 1113 (48.1)  
Diffuse 103 (9.3) 125 (10.4) 228 (9.8)  
Unknown 64 (5.8) 46 (3.8) 110 (4.8)  
Histological subtype    < 0.001 
Intestinal 314 (28.3) 487 (40.4) 801 (34.6)  
Diffuse 366 (33.0) 242 (20.1) 608 (26.3)  
Mixed 57 (5.1) 51 (4.2) 108 (4.7)  
Unknown 372 (33.5) 426 (35.3) 798 (34.5)  
Tumour grade    < 0.001 
Good 41 (3.7) 60 (5.0) 101 (4.4)  
Average 211 (19.0) 341 (28.3) 552 (23.8)  
Poor 553 (49.9) 517 (42.9) 1070 (46.2)  
Unknown 304 (27.4) 288 (23.9) 592 (25.6)  
Table 1 continues on next page 
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Continuation of table 1 
 
Type of resection < 0.001 
Continuation of table 2 
 
 
< 70 years 
(n = 1109) 
 
 
> 70 years 
(n = 1206) 
 
 
Total P† 
(n = 2315) 
Hospital resection volume 0.023 
< 10 283 (25.5) 357 (29.6) 640 (27.6) 
10–19 474 (42.7) 526 (43.6) 1000 (43.2) 
≥ 20 352 (31.7) 322 (26.7) 674 (29.1) 
Unknown 0 (0) 1 (0.1) 1 (0.0) 
Intention of surgery 0.002 
Curative 1061 (95.7) 1119 (92.8) 2180 (94.2)  
Palliative 30 (2.7) 69 (5.7) 99 (4.3) 
Unknown 18 (1.6) 18 (1.5) 36 (1.6) 
Urgency of surgery    0.034 
Elective 1067 (96.2) 1130 (93.7) 2197 (94.9)  
Urgent 30 (2.7) 51 (4.2) 81 (3.5)  
Acute 12 (1.1) 23 (1.9) 35 (1.5)  
Unknown 0 (0) 2 (0.2) 2 (0.1)  
Chemotherapy < 0.001 
None 221 (19.9) 725 (60.1) 946 (40.9 
Preoperative 302 (27.2) 192 (15.9) 494 (21.3) 
Postoperative 36 (3.2) 30 (2.5) 66 (2.9) 
Preoperative and postoperative 529 (47.7) 214 (17.7) 743 (32.1) 
Unknown 21 (1.9) 45 (3.7) 66 (2.9) 
Values in parentheses are percentages unless indicated otherwise; *values are median (range). †Chi-Square test, 
except ‡ t test. 
 
Treatment outcomes 
 
 
No. of lymph nodes retrieved < 0.001 
pT category 0.259 
 
pT0/is 60 (6.0) 51 (4.8) 111 (5.4) 
pT1 159 (15.9) 145 (13.5) 304 (14.7) 
pT2 146 (14.6) 167 (15.6) 313 (15.1) 
pT3 369 (37.0) 430 (40.1) 799 (38.6) 
pT4 223 (22.3) 246 (22.9 469 (22.6) 
Unknown 41 (4.1) 34 (3.2) 75 (3.6) 
pN category 0.480 
pN0 425 (42.6) 444 (41.4) 869 (42.0) 
pN1 168 (16.8) 212 (19.8) 380 (18.3) 
pN2 162 (16.2) 177 (16.5) 339 (16.4) 
pN3 195 (19.5) 193 (18.0) 388 (18.7) 
Unknown 48 (4.8) 47 (4.4) 95 (4.6) 
pM category 0.967 
pM0 854 (85.6) 919 (85.6) 1773 (85.6) 
pM1 68 (6.8) 75 (7.0) 143 (6.9) 
Unknown 76 (7.6) 79 (7.4) 155 (7.5) 
Pathological tumour stage 0.772 
0/I 238 (23.8) 266 (24.8) 504 (24.3) 
II/III 568 (56.9) 614 (57.2) 1182 (57.1) 
IV 68 (6.8) 75 (7.0) 143 (6.9) 
Unknown 124 (12.4) 118 (11.0) 242 (11.7) 
There was a difference in postoperative outcome between the two age groups (Table 2). Some 
360 of 1109 patients younger than 70 years (32.5 per cent) had a complication compared with 
Peroperative or postoperative 
complications 
360 (32.5) 497 (41.2) 857 (37.0) < 0.001 
857 of 1206 aged 70 years or more (41.2 per cent) (P<0.001). However, after a complication, 
there was no statistically significant difference between groups in the rate reinterventions. 
Thirty-five of 1109 patients younger than 70 years (3.2 per cent) died within 30 days after 
surgery compared with 95 of 1206 (7.9 per cent) aged 70 years or more (P<0.001). 
Table 2 Outcome after gastrectomy according to age. 
Clavien–Dindo classification 0.038 
I 2 (0.6) 1 (0.2) 3 (0.4) 
II 164 (45.6) 220 (44.3) 384 (44.8) 
III 62 (17.2) 62 (12.5) 124 (14.5) 
IV 6 (1.7) 8 (1.6) 14 (1.6) 
V 18 (5.0) 52 (10.5) 70 (8.2) 
< 70 years 
(n = 1109) 
> 70 years 
(n = 1206) 
Total P† 
(n = 2315) 
Unknown 108 (30.0) 154 (31.0) 262 (30.6) 
Reintervention for complication 0.436 
Pathological data n = 998 n = 1073 n = 2071 
Radicality of operation 0.056 
R0 857 (85.9) 888 (82.8) 1745 (84.3) 
R1 103 (10.3) 124 (11.6) 227 (11.0) 
R2 9 (0.9) 24 (2.2) 33 (1.6) 
Unknown 29 (2.9) 37 (3.4) 66 (3.2) 
Table 2 continues on next page 
No 215 (59.7) 318 (64.0) 533 (62.2) 
Yes 143 (39.7) 176 (35.4) 319 (37.2) 
Unknown 2 (0.6) 3 (0.6) 5 (0.6) 
 
Duration of hospital stay (days)* 8.5 (1–385) 9.5 (1–386) 9 (1–386) 0.883‡ 
Duration of ICU stay (days)* 0 (0–62) 0 (0–93) 0 (0–93) 0.097‡ 
30-day postoperative mortality 35 (3.2) 95 (7.9) 130 (5.6) < 0.001 
Values in parentheses are percentages unless indicated otherwise; *values are median (range). †Chi-Square test, 
except ‡t test. 
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< 15 282 (28.3) 394 (36.7) 676 (32.6) 
≥ 15 695 (69.6) 646 (60.2) 1341 (64.8) 
Unknown 21 (2.1) 33 (3.1) 54 (2.6) 
 
Total gastrectomy 500 (45.1) 365 (30.3) 865 (37.4) 
Partial gastrectomy 498 (44.9) 708 (58.7) 1206 (52.1) 
No resection 111 (10.0) 133 (11.0) 244 (10.5) 
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Predictors of postoperative morbidity and mortality 
In addition to the variables in Table 1, previous abdominal surgery, year of surgery, type of 
operation (laparoscopy or laparotomy) and the use of immunosuppressant medicine were 
entered into univariable analysis. Only significant factors were entered in the multivariable 
model. 
Multivariable analysis showed that patients aged 70 years or more had significantly more 
perioperative or postoperative complications than younger patients (OR 1.29, 95 per cent 
c.i. 1.05 to 1.59) (Table 3). Other factors associated with morbidity were: ASA grade, type of 
resection, receipt of neoadjuvant chemotherapy and tumour location. Underweight patients 
also had a significantly higher risk of developing complications (OR 1.86, 1.10 to 3.15), but 
obese patients (BMI over 30 kg/m2) did not. 
 
Table 3 Multivariable logistic regression analysis of factors influencing perioperative or postoperative 
complications 
Odds ratio P 
 
Age (years) 
< 70 1.00 (reference) 
≥ 70 1.29 (1.05 - 1.59) 0.019 
BMI (kg/m2) 
< 18.5 1.86 (1.10 - 3.15) 0.021 
18.5–25.0 1.00 (reference)  
25.1–30.0 1.17 (0.95 - 1.44) 0.141 
> 30.0 1.20 (0.89 - 1.62) 0.229 
Unknown 0.74 (0.45 - 1.20) 0.226 
ASA grade 
I 1.00 (reference)  
II 1.06 (0.80 - 1.42) 0.684 
III 1.60 (1.17 - 2.20) < 0.001 
IV–V 4.50 (1.66 - 12.17) 0.003 
pT category 
pT0/is/1 0.88 (0.65 - 1.18) 0.390 
pT2 0.92 (0.68 - 1.23) 0.580 
pT3 1.00 (reference)  
pT4 1.07 (0.83 - 1.38) 0.575 
Unknown 1.34 (0.67 - 2.67) 0.405 
pN category   
Continuation of table 3 
 
 
  Odds ratio P  
pM category 
pM0 1.00 (reference) 
Unknown 1.06 (0.74 - 1.53) 0.742 
Tumour grade 
Good 0.85 (0.54 - 1.34) 0.480 
Average 0.96 (0.76 - 1.20) 0.715 
Poor 1.00 (reference) 
Unknown 0.67 (0.50 - 0.90) 0.008 
Tumour location 
Fundus and corpus 1.12 (0.89 - 1.41) 0.330 
Antrum and pylorus 1.00 (reference) 
Diffuse 1.45 (1.01 - 2.08) 0.043 
Unknown 1.12 (0.69 - 1.81) 0.647 
Neoadjuvant chemotherapy 
No 1.00 (reference) 
Yes 0.76 (0.61 - 0.94) 0.011 
Radicality of operation 
R0 1.00 (reference) 
R1/R2 0.82 (0.61 - 1.12) 0.216 
Unknown 0.89 (0.50 - 1.59) 0.695 
Type of resection 
Total gastrectomy 1.50 (1.19 - 1.89) 0.001 
Partial gastrectomy 1.00 (reference) 
No resection 9.80 (3.03 - 31.67) < 0.001 
Urgency of surgery 
Elective 1.00 (reference) 
Urgent/emergency 1.18 (0.74 - 1.87) 0.481 
 
Values in parentheses are 95 per cent confidence intervals. 
 
Age was not associated with mortality (Table 4). Factors associated with mortality were 
ASA grade, type of resection and neoadjuvant chemotherapy. 
 
Table 4 Multivariable logistic regression analysis of factors influencing 30-day or in hospital mortality. 
 
 
Odds ratio P 
 
 
 
 
 
 
Table 3 continues on next page 
 
Age (years) 
< 70 1.00 (reference) 
≥ 70 1.56 (0.99 - 2.46) 0.057 
Neoadjuvant chemotherapy 
No 1.00 (reference) 
Yes 0.57 (0.36 - 0.90) 0.016 
Table 4 continues on next page 
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pM1 1.17 (0.80 - 1.71) 0.421 
   
   
   
   
   
   
   
   
   
   
   
   
 
pN0 1.00 (reference)  
pN1 1.17 (0.90 - 1.54) 0.232 
pN2 1.03 (0.77 - 1.38) 0.801 
pN3 1.21 (0.90 - 1.61) 0.197 
Unknown 0.90 (0.48 - 1.70) 0.755 
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Continuation of table 4 
Values in parentheses are 95 per cent confidence intervals. 
 
Discussion 
 
This nationwide study showed that patients aged 70 years or older were less often treated 
with chemotherapy and more likely to undergo partial gastrectomy with fewer lymph 
nodes retrieved. These patients had significantly higher 30-day postoperative mortality and 
morbidity rates than younger patients. Multivariable analysis showed that patients aged 70 
years or more had a significantly higher chance of developing complications, but age had 
no influence on 30-day mortality rates. Multivariable analyses identified ASA grade, type  
of resection and treatment with neoadjuvant chemotherapy as the best overall predictors 
of postoperative morbidity and death in the overall cohort of patients with gastric cancer. 
Previous studies of age-related differences in treatment and postoperative outcome in 
gastric cancer were often based on relatively small cohorts in Asia. The vast majority of 
these studies concluded that age alone was not a good predictor of postoperative outcome. 
However, most studies failed to address a good alternative for pre-operative risk assessment 
by multivariable analysis of patient, tumour and treatment characteristics. In line with the 
present results, Shin and colleagues12 reported that older age (at least 70 years) and BMI were 
independent risk factors for the occurrence of complications. Here, BMI below 18.5 kg/m2 
was also an independent risk factor for complications in the entire cohort. 
The literature is ambiguous when it comes to the possible influence of co-morbidities on 
postoperative outcomes. Some studies suggested an independent effect of co-morbidity on 
postoperative complications, but others did not find the number of co-morbidities to influence 
 
postoperative outcome.1,12,14,15 In the present study, the absolute number of co-morbidities 
did not affect postoperative outcome, but ASA grade had a strong influence on morbidity and 
mortality. This is supported by other studies25,26, in which ASA grade above II was identified 
as a prognostic factor for complications. 
A difficulty with using ASA grade in preoperative risk assessment is the limited 
interobserver reliability.27,28 Several studies have shown a moderate level of agreement 
between raters in assigning ASA grade. The k value ranged from 0.4 to 0.6 and did not increase 
with a higher level of training for anaesthesiologists.27,28 The present study showed a marked 
difference in risk of morbidity and mortality between ASA II and ASA III grades. Assigning 
patients to ASA I–II or ASA III–V groups might result in higher interobserver reliability and 
improved preoperative risk assessment. A similar difficulty exists in assigning an absolute 
number of co-morbidities to a patient, or assigning a co-morbidity score such as the Charlson 
co-morbidity index.29 
Shin and colleagues12 reported that type of resection was not associated with postoperative 
complications. Nevertheless, several other studies13,15,16 have underlined the importance of 
limiting the extent of surgery in elderly patients when possible. For instance, Katai and co- 
workers16 showed a significant difference in postoperative mortality and morbidity rates 
after total gastrectomy between young and elderly patients. This age-related difference 
was not seen after partial gastrectomy. Moreover, Lee et al.25 noted that older age (at least 
60 years) and total gastrectomy were independent risk factors for overall complications of 
gastrectomy (OR 1.97, 95 per cent c.i. 1.24 to 3.14). In the present study, patients undergoing 
total gastrectomy had a significantly higher risk of morbidity and death than those having 
partial gastrectomy. 
Following the results of the MAGIC (MRC Adjuvant Gastric Infusional Chemotherapy) 
trial30, perioperative chemotherapy has been the standard treatment in Europe for patients 
with gastric cancer.31 In the present study, patients who received neoadjuvant chemotherapy 
had a significant lower mortality rate. Neoadjuvant chemotherapy obviously does not act as 
a protective agent, but fitter patients more often receive such therapy. Previous observational 
and randomized studies showed that neoadjuvant chemotherapy does not result in less 
morbidity or mortality.30,32 In the MAGIC trial30, no significant difference was seen in rates 
of postoperative complication (45.7 versus 45.3 per cent) or mortality (5.6 versus 5.9 per 
cent) between patients who did or did not receive neoadjuvant chemotherapy. The ability of 
patients to undergo chemotherapy could assist in preoperative risk assessment, as not having 
perioperative chemotherapy was shown to be an independent risk factor for postoperative 
morbidity and mortality in the overall cohort here. 
Multivariable analysis in the present study did not identify any association between 
intention of surgery (palliative versus curative) or urgency of surgery and morbidity or 
mortality. Previous studies11,33,34 with fewer patients suggested that palliative and emergency 
resections had substantially higher rates of postoperative morbidity and mortality. Here, 
urgency and intention of surgery only had a significant impact in univariable analysis. This 
effect disappeared in multivariable analysis. However, most studies failed to address a good 
alternative for pre-operative risk assessment by multivariable analysis of patient, tumour 
and treatment characteristics. A palliative gastrectomy could improve survival and quality 
Pathological tumour stage   
0–I 1.00 (reference)  
II–III 1.80 (1.00 - 3.24) 0.050 
IV 1.49 (0.58 - 3.83) 0.651 
Unknown 1.56 (0.68 - 3.62) 0.693 
ASA grade   
I 1.00 (reference)  
II 2.38 (0.84 - 6.75) 0.104 
III 5.87 (2.07 - 16.69) < 0.001 
IV–V 18.04 (4.37 - 74.39) < 0.001 
Type of resection   
Total gastrectomy 1.84 (1.19 - 2.84) 0.006 
Partial gastrectomy 1.00 (reference)  
No resection 2.23 (0.98 - 5.06) 0.056 
Urgency of surgery   
Elective 1.00 (reference)  
Urgent/emergency 1.34 (0.68 - 2.65) 0.396 
Intention of surgery   
Curative 1.00 (reference)  
Palliative 1.58 (0.78 - 3.20) 0.207 
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of life, but is nowadays performed rarely in the Netherlands, possibly owing to the perceived 
high risk of morbidity and death.35 
This study has some limitations. First, data in the DUCA database are reported by hospitals 
and surgeons, and not by specially trained and independent registration clerks. Independent 
and trained personnel could potentially create a more reliable database. No data are available 
on the exact type and severity of co-morbidity. Nor is there any information on the grounds 
for administering or refraining from using a specific treatment. For instance, the lower rate 
of chemotherapy in elderly patients could be due to co-morbidity or the unwillingness of 
some patients to undergo chemotherapy. Previous research36 showed that not only patient- 
and tumour-related factors but also hospital-related factors lead to variation in treatment. 
Another limitation is that the DUCA database does not contain any information about frailty. 
This would be a valuable addition for the present study, as the predictive value of age alone 
might not encompass the complex condition of elderly patients. Finally, the DUCA database 
does not provide data on long-term survival, which is a limitation for this study. 
The main strength of this population-based study is size of the study population. This 
made it possible to carry out a thorough investigation of age-related differences in short- 
term postoperative outcomes for Caucasian patients with gastric cancer, and to identify 
independent risk factors for postoperative morbidity and death after gastrectomy. 
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Abstract 
 
Introduction: 
This study investigates the treatment and survival of young vs. elderly potentially curable 
gastric cancer patients in the Netherlands. 
 
Methods: 
All non-cardia gastric cancer patients with potentially curable gastric cancer according to 
stage (cTx-3, cNx-3, and cMx-0) diagnosed between 1989 and 2013 were selected from  
the Netherlands Cancer Registry. Trends in treatment and overall survival were compared 
between young (<70 years) and elderly patients (≥70 years). Multivariable logistic regression 
analysis was used to examine the probability of undergoing surgery and chemotherapy in the 
most recent period. Multivariable cox regression analysis was used to identify independent 
factors associated with survival. 
 
Results: 
8,107 young and 13,814 elderly gastric cancer patients were included. There was a major 
increase in patients treated with resection and chemotherapy since 2004-2008. In young 
patients this increased from 2.6 per cent in 1999-2003 to 63 per cent in 2009-2013 (P<0.01). 
Also an increase was noticed among elderly patients, from 0.1 per cent to 16 per cent, 
respectively (P<0.01). Median survival increased from 2004-2008 onwards particular in 
young patients and to a lesser extent in elderly patients(from 28 to 41 months vs. from 11 to 
13 months). Multivariable Cox regression analyses confirmed that overall survival improved 
for young and elderly patients. 
 
Discussion:                                                                                                                                             
Young patients experienced a stronger improvement in survival than elderly patients, resulting 
in an increasing survival gap. Literature shows it not only to be a problem in the Netherlands, 
but throughout Europe. The dissimilarity in treatment between young and elderly patients 
could be the reason for this difference. 
Introduction 
 
Gastric cancer is a disease of the elderly with almost 60 per cent of all patients being over 70 
years of age in 2015.1 Since elderly patients are often not included in clinical trials, evidence- 
based guidelines are mainly based on results of treatment in young patients. Therefore, the 
best treatment in the fit or frail elderly with gastric cancer, and the distinction with young 
patients remains unclear.2-4 
The care for elderly gastric cancer patients differs in various aspects compared to young 
patients. One of the most important differences is the large and growing prevalence of 
comorbidity in elderly people; 72 per cent of the male patients aged over 80 years suffers from 
comorbidity.5 As a result, elderly patients are considered less often to be able to undergo a 
(partial) gastrectomy, despite the fact that a curative resection offers the only chance for cure. 
The high prevalence of comorbidity also results in increasing 30-day post-operative mortality 
rates being more than 10 per cent in elderly (≥74 year) gastric cancer patients, compared 
to less than 5 per cent for patients under 65 years of age.5,6 Furthermore, previous studies 
suggested that elderly gastric cancer patients often have a more advanced stage of disease 
and a larger proportion of cardia cancers, which are associated with a poorer prognosis.7-9 
Among other reasons this might have led to the increasing survival difference between older 
and young patients in Europe in a previous study.10 
Outcome for gastric cancer patients remains poor, and until recently the 5-year relative 
survival rate of gastric cancer had not improved in any age group.11-14 In order to improve 
survival, the treatment of gastric cancer patients in the Netherlands has changed in recent 
years. This included centralization of gastric cancer surgery with a minimal annual volume 
of 20 gastrectomies, and an increased use of (neo-)adjuvant chemotherapy. 
It is unclear if survival has improved through changing management of gastric cancer  
in the Netherlands, and it is not known to what extent the variation in treatment between 
young and elderly patients resulted in an age-related survival difference. This study, therefore, 
investigates treatment patterns and survival for young and elderly patients with potentially 
curable gastric cancer in the Netherlands. 
 
Methods 
 
Data were obtained from the population-based Netherlands Cancer Registry (NCR). This 
registry serves the total Dutch population of approximately 17 million inhabitants. The 
NCR is based on notification of all newly diagnosed malignancies in the Netherlands by the 
national automated pathological archive (PALGA). Additional sources are the national registry 
of hospital discharge and radiotherapy institutions. Information on diagnosis, staging and 
primary treatment is routinely extracted from the medical records by specially trained data 
managers of the NCR. The information on vital status is obtained by an annual linkage with 
the Municipal Administrative Databases, which registers all deceased and emigrated persons 
in the Netherlands. 
Topography and morphology were coded according to the International Classification 
of Diseases for Oncology (ICD-O-3).15 Distribution of the location in the stomach is divided 
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as follows: proximal / middle (fundus, corpus, lesser and greater curvature (C16.1, C16.2, 
C16.5, and C16.6)), pyloric and antrum (C16.3, C16.4), and overlapping or not otherwise 
specified (C16.8, C16.9). Tumour staging was performed according to different versions of 
UICC TNM classifications, but all records were recoded to the 5th UICC TNM classification.16 
For clinical UICC TNM N-classification, we used only N0 or N+ stadium, since reliability of 
evaluating exact pre-operative N-stadium is low.17 To calculate tumour stage, the pathological 
TNM classification was used, if this was unknown a clinical TNM classification was used. 
For this study we selected all patients with non-cardia gastric cancer diagnosed in the 
period 1989-2013, who had no clinically distant metastases (UICC TNM Classification cM0 or 
cMx). Tumour size was limited to tumours penetrating up to the serosa without invasion of 
adjacent structures on clinical examination (cT0-3 or cTx according to UICC TNM 5). These 
patients were considered as potentially curable according to their clinical TNM classification. 
Patients were analysed per age group (<70 years vs. ≥70 years) according to the limits 
Results 
 
The number of patients with potentially curable non-cardia gastric cancer compared to all 
patients with non-cardia gastric cancer is demonstrated in table 1. In total, 21,867 (58 per 
cent) patients with potentially curable non-cardia gastric cancer were selected from 38,004 
patients with non-cardia gastric cancer. Not only the total number of patients decreased, 
but also the percentage of young patients with potentially curable non-cardia gastric cancer 
decreased from 57 per cent in 1989-1993 to 48 per cent in 2009-2013, whereas in the elderly 
patients this decreased from 63 per cent to 57 per cent. 
Table 1 The ratio between all non-cardia gastric cancer patients and the amount of patients with 
potentially curable gastric cancer (cTx-3, cNx-3, cMx-0) in the Netherlands according to age group and 
period of diagnosis 
 
 
Young (<70 years) Elderly (≥ 70 years) Total 
proposed by the European Society of Medical Oncology and the Dutch clinical guideline.5,18  All Curative (%)  All Curative (%)  All Curative (%) 
 1989-1993 3825 2191(57)  5482 3467(63)  9307 5658(60) 
Statistical analysis 1994-1998 3209 1758(55)  4881 3013(62)  8090 4771(59) 
Descriptive statistics were used to characterize the patients younger and older than 70 years. 1999-2003 2916 1481(51)  4425 2710(61)  7341 4191(57) 
Bar graphs were made to assess the variation in treatment modalities and tumour stage 2004-2008 2657 1354(51)  4038 2383(59)  6695 3737(55) 
throughout the years for young and elderly patients. Univariable and multivariable logistic 2009-2013 2676 1294(48)  3895 2216(57)  6571 3510(54) 
regression analyses were performed for young and elderly patients to examine the influence Total 15283 8095(53)  22721 13789(61)  38004 21867(58) 
of different clinicopathological factors to receive surgery and chemotherapy in the period          
2009-2013. As the treatment paradigm for gastric patients changed over time, we decided 
that investigating the factors related to treatment decisions was most interesting for recent 
patients. Therefore the logistic regression analyses were limited to patients diagnosed in the 
period 2009-2013. 
Survival time was defined as time from diagnosis to death or until February 1st 2016 for 
patients who were still alive. Kaplan Meier curves were generated to examine the overall 
survival for young and elderly patients over sequential periods of time. The difference       
in median overall survival between young and elderly patients over time was calculated. 
Multivariable Cox regression analyses were performed for young and elderly patients to 
investigate the influence of various patient-, tumour- and treatment specific variables on 
overall survival over time. Results from survival analyses using Cox regression analyses were 
The patient and tumour characteristics of the patients with potentially curable disease are 
presented in table 2. Compared to younger patients, elderly patients were more often female. 
Tumour location of elderly patients was more often specified as not otherwise specified or 
overlapping (27 per cent vs 32 per cent, P<0.05). Young patients were more often diagnosed 
with a poorly or undifferentiated tumour (55 per cent vs. 47 per cent, P<0.05) or a signet cell 
carcinoma (25 per cent vs. 15 per cent, P<0.05). Elderly patients more often underwent no 
resection or no chemotherapy (39 per cent) in contrast to the young patients (10 per cent, 
P<0.05) and as a result were more often staged with an unknown pT, pN and pM-stage. 
 
Table 2 Patient characteristics of patients with potential curable (cTX-3, cNx-3, cMx-0) non-cardia gastric 
cancer diagnosed between 1989 and 2013 by age. 
 
 
reported as hazard ratios (HR) and 95 per cent confidence intervals (c.i.). Reported p values 
of <0.050 were considered statistically significant. All analyses were conducted using IBM 
Young 
(<70 years) 
% Elderly 
(≥ 70 years) 
% Total % 
N=21.867 
SPSS Statistics Version 23 (International Business Machines Statistical Package for the Social  N=8.095  N=13.789  
Sciences). Mean age in years (min-max) 
Sex 
59.0 (13-69)  79.4 (70-103)  71.9(13-103)  
 Male ( %) 5152 64 7733 56 12885 59 
 Female (%) 2926 36 6056 44 8982 41 
Table 2 continues on next page 
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Continuation of table 2  
In young patients the proportion of patients receiving neither surgery nor chemotherapy 
remained stable over sequential years (9.5 per cent vs. 8.6 per cent, P=0.23). For elderly 
patients this percentage increased significantly, i.e. between 1989-1993 35 per cent of all 
elderly patients did not undergo surgery or chemotherapy, whereas this percentage increased 
to 42 per cent in the period 2009-2013 (P<0.01) (figure 1). In both the young and elderly 
patients there was a strong increase in the number of patients treated with resection and 
chemotherapy since 2004-2008; in young patients this percentage increased from 2.6 per 
cent in 1999-2003 to 63 per cent in 2009-2013 (P<0.01), whereas a smaller increase was 
noticed among the elderly patients, from 0.1 per cent to 16 per cent (P<0.01). 
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Figure 1 Treatment modality according to year of diagnosis for young (Figure 1A) and elderly patients 
(Figure 1B) with potentially curable non-cardia gastric-cancer 
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pT-stage       
0/1 1404 17 1509 11 2913 13 
2 2940 36 3796 28 6736 31 
3 2062 26 2393 17 4455 20 
4 395 4.9 415 3.0 810 3.7 
Unknown 1227 16 5676 41 6903 32 
pN-stage       
0 2592 32 3025 22 5617 26 
1 2405 30 2793 20 5198 24 
2 1023 13 1050 7.6 2073 9.5 
3 247 3.1 250 1.8 497 2.3 
Unknown 1811 22 6671 48 8482 39 
pM-stage       
0 3819 47 4651 34 8470 39 
1 280 3.5 271 2.0 551 2.5 
Unknown 3797 49 8867 64 12664 58 
Tumour location       
Proximal and middle 2621 32 3866 28 6487 30 
Fundus and antrum 3260 40 5465 40 8725 40 
NOS and overlapping 2214 27 4471 32 6685 31 
Tumour grade       
Well differentiated 266 3.3 517 3.7 783 3.6 
Moderately differentiated 1444 18 3263 24 4707 22 
Poorly or undifferentiated 4466 55 6545 47 11011 50 
Unknown 1919 24 3477 25 5396 25 
Tumour morphology       
Adenocarcinoma 5162 64 10614 77 15776 72 
Non-adenocarcinoma 389 4.8 558 4.0 947 4.3 
Linitis plastica 504 6.2 579 4.2 1083 5.0 
Signet ring carcinoma 2040 25 2051 15 4091 19 
Treatment group       
No resection. no chemotherapy 813 10 5425 39 6238 29 
Resection 5698 70 7733 56 13431 61 
Chemotherapy 320 4.0 174 1.3 494 2.3 
Resection and chemotherapy 1264 16 470 3.4 1734 7.9 
Hospital of diagnosis       
University 638 7.9 751 5.4 1389 6.4 
Training hospital 4771 59 8186 59 12957 59 
Non-training hospital 2669 33 4852 35 7521 34 
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There were only minor, non-significant differences in tumour stage distribution through 
the years. A shift from stage I to stage II was seen in both young and elderly patients with 
gastric cancer. Between 1989-1993 40 per cent and 25 per cent of all young gastric cancer 
patients had respectively stage I and stage II disease. Between 2009-2013 stage I decreased 
towards 34 per cent, and stage II increased towards 36 per cent. A similar trend was seen in 
elderly patients (figure 2). 
Table 3 Multivariable logistic regression analysis on the influence of different clinicopathological factors 
on the probability to undergo surgery and chemotherapy between 2009-2013 for young and elderly 
patients with potentially curable non-cardia gastric cancer. 
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Figure 2 Pathological tumour stage distribution by year of diagnosis for young (Figure 2A) and elderly 
patients (Figure 2B) with potentially curable non-cardia gastric-cancer 
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YOUNG (<70 years) ELDERLY (≥ 70 years) 
 OR 95 per cent c.i. Sig.  OR 95 per cent c.i. Sig. 
  Lower Upper    Lower Upper  
Sex          
Male  Ref.    Ref.  
Female 0.93 0.73 1.20 0.58  0.84 0.62 1.12 0.23 
Age 0.97 0.96 0.99 <0.01  0.74 0.71 0.76 <0.01 
Year of diagnosis          
2009  Ref.    Ref.  
2010 0.81 0.55 1.20 0.30  1.17 0.74 1.86 0.50 
2011 1.09 0.73 1.62 0.68  1.29 0.82 2.03 0.27 
2012 1.01 0.69 1.49 0.94  1.22 0.77 1.94 0.40 
2013 0.98 0.66 1.46 0.94  1.33 0.84 2.11 0.22 
cT-stage          
0/1 0.18 0.10 0.32 <0.01  0.32 0.16 0.65 <0.01 
2  Ref.    Ref.  
3 0.67 0.36 1.26 0.22  1.10 0.50 2.42 0.81 
Unknown 0.64 0.49 0.84 <0.01  0.60 0.45 0.81 <0.01 
cN-stage          
0  Ref.    Ref.  
+ 1.08 0.82 1.44 0.58  1.14 0.83 1.58 0.41 
Unknown 0.54 0.38 0.77 <0.01  0.43 0.27 0.68 <0.01 
Tumour morphology          
Adenocarcinoma  Ref.    Ref.  
Non-adenocarcinoma 1.13 0.73 1.73 0.58  0.87 0.51 1.49 0.61 
Linitis Plastica 0.92 0.56 1.53 0.76  0.71 0.37 1.35 0.30 
Signet ring carcinoma 1.06 0.78 1.44 0.69  1.16 0.81 1.65 0.42 
Tumour grade          
Well differentiated 0.30 0.11 0.82 0.02  0.46 0.15 1.45 0.19 
Moderately differentiated 0.56 0.38 0.84 0.01  0.66 0.44 1.01 0.06 
Poorly and undifferentiated  Ref.    Ref.  
Unknown 1.01 0.78 1.31 0.96  1.15 0.85 1.56 0.36 
Tumour location          
Proximal and middle  Ref.    Ref.  
Fundus and antrum 0.89 0.67 1.18 0.42  0.57 0.41 0.79 <0.01 
NOS and overlapping 0.60 0.43 0.85 <0.01  0.79 0.55 1.12 0.18 
Diagnosing hospital          
University 0.40 0.26 0.62 <0.01  0.60 0.33 1.07 0.08 
Training hospital  Ref.    Ref.  
Non-training hospital 1.16 0.89 1.51 0.27  1.12 0.83 1.50 0.46 
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The results of the multivariable logistic regression analyses on the chance of being treated 
with resection and chemotherapy in the period 2009-2013 are presented in table 3. The 
factors that significantly influenced the chances of receiving chemotherapy and a resection 
were mostly the same for the young and the elderly patients. In both age groups there was a 
 
Patients with potentially curable gastric cancer who underwent surgery and chemotherapy 
had the best 5-year overall survival rates of 47 per cent and 39 per cent for the young and elderly 
patients, respectively (figure 4). Patients who did not receive resection or chemotherapy or 
who only received chemotherapy had the worst survival. 
decreased chance of undergoing chemotherapy and surgery with increasing age and lower 
cT-stage (cT0/1 vs. cT2). Also in young patients, tumours with a favourable histological grade, 
overlapping or not otherwise specified tumours and patients diagnosed in an academic 
hospital had a lower chance of receiving chemotherapy and surgery. Elderly patients with a 
tumour of the fundus or antrum had a significant lower chance of undergoing both treatment 
options. 
Median overall survival over time for both age groups of patients treated with curative 
intent is presented in figure 3. Median survival of patients under 70 years of age increased 
from 30.3 months between 1989-1993 to 40.5 months between 2009-2013(P<0.01). For 
elderly patients this was 10.7 months and 13.1 months respectively (P<0.01). Additionally 
performed survival analyses on all non-cardia gastric cancer patients (i.e. patients treated with 
curative and palliative intent) in the Netherlands between 1989-2013 showed a significant 
improvement of overall survival for all gastric cancer patients from 7.6 months between 
1989-1993 to 8.4 months between 2009-2013 (P<0.01) (data not shown). 
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Figure 3 Median survival per period of diagnosis for patients with potentially curable non-cardia gastric- 
cancer and the difference between both age groups. 
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Figure 4 Kaplan Meier 5-year overall survival curve per treatment method for young (Figure 4A) and 
elderly patients (Figure 4B) with potentially curable non-cardia gastric cancer 
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Multivariable Cox regression confirmed the improved survival over time (table 4). In 
young patients survival improved since 2004-2008, with a hazard-ratio (HR) of 0.74 (95 
per cent c.i. 0.65 to 0.83) in 2009-2013 compared to 1989-1993. For the elderly patients the 
Continuation of table 4 
 
 
YOUNG (<70 years) ELDERLY (≥ 70 years) 
HR       95.0 per cent c.i.   Sig. HR 95.0 per cent c.i. Sig. 
survival improved since 1999-2003, with a HR of 0.85 (95 per cent c.i. 0.80 to 0.90). Others 
factors that significantly affected overall survival were gender, age, pathological T, N and M 
stage, tumour location, morphology and grade, treatment and type of diagnosing hospital, 
with only limited differences between young and elderly patients. 
 
Table 4 Cox regression analyses on the influence of different clinicopathological factors on overall 
survival in young and elderly patients with potentially curable non-cardia gastric cancer. 
YOUNG (<70 years) ELDERLY (≥ 70 years) 
  Lower     Upper Lower Upper  
Tumour morphology 
Adenocarcinoma Ref. Ref. 
 
Non-adenocarcinoma 1.25 1.10 1.41 <0.01 1.20 1.09 1.31 <0.01 
Linitis plastica 1.79 1.61 1.99 <0.01 1.47 1.34 1.60 <0.01 
Signet ring carcinoma 1.07 1.00 1.14 0.05 1.11 1.05 1.16 <0.01 
Tumour grade 
Well differentiated 1.03    0.90 1.20 0.65 0.84    0.76 0.92 <0.01 
Moderately differentiated 0.90    0.84 0.97 <0.01 0.90    0.86 0.94 <0.01 
 HR   95.0 per cent c.i. Sig.  HR   95.0 per cent c.i. Sig.  Poorly and undifferentiated  Ref.    Ref.  
 Lower Upper    Lower Upper   Unknown 0.94 0.88 1.01 0.08 0.86 0.82 0.90 <0.01 
Sex         Treatment         
Male  Ref.    Ref.   No resection/No chemotherapy   Ref.    Ref.  
Female 0.92 0.88 0.98 <0.01  0.83 0.80 0.86 <0.01  Resection 0.25 0.21 0.30 <0.01 0.42 0.37 0.48 <0.01 
Age 1.03 1.02 1.03 <0.01  1.03 1.02 1.03 <0.01  Chemotherapy 0.92 0.80 1.05 0.21 0.99 0.85 1.16 0.93 
Year of diagnosis         Resection and chemotherapy 0.20 0.17 0.25 <0.01 0.30 0.25 0.36 <0.01 
1989-1993  Ref.    Ref.   Diagnosing hospital         
1994-1998 1.01 0.94 1.08 0.82  1.01 0.96 1.06 0.69  University 0.79 0.71 0.88 <0.01 0.84 0.77 0.91 <0.01 
1999-2003 0.97 0.90 1.05 0.46  0.90 0.85 0.95 <0.01  Training Hospital   Ref.    Ref.  
2004-2008 0.90 0.83 0.99 0.02  0.85 0.80 0.90 <0.01  Non-training hospital 0.97 0.92 1.02 0.26 1.03 1.00 1.07 0.08 
2009-2013 0.74 0.65 0.83 <0.01  0.72 0.67 0.76 <0.01  (NOS = not otherwise specified)         
pT-stage                  
0/1 0.36 0.33 0.40 <0.01  0.56 0.51 0.60 <0.01  Discussion         
2  Ref.    Ref.            
3 0.72 0.67 0.77 <0.01 0.78 0.73 0.82 <0.01 This study is the first study to show a significantly improved overall survival for patients with 
4 1.32 1.17 1.49 <0.01 1.35 1.20 1.51 <0.01 potentially curable non-cardia gastric cancer in the Netherlands in recent years. Improvement 
Unknown 1.14 0.97 1.33 0.11 1.32 1.17 1.50 <0.01 of overall survival was more pronounced in young patients, which led to an increasing 
pN-stage 
0 Ref. Ref. 
1 1.74 1.62 1.86 <0.01 1.54 1.46 1.64 <0.01 
2 2.28 2.09 2.49 <0.01 2.09 1.94 2.26 <0.01 
3 2.98 2.54 3.49 <0.01 2.42 2.09 2.80 <0.01 
Unknown 1.08 0.96 1.21 0.21 1.18 1.09 1.27 <0.01 
pM-stage 
0 Ref. Ref. 
1 1.92 1.69 2.18 <0.01 1.83 1.61 2.07 <0.01 
Unknown 0.96 0.90 1.02 0.16 1.05 1.00 1.10 0.05 
Tumour location 
Proximal and middle Ref. Ref. 
Fundus and antrum 1.09    1.03 1.16 0.01 1.04    1.00 1.09 0.05 
     NOS and overlapping 1.26    1.18 1.35 <0.01 1.23    1.17 1.28 <0.01  
Table 4 continues on next page 
survival difference between young and elderly patients with potentially curable non-cardia 
gastric cancer. Both young and elderly patients were increasingly treated with surgery and 
chemotherapy. 
A lack of improvement in survival was reported in various previous studies throughout 
the world. Previous Dutch and Japanese studies did not show any improvement of survival 
for stage I-III gastric cancer patients.11,13,14,19 In the present study median overall survival 
improved in potentially curable patients with 34 per cent in young patients and 23 per cent 
in elderly patients between 1989-2013, which was comparable to a previous large European 
study.20 
There are several possible explanations for the improvement of survival in potentially 
curable non-cardia gastric cancer patients. First, it might be caused by stage migration, 
because patients who were previously diagnosed with non-metastasized disease, might 
nowadays be diagnosed with metastasized disease possibly due to the improvement of pre- 
operative diagnostic imaging. This would consequently lead to a group of potentially curable 
5 5 
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patients with a better prognosis. Nevertheless, this study showed that survival analysis     
of all non-cardia gastric cancer patients (both non-metastasized and metastasized) also 
improved significantly, which indicates that stage migration cannot be the only cause for the 
improvement in survival. 
An additional explanation for the improvement of overall survival in potentially curable 
non-cardia gastric cancer patients can be the effect of centralization of gastric cancer surgery 
in the Netherlands. Although the beneficial effect of centralization of gastric surgery on long- 
term survival has not been proven so far, it is thought to improve outcome after gastrectomy. 
21,22 Since 2012 gastrectomies in the Netherlands have been centralized to a minimum of 10 
per hospital per year and as of 2013 to a minimum of 20 per year. In this study, overall survival 
already started to improve before 2012, indicating that the introduction of the minimal annual 
volume norm is also not the only cause of improvement of survival but it could partly explain 
the survival benefit of recent years. 
Data of the Magic trial reported better survival rates for patients who received 
perioperative chemotherapy and surgery compared to surgery alone for gastric cancer. Since 
2006 chemotherapy is increasingly being used in the Netherlands.13,23 Since then two meta- 
analyses on the effect of adjuvant and neo-adjuvant chemotherapy on overall and disease 
free survival have demonstrated a positive effect on survival.24,25 In the present study a strong 
increase in the use of chemotherapy was observed in the Netherlands, in particular in young 
patients. This increased use of perioperative chemotherapy might be an important factor in 
the improved survival demonstrated in recent years. 
Apart from increased overall survival in young and elderly patients, the present study 
showed an increasing survival gap between young and elderly patients. When these results 
are put into an European perspective, a similar result was observed in a large number of 
population-based Cancer Registries throughout Europe.26,27 10 The EUROCARE IV and V 
studies as well as the EUROCARE study on age related survival differences, showed not only 
a significant improved overall survival but also an increased survival difference between 
young and elderly patients.10,26,27 
The present study observed an even greater increase in overall survival difference of 
young compared to elderly patients compared to the EUROCARE studies, especially in recent 
years. Among other reasons, this might be caused by differences in treatment between young 
and elderly patients. Noticeable is the proportion of patients who received no surgery or no 
chemotherapy at all. In young patients this proportion of patients remained stable around 10 
per cent in the last 20 years. For elderly patients this percentage increased significantly from 
35 per cent to 42 per cent in the same period. An explanation for this increasing percentage 
might be the better understanding of age-related differences in treating gastric cancer. Many 
studies have reported potential risks of surgery and/or chemotherapy in elderly patients, 
which could have withheld clinicians from treating patients over 70 years of age.28,29 
On the other hand, the percentage of patients receiving both surgery and chemotherapy 
increased in both age groups, but to a much lesser extent in elderly patients. Patients treated 
with both chemotherapy and resection have the highest survival rate in the present study. 
However, there most likely is a selection bias, as fitter patients are more likely to being treated 
more extensively. 
 
It remains unclear whether omitting any form of treatment is caused by good clinical 
judgement or because of the clinicians’ assumption that chronological age makes elderly 
patients unfit for therapy.10 Previous studies based on data from the Netherlands Cancer 
Registry showed a large variation in the probability of receiving surgery, ranging from 53 per 
cent to 83 per cent according to hospital of diagnosis between 2005-2013.33,12 This suggests 
that treatment regimen is not only determined by patient- and/or disease specific items. This 
variation significantly impacted survival.33 Furthermore, the chance to receive (neo)-adjuvant 
treatment also varied between regions. Depending on the region of treatment the odd ratio 
of receiving (neo)-adjuvant treatment ranged from 0.7 to 4.5.12 
Limitations of this study are the lack of data on comorbidity, performance status and the 
possible contributing reasons to forgo surgery or chemotherapy. These items are known to 
impact treatment choice and survival. We were, however, unable to adjust for these items 
in our analyses since these items are not routinely collected by the NCR on a national level. 
The main strength of the study is the size of the study population and the fact that it is 
based on nationwide population-based data which makes it possible to investigate trends 
in treatment, survival and influence of various clinicopathological items on treatment and 
survival, representing daily clinical practice. 
In conclusion, overall survival of potentially curable non-cardia gastric cancer patients 
has significantly improved over the last years. Especially young patients showed a strong 
improvement of survival, a trend which is seen throughout Europe.26,27 This strong 
improvement of overall survival could be caused by a higher proportion of patients receiving 
both surgery and chemotherapy. Besides, further research will be needed in order to improve 
survival in (frail) elderly gastric cancer patients, to prevent a further increasing survival gap 
between young and elderly gastric cancer patients. 
5 5 
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Abstract 
 
Introduction: 
To predict prognosis of gastric cancer, an adequate assessment of the stage of gastric cancer 
is important. The UICC/AJCC TNM-classification is the most commonly used classification 
system. For adequate N-staging at least 15 lymph nodes should be retrieved. In some countries, 
this amount of lymph nodes is not met, which can lead to under staging. Therefore, the lymph 
node ratio (LNR) is proposed as an alternative N-staging modality. The purpose of this study 
was to compare the different staging modalities. 
 
Methods: 
We included all patients who underwent surgery for gastric cancer, newly diagnosed between 
2000-2009 and staged patient by UICC/AJCC TNM 5th/6th or 7th and by lymph node ratio. We 
conducted crude survival analysis, univariate and multivariate analyses of according to the 
different staging systems. 
 
Results: 
The 5-year overall survival rates ranged from 58 per cent for N0 disease to 18 per cent in case 
of more than 15 metastatic lymph nodes. The distribution of overall 5-year survival according 
to LNR was 58 per cent for LNR0 and 10 per cent for LNR3. Univariate analysis showed that all 
the UICC/AJCC TNM classification systems as well as the LNR were strong prognostic factors 
for overall survival. The LNR correlated less with the number of nodes examined. 
 
Discussion: 
LNR is a good prognostic tool for overall survival, it is an independent prognostic factor with a 
more homogenous spread of hazard ratios and 5-year survival rates than UICC/AJCC systems. 
Furthermore, the LNR has a lower correlation with the number of nodes examined, making 
it less vulnerable for stage migration. 
Introduction 
 
Gastric cancer is the fourth most common type of cancer worldwide and ranks second with 
respect to cancer-related death in Europe.1 In 2009, nearly 2000 people were newly diagnosed 
and almost 1500 patients died from gastric cancer.2 Although incidence and mortality rates 
are decreasing, survival is worsening.3 To predict prognosis the assessment of the stage of 
gastric cancer is important. 
The number of metastatic lymph nodes is considered to be the most reliable prognostic 
indicator for patients with radically resected gastric cancer.4 In 1968 the Union Internationale 
Contra le Cancer (UICC) founded the UICC/AJCC TNM (Tumour Node Metastasis)-classification 
system for malignant tumours. Several versions of this classification system have been used. 
The Japanese Gastric Cancer Association developed another classification for gastric cancer, 
however the UICC/AJCC is the superior and most commonly used classification system.5 
However, the difficulty of the UICC/AJCC TNM-classification is that for adequate N-staging 
at least 15 lymph nodes should be retrieved. Literature expresses that in some Western 
countries including the Netherlands, this amount of lymph nodes is not met by surgeons or 
pathologists, which can lead to under staging.6 Apart from the UICC/AJCC system, another 
N-staging system was developed, which would not need the required 15 lymph nodes for 
adequate staging, i.e. the so-called metastatic lymph node ratio (LNR). The purpose of this 
study is to compare the different UICC/AJCC TNM 5th/6th/7th-staging systems with the LNR 
and to determine which system has the best prognostic value for gastric cancer patients. 
 
Methods 
 
Patients 
Data from the Eindhoven Cancer Registry (ECR) were used, which is maintained and hosted 
by the Comprehensive Cancer Centre South. The ECR collects data on all patients diagnosed 
with cancer in the south of the Netherlands, an area with about 2.4 million inhabitants. The 
ECR is served by ten community hospitals, six pathology departments and two radiotherapy 
institutes. We included 973 surgical patients with M0 primary gastric cancer, newly diagnosed 
between 2000 and 2009. 
Patient characteristics such as gender, date of birth, postal code, co morbidities and 
socio-economic status (SES) as well as tumour characteristics such as date of diagnosis, 
subsite (International Classification of Diseases for Oncology (ICD-O-3)), histology, stage, 
grade and treatment were obtained routinely from the medical records by specially trained 
administrators.7 Follow-up of vital status of all patients was complete up to 1 January 2011. 
In addition to passive follow-up via the hospitals, information was actively obtained from civil 
municipal registries and the Central Bureau for Genealogy. 
Tumour sub-localization was divided as follows: cardia, middle part fundus, corpus, 
lesser and greater curvature, pyloric part, overlapping lesions, and not otherwise specified. 
Furthermore, tumour characteristics included number of lymph nodes examined, number of 
positive nodes, and grade of tumour differentiation. Relevant co-morbidities were recorded 
from the medical records according to a slightly adapted version of the Charlson Index.8 SES 
6 6 
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of the patients was defined at neighbourhood level; postal codes were assigned to one of three 
SES categories: low (1st-3rd decile), intermediate (4th-7th decile), and high (8th-10th decile). 
For patients residing in nursing homes, a special SES category was assigned. 
Registration took place 6 to 18 months after diagnosis. The quality of the data is high, 
due to thorough training of the registration clerks and a variety of computerized consistency 
checks at regional and national levels. Completeness is estimated to be at least 95 per cent.9 
 
Staging 
Patients were classified according to the UICC/AJCC TNM 5th/6th, 7th and to the LNR. LNR is 
defined as the number of positive lymph nodes divided by the total number of lymph nodes 
found in the specimen (Table 1). 
Table 1 The different classification systems 
 
Pre-operative treatment was given to a small proportion of patients and subtotal gastrectomy 
was the most common type of resection. In the majority of patients between 3 and 10 lymph 
nodes were examined (41 per cent) (Table 2). 
Table 2 Descriptives of the study population (n=973) 
 
 
  n % 
Stage UICC/AJCC TNM 5/6 
N-classification 
(number of metastatic 
lymph nodes) 
UICC/AJCC TNM 7 
N-classification 
(number of metastatic 
lymph nodes) 
LNR 
 
(percentage of metastatic 
lymph nodes) 
 
 
 
 
 
 
The LNR cut-off points were based on the most common used cut-off points for the LNR 
used in literature. Second, we compared different cut-off points by means of the distribution 
of patients on the categories and we used survival as an independent variable and determined 
by log-rank test. 
 
Statistical analysis 
Survival was calculated according to the Kaplan-Meier method and compared by log-rank test. 
Survival time was calculated from the date of diagnosis to death or the 1st of January 2011 for 
those alive. Univariate and multivariate analyses of prognostic factors were performed using 
the Cox proportional hazard model. The LNR categories were stratified into UICC/AJCC TNM 
N categories and vice versa. This to assess whether LNR or TNM N-classification shows any 
survival benefit where the opposing staging system fails to predict this. The accepted level of 
significance was P<0.05. The data were analysed using SAS statistical software (SAS system 
9.2, SAS Institute, Cary, NC). 
 
Results 
 
The median age of M0 gastric cancer patients was 69 years (27- 94 years). The majority of 
patients were male and 59 per cent of the patients had one or more co-morbidities. Most 
tumours were found in the antrum and pylorus of the stomach and were poorly differentiated. 
 
Tumour site 
Cardia 183 19 
Middle part 236 24 
Antrum and pylorus 364 37 
Overlapping, unknown 190 20 
Stage 
IA 123 13 
IB 259 27 
II 307 32 
IIIA 213 22 
IIIB 36 4 
IV 35 4 
Differentiation grade 
Moderate/well 275 28 
Poor 563 58 
Unknown 135 14 
Preoperative treatment 
Chemo- and/or radiotherapy 133 14 
None 840 86 
Type of resection 
Table 2 continues on next page 
6 6 
Median age (range) (yrs.) 69 (27-94) 
Gender 
Males 625 64 
Females 348 36 
Socio-economic status 
Low 286 29 
Intermediate 352 36 
High 280 29 
Institutionalized 29 3 
Unknown 26 3 
Comorbidity   
None 320 33 
1 293 30 
≥2 283 29 
Unknown 77 8 
 
0 0  0 0 per cent 
1 1-6  1-2 0.1-19 per cent 
2 7-14  3-6 20-29 per cent 
3 ≥15 A: 7-14 ≥30 per cent 
  B: ≥15  
 
Total gastrectomy 223 59 
Subtotal gastrectomy 571 23 
Oesophageal-cardiac resection 126 13 
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Continuation of table 2 
 
Multi-organ resection 31 3 
Unspecified type of resection 22 2 
Number of lymph nodes evaluated   
0 58 6 
1-2 69 7 
3-6 198 20 
7-10 203 21 
11-14 151 16 
≥15 145 15 
Exact number unknown 145 15 
Unknown 4 0 
Figures 1 and 2 show the crude overall survival according to the UICC/AJCC TNM 5th/6th and 
7th classification systems. The 5-year overall survival ranged from 58 per cent for N0 disease 
to 18 per cent in case of more than 15 metastatic lymph nodes. In stage N1 according to the 
5th/6th TNM classification overall 5-year survival was 19 per cent. In the 7th TNM classification 
the 5th/6th TNM N1 stage is divided in N1 and N2, with a 5-year survival of 27 per cent and 11 
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0 6 12 18 24 30 36 42 48 54 60 
Follow-up (months) 
TNM 7 N-stage 
N0 
N1 
N2 
N3a 
N3b 
per cent respectively. In this cohort of patients having M0 gastric cancer, stage N3b of the 7th 
TNM-classification showed a better prognosis then the N3a stage in terms of overall survival. 
Figure 2 Overall crude survival of M0 gastric cancer patients diagnosed in the ECR region between 2000 
and 2009 according to TNM7 N stage. Log Rank P<0.001 
The distribution of overall crude 5-year survival according to LNR ranged from 58 per cent 
for LNR0 to 10 per cent for LNR3 (Figure 3). 
100 
90 
Lymph node ratio 
LNR0 (0) 
LNR1 (0.1-0.199) 
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
0 
TNM 6 N-stage 
N0 
N1 
N2 
N3 
80 
70 
60 
50 
40 
30 
20 
10 
0 
0 6 12 18 24 30 36 42 48 54 60 
Follow-up (months) 
LNR2 (0.2-0.299) 
LNR3 (>0.3) 
0 6 12 18 24 30 36 42 48 54 60 
Follow-up (months) 
Figure 1 Overall crude survival of M0 gastric cancer patients diagnosed in the ECR region between 2000 
and 2009 according to TNM6 N stage. Log rank p<0.001 
Figure 3 Overall crude survival of M0 gastric cancer patients diagnosed in the ECR region between 2000 
and 2009 according to Nratio. P<0.001 
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Univariate Cox survival showed that either the TNM 5th/6th and 7th classification as well as 
the LNR were strong prognostic factors for overall survival. The univariate analyses showed 
Continuation of table 3 
 
 
      Hazard Ratio (95 per cent c.i.)  
similar results as multivariate analyses after adjustment for relevant patient and tumour 
characteristics listed in table 3. 
  N Model 1 Model 2 Model 3  
Number of lymph nodes examined 
 
 
 
 
 
 
 
 
 
 
 
 
N3a 99 3.56 (2.70 - 4.70)* 
N3b 12 2.54 (1.35 - 4.78)** 
Exact number unknown 49 2.39 (1.68 - 3.41)* 
N ratio 
0 (0) 382 1.0 
1 (0.01-0.19) 87 1.72 (1.25 - 2.37)* 
2 (0.20-0.29) 63 2.54 (1.81 - 3.55)* 
3 (0.30-1.00) 288 3.22 (2.59 - 4.10)* 
Missing 207 2.29 (1.81 - 2.91)* 
Age (yrs.) 
 
In multivariate analysis, the 5th/6th TNM N-stage, age, co- morbidities and 6th TNM T-
stage had an independent effect on survival in the first model. UICC/AJCC 5th/6th TNM N2- 
stage had a higher hazard ratio than N3-stage, 3.48 (95 per cent c.i. 2.64 to 4.59) versus 2.51 
(95 per cent c.i. 1.33 to 4.72). In our models concerning TNM 7th and LNR the aforementioned 
factors also had an independent effect on survival. In the second model UICC/AJCC 7th TNM N2 
and N3a stage had a higher hazard ratio then stage N3b. In the last model the hazard ratios for 
the various LNR stages increased from 1.72 (95 per cent c.i. 1.25 to 2.37) in LNR1 to 3.22 in 
LNR3 (95 per cent c.i. 2.59 to 4.10) (Table 3). This table also shows that patient distribution 
among different classification systems is best in UICC/AJCC TNM 7th. 
<70 491 1.0 1.0 1.0 There was a significant correlation between number of lymph nodes examined and the 
70+ 482 1.25 (1.06 - 1.47)* 1.29 (1.09 - 1.52)* 1.28 (1.08 - 1.51)** UICC/AJCC TNM 7th (correlation coefficient =0.33; P<0.001) or TNM 5th/6th N-classification 
Gender     (correlation coefficient = 0.33; P<0.001). The LNR correlated less but was still significant 
Males 625 1.0 1.0 1.0 (correlation coefficient= 0.11; P=0.0019). 
Females 348 0.92 (0.78 - 1.09) 0.94 (0.80 - 1.12) 0.98 (0.83 - 1.17)  
Comorbidity      
None 320 1.0 1.0 1.0  
1 293 1.23 (1.00 - 1.50)** 1.21 (0.99 - 1.48) 1.18 (0.97 - 1.45)  
2 or more 283 1.51 (1.23 - 1.86)* 1.54 (1.25 - 1.90)* 1.45 (1.18 - 1.78)**  
Unknown 54 1.17 (0.82 - 1.67) 1.20 (0.84 - 1.71) 1.09 (0.76 - 1.56)  
TNM 6 T stage      
T1 152 0.52 (0.38 - 0.70)* 0.54 (0.40 - 0.73)* 0.47 (0.35 - 0.64)*  
T2 528 1.0 1.0 1.0  
T3 255 1.28 (1.07 - 1.52)** 1.28 (1.07 - 1.53)* 1.31 (1.09 - 1.56)**  
T4 35 1.87 (1.28 - 2.74)** 1.97 (1.34 - 2.89)* 1.92 (1.31 - 2.81)**  
 
Table 3 continues on next page 
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<7 325 1.18 (0.98 - 1.42) 1.18 (0.98 - 1.42) 1.00 (0.84 - 1.20) 
Table 3 Overall multivariate survival analysis for M0 gastric cancer patients. Model 1: Multivariate ≥7 499 1.0 1.0 1.0 
analysis with TNM 5/6 N-stage, model 2: Multivariate analysis with TNM 7 N-stage, model 3: Multivariate 
analysis with lymph node ratio. 
Tumour site 
Cardia 
 
183 
 
0.89 (0.65 - 1.22) 
 
0.87 (0.64 - 1.19) 
 
0.90 (0.66 - 1.23) 
Hazard Ratio (95 per cent c.i.) Middle part 236 0.82 (0.66 - 1.02) 0.83 (0.67 - 1.04) 0.84 (0.68 - 1.05) 
 N Model 1 Model 2 Model 3 Pyloric part 364 1.0 1.0 1.0 
TNM 5/ 6 N stage     Other/unknown 190 1.10 (0.87 - 1.38) 1.08 (0.86 - 1.36) 1.03 (0.83 - 1.29) 
N0 387 1.0   Type of resection     
N1 372 2.32 (1.92 - 2.80)*   Total gastrectomy 191 1.18 (0.96 - 1.46) 1.19 (0.96 - 1.47) 1.31 (1.06 - 1.61)* 
N2 99 3.48 (2.64 - 4.59)*   Subtotal gastrectomy 571 1.0 1.0 1.0 
N3 12 2.51 (1.33 - 4.72)*   Oesophageal-cardia resection 126 1.28 (0.91 - 1.81) 1.30 (0.92 - 1.83) 1.41 (1.00 - 1.99) 
Exact number unknown 49 2.35 (1.64 - 3.34)*   Multi-organ resection 31 1.29 (0.83 - 2.00) 1.26 (0.81 - 1.96) 1.43 (0.92 - 2.22) 
TNM 7 N stage     Neoadjuvant treatment     
N0 387 1.0 No 840 1.0 1.0 1.0 
N1 189 1.85 (1.48 - 2.32)* Yes 133 0.99 (0.76 - 1.28) 1.00 (0.77 - 1.30) 1.07 (0.83 - 1.40) 
N2 183 3.07 (2.46 - 3.84)* *P≤ 0.001; ** P<0.05     
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There was no significant difference in survival after stratifying LNR stage 3 in different 
UICC/AJCC TNM N-stages. For the other LNR groups, stratification for N stage was not possible 
due to small numbers and little variation within the LNR group. The LNR showed significant 
differences within N1 stage of the 5th/6th or 7th TNM in terms of survival. In the 7th TNM 
classification patients with a N1 stage and a LNR1 had a 5-year overall survival of 39 per cent, 
while patients with a LNR stage 3 had a 5year overall survival of 15 per cent (P=0.0404). For 
TNM 6th N1 patients similar survival differences were found (Table 4a and 4b). 
Table 4a 5-yr overall survival for N stage 1 and N stage 2 (TNM 7) according to lymph node ratio 
TNM 7 N1 n=187 TNM 7 N2 n=183 
 N 5-yr overall survival  N 5-yr overall survival 
Lymph node ratio      
1 (0.1-0.19) 78 39*  8 a 
2 (0.20-0.29) 38 18  20 18 
3 (0.30-1.00) 52 15  137 11 
     Missing  19  21   18  a  
*P<0.05; a: not available due to small numbers 
 
Table 4b 5-yr overall survival for N stage (TNM 6) according to lymph node ratio 
  TNM 6 N1 n=370    TNM 6 N2 n=183  
  N  5-yr overall survival  N  5-yr overall survival  
Lymph node ratio   
1 (0.1-0.19) 86 35* 8 a 
2 (0.20-0.29) 58 18 20 17 
3 (0.30-1.00) 189 12 137 11 
Missing 37 11 18 a 
*P<0.05; a: not available due to small numbers 
 
Discussion 
 
The results of this study show that the various versions of the TNM classification and the 
lymph node ratio are independent prognostic factors for overall survival. The LNR had the 
best homogenous spread of overall crude 5-year survival and hazard ratios, and correlated 
the least with the total amount of lymph nodes examined. 
In 1997 the UICC/AJCC introduced the 5th edition of the UICC/AJCC TNM Classification 
of Malignant Tumours.10 At this time N-stage was defined as: N1 having metastases in 1-6 
lymph nodes, N2 having metastases in 7-15 lymph nodes and N3 as having metastases in more 
than 16 lymph nodes. Subsequently in 2002, the UICC/AJCC came with the 6th edition of the 
UICC/AJCC TNM-staging system, which was only slightly different from the previous one and 
remained the same in terms of N-stage. After the 7th edition was published in 2010 there was 
a reclassification for the T and the N-stage, which resulted in a shift from stage IV to stage III 
disease.11 In this edition N-stage was defined as N1 having metastases in 1-2 lymph nodes, 
N2 in 3-6 lymph nodes, N3a in 7-15 lymph nodes, and N3b in more than 15 lymph nodes.12 
A minimum of 15 lymph nodes examined is necessary for adequate staging using the TNM 
 
classification system. In the Netherlands and various other countries this amount is often not 
met. Previous research done in the Comprehensive Cancer Centre South showed that this can 
partly be explained by differences between the various pathology departments6, showing a 
difference in the median number of detected lymph nodes. The region of the Comprehensive 
Cancer Centre South is served by six departments of pathology and the number of lymph 
nodes assessed varied between 5 and 9 lymph nodes per patient, with a median number of 
7 in the whole region. Also after adjustment in a multi-level analysis for relevant factors, 
differences between departments of pathology remained, probably suggesting variation in 
diligence and effort put in these time-consuming examinations. They did not find an effect of 
age, gender or operating volume. The latter would make centralization of surgery for gastric 
cancer less effective for harvesting more lymph nodes. 
Centralization of gastric cancer surgery has been a frequently discussed topic in the 
Netherland. Recent literature on the difference between low(1-5 gastrectomies) and high(over 
20 gastectomies) volume hospitals confirmed the improved harvesting of lymph nodes in high 
volume hospitals.13 On the other hand does this study fail to show if they meet the minimal 
amount of lymph nodes needed, making an alternative N staging modality still necessary. 
However, since 2012 gastrectomies in the Netherlands are centralized to a minimum of 10/ 
year and as of 2013 to a minimum of 20/year. 
Further known factors associated with a higher detected number of lymph nodes are 
younger age, comorbidity, female gender, Asian race, obesity and more radical surgery.6,14-16 
Obviously, in a total gastric resection more surrounding tissue is removed, resulting in more 
lymph nodes retrieved and assessed. In the Netherlands, mostly a D1 resection is performed. 
The type of lymph node dissection during surgery is still subject to discussion and there is 
no worldwide consensus about this. There are different types of lymphadenectomy. In a D1 
resection perigastric lymph nodes are removed, while in a D2 resection additionally the 
lymph nodes around the left gastric artery, the common hepatic artery and splenic artery are 
removed, depending on location of the tumour.17 Limited research has been done for LNR for 
gastric cancer treated with a limited lymphadenectomy, as usually conducted in the Western 
world including the Netherlands. Nevertheless adequate research has been done in extended 
lymphadenectomy and for various other types of carcinomas.18 
This study implicates that  LNR  is  as  a  good  prognostic  tool  for  overall  survival  in 
a population with a limited lymphadenectomy and a minimal amount of lymph nodes 
harvested during surgery and/or examined during pathology. The results show that LNR is 
an independent prognostic factor with a more homogenous spread of hazard ratios and crude 
5-year overall survival rates than UICC/AJCC TNM-classification systems 5th, 6th and 7th version. 
Furthermore, the LNR has a lower correlation with the number of lymph nodes examined, 
making it less vulnerable for stage migration. Finding metastases that had previously been 
unidentified, results in upstaging since patients who previously would have been classified 
in a lower TNM stage are now assigned to a higher stage. The identification of metastases can 
be done by examining and/or harvesting more (metastatic) lymph nodes during surgery and 
pathology.19 In a small population the LNR showed a survival benefit where the conventional 
staging system failed to predict any benefit. Patients with a UICC/AJCC TNM 5th/6th or 7th N1 
stage and a LNR stage 3, have a prognosis that is closer to an UICC/AJCC TNM N2 stage disease. 
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Compared to the 5th/6th version of the UICC/AJCC TNM classification, the 7th version 
had a more homogenous spread in 5-year overall survival. Although the 7th TNM N3b stage 
had a better 5 year overall survival then N2 and N3a, the spread among all curves is more 
homogenous when comparing UICC/AJCC TNM 5th/6th with 7th. Nevertheless it failed to show 
a benefit in multivariate survival analysis, with 7th TNM N3b-stage having a better prognostic 
value then N2 and N3a-stage. This is probably due to the small amount of patients in N3b 
stage. UICC/AJCC 7th TNM classification correlated as strong as the 5th and 6th version with 
the total number of lymph nodes examined, making it more vulnerable for stage migration. 
It seemed to be less influenced by confounding factors when comparing univariate with 
multivariate analysis. 
When reviewing the literature for the prognostic impact of LNR compared to the 5th/6th 
UICC/AJCC TNM-classification, most studies demonstrate that LNR is a better prognostic 
tool than the 5th/6th UICC/AJCC TNM-classification. The LNR is proven to be the strongest 
independent prognostic factor in terms of overall survival and a prognostic factor for 
recurrence of disease.20,21 It also minimizes stage migration by being an independent 
prognostic factor without being influenced by the amount of lymph nodes examined.18 
Whereas stage migration is suggested to be at least 10 per cent and up to 25 per cent  in 
the conventional TNM classification systems, LNR halves the stage migration phenomenon 
22,23: in a study done by Persiani et. al.24, stage migration was found in 19 per cent of the 
cases classified by the 5th/6th UICC/AJCC TNM-system, and in only 11 per cent of the cases 
when LNR was applied.24 As stated by our results and in the literature the LNR gives a more 
homogenous stratification of the survival curves.25 In addition, literature shows that LNR 
can make a prognostic difference between different UICC/AJCC TNM N-stages: N1 patients 
having a LNR less than 9 per cent have similar survival as patients with N0 gastric cancer, and 
patients with a LNR between 10 per cent and 25 per cent have a prognosis similar to a TNM 
7th N2-stage. On the contrary, UICC/AJCC TNM N-stages cannot significantly distinguish in 
survival between different LNR groups.26 The power of our research refrains us from drawing 
this conclusion, but our evidence suggests a prognostic benefit for LNR within different TNM 
stages in terms of survival. Several studies also endorse these benefits for a D1 lymph node 
dissection, but all studies have a higher average amount of lymph nodes harvested.23 
When  comparing  literature  about  the  5th/6th   UICC/AJCC   TNM-classification   with 
its successor, conclusions vary. Some evidence suggests the 7th edition being the best 
classification for predicting overall survival: they found in that the 7th edition N-stage is  
an independent factor for predicting overall survival instead of the 5th/6th edition N-stage 
multivariate survival analysis. They also showed a statistically significant difference between 
survival in 7th N1 and N2 stages, but not in 5th/6th N2 and N3 stages. This research has been 
done in both extended as limited lymph node dissection12,17, and could not be confirmed by our 
results. Others suggest the new TNM system to be a major reclassification, without improving 
the assessment of patient prognosis even showing inferior distribution in survival curves. In 
this study, the type of lymph node dissection is not mentioned.27 Our results do also show a 
major redistribution but also a more homogenous spread of survival curves. 
Little is published about the prognostic value of the 7th UICC/AJCC TNM classification 
compared to the LNR. However, it has been reported that in the 7th edition of the TNM staging 
 
system the proportion of advanced TNM N-stage increases when the number of examined 
lymph nodes increases, being prone to stage migration. This in contrast to the LNR which was 
constant regardless of the number of lymph nodes examined. It also showed better patterns 
of patient distribution between LN stages and a better distribution of survival curves. The 
research has been done in both limited as extended lymphadenectomy. Literature showing 
small numbers of lymph nodes after surgery demonstrated the LNR to be of low clinical 
utility due to a small number of patients in the first LNR stage.28,29 The latter was not being 
reproduced in our research, nor did the LNR show a better distribution of patients, but it did 
show a better distribution of survival curves. 
From a critical point of view the weaker aspect of this study might be found in the cut off 
points of the LNR. These are chosen by the authors and could be chosen in favour of this study 
or LNR itself. Another point of criticism is that this research used overall survival instead of 
disease specific survival. Unfortunately the use of disease specific survival was not possible 
because the ECR does not register the cause of death. 
 
Conclusion 
 
In this population-based study on patients with M0 gastric cancer who usually underwent 
a limited lymph node dissection and who thus generally have a small number of lymph 
nodes examined, the lymph node ratio is a good and simple prognostic instrument. It has 
the best homogenous spread of overall crude 5-year survival and hazard ratios and it is less 
vulnerable for stage migration then the UICC/AJCC TNM classification and might be able to 
make a significant difference within different N-stadia. 
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Abstract 
 
Introduction: 
This study assessed trends in the treatment and survival of palliatively treated patients with 
gastric cancer, with a focus on age-related differences. 
 
Methods: 
For this retrospective, population-based, nationwide cohort study, all patients diagnosed 
between 1989 and 2013 with non-cardia gastric cancer with metastasized disease or invasion 
into adjacent structures were selected from the Netherlands Cancer Registry. Trends in 
treatment and 2-year overall survival were analysed and compared between younger (age 
less than 70 years) and older (aged 70 years or more) patients. Analyses were done for  
five consecutive periods of 5 years, from 1989–1993 to 2009–2013. Multivariable logistic 
regression analysis was used to examine the probability of undergoing surgery. Multivariable 
Cox regression analysis was used to identify independent risk factors for death. 
 
Results: 
Palliative resection rates decreased significantly in both younger and older patients, from 
24.5 and 26.2 per cent to 3.0 and 5.0 per cent respectively. Compared with patients who 
received chemotherapy alone, both younger (21.6 versus 6.3 per cent respectively; P<0.001) 
and older (14.7 versus 4.6 per cent; P<0.001) patients who underwent surgery had better 
2-year overall survival rates. Multivariable analysis demonstrated that younger and older 
patients who received chemotherapy alone had worse overall survival than patients who had 
surgery only (younger: hazard ratio (HR) 1.20, 95 per cent c.i. 1.10 to 1.30; older: HR 1.12, 
1.01 to 1.24). After 2003 there was no association between period of diagnosis and overall 
survival in younger or older patients. 
 
Conclusion: 
Despite changes in the use of resection and chemotherapy as palliative treatment, overall 
survival rates of patients with advanced and metastatic gastric cancer did not improve. 
Introduction 
 
Gastric cancer incidence rates are declining in the western world, including the Netherlands1. 
Survival rates of patients with gastric cancer have remained dismal through the years, despite 
developments in treatment1. One of the important reasons for the generally poor prognosis 
is that a considerable proportion of patients (45 per cent) are diagnosed with metastatic 
disease (stage IV)1,2. With a median overall survival of less than 4 months for patients with 
stage IV gastric cancer, their survival rate is amongst the lowest in gastrointestinal oncology.3,4 
The preferred treatment approach for patients with stage IV or locally advanced gastric 
cancer is debated worldwide. In particular, the effect of palliative gastrectomy on survival 
and quality of life remains unclear.5–7 This is particularly relevant as postoperative mortality 
rates in gastric cancer are amongst the highest of all gastrointestinal cancers.8 In addition, 
the effect of palliative chemotherapy on survival and quality of life is debated.4 
According to the national clinical practice guideline for treatment of gastric cancer9, 
palliative gastrectomy can be performed to improve quality of life and/or survival. This 
guideline9 and some previous studies5,6 suggest that palliative resection should be performed 
only in patients aged less than 70 years. Although surgical morbidity and mortality are indeed 
higher in older patients with gastric cancer, palliative resection is suggested to have an equally 
positive effect on survival in both younger and older patients.10–13 
The aim of the present study was to investigate trends and the incidence of palliative 
treatment among younger and older patients in a nationwide setting, and assess which 
patient, tumour and treatment characteristics are related to the likelihood of having a 
palliative resection. The study also investigated the survival of younger and older patients 
according to the type of treatment. 
 
Methods 
 
Data source 
Data were obtained from the population-based Netherlands Cancer Registry (NCR). This 
registry serves the total Dutch population of almost 17 million. The NCR is based on 
notification of all newly diagnosed malignancies in the Netherlands by the national automated 
pathological archive (PALGA). Additional sources are the national registry of hospital discharge 
and radiotherapy institutions. Information on diagnosis, staging and treatment is extracted 
routinely from the medical records by specially trained data managers of the NCR. The 
information on vital status is obtained by annual linkage with the municipal administrative 
databases, which register all deceased and emigrated persons in the Netherlands. The study 
period was from January 1989 to December 2013. 
 
Ethical approval 
According to the Netherlands Central Committee on Research involving Human Subjects, this 
type of study does not require approval from an ethics committee in the Netherlands. This 
study was approved by the Privacy Review Board of the NCR. All procedures followed were 
in accordance with the Helsinki Declaration of 1964 and later versions.14 
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Patient selection criteria 
The reporting of this study followed the Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) guidelines.15 For this retrospective, population-based, nationwide 
cohort study, patients with non-cardia gastric cancer who received palliative treatment for 
clinically distant metastases or a tumour infiltrating surrounding organs were selected. 
Topography and morphology of the disease were coded according to ICD-O-3.16 
 
Tumour location and stage 
The distribution of the location in the stomach was considered as follows: proximal/middle 
(fundus, corpus and lesser and greater curvature: C16.1, C16.2, C16.5 and C16.6), pylorus and 
antrum (C16.3, C16.4), and overlapping or not otherwise specified (C16.8, C16.9). 
Tumour staging was performed according to the fourth, fifth, sixth or seventh edition of 
the UICC TNM classification, as was valid at the time of diagnosis. An important change was 
made in the seventh UICC TNM classification. Before TNM-7 (which was implemented in the 
NCR in 2010) malignancies infiltrating surrounding organs were categorized as cT4, and 
since TNM-7 tumours infiltrating surrounding organs have been categorized as cT4B. cT4A 
in TNM-7 corresponds to tumours that perforate the gastric serosa, which were previously 
coded as cT3. Therefore, the present study included all cT4 tumours before 2010 and only 
cT4B tumours after 2010. 
 
Hospital type 
The three types of hospital in which diagnosis was made were academic, teaching and non- 
teaching hospitals. A hospital was considered a teaching hospital if it offered (part of) a 
surgical residency programme. 
 
Age groups 
Patients were analysed according to age (less than 70 years versus 70 years or above), in 
accordance with the guidelines proposed by the European Society of Medical Oncology and 
the Dutch clinical guideline.8,9 
 
Statistical analysis 
All analyses were conducted using SPSS® version 23 (IBM, Armonk, New York, USA). Analyses 
were performed for five consecutive periods of 5 years, from 1989–1993 to 2009–2013. To 
investigate trends over time in the proportion of patients treated with palliative intent, ratios 
of palliative patients for sequential time periods were calculated for all patients, and for both 
younger and older patients And were compared using the χ2 test. 
Descriptive statistics were used to characterize patients younger or older than 70 years. 
Bar graphs were used to assess differences in treatment modalities throughout the years 
for the two groups of patients and were compared using the χ2 test. Postoperative 30-day 
mortality rates were available in the NCR from 2005, and were calculated and compared using 
the χ2 test. Univariable and multivariable logistic regression analyses were performed for 
younger and older patients to examine the influence of different clinicopathological factors 
 
associated with the receipt of palliative surgery. Results of these analyses were reported as 
odds ratios (ORs) with 95 per cent confidence intervals. 
Survival time was defined as time from diagnosis to death, or until 1 January 2015 
for patients who were still alive. Kaplan–Meier curves were generated and compared by log 
rank test to examine overall survival in younger and older patients according to treatment. 
Multivariable Cox regression analyses were performed to investigate the prognostic 
impact of palliative treatment options on overall survival in both groups of patients after 
adjustment for patient, tumour and treatment characteristics. Results of survival analyses 
using Cox regression were reported as hazard ratios (HRs) with 95 per cent confidence 
intervals. P<0.050 was considered statistically significant. 
 
Results 
 
A total of 38 004 patients were diagnosed with non-cardia gastric cancer, of whom 15 011 
were included in the study as they had clinically distant metastasis or a tumour infiltrating 
surrounding organs, and therefore were considered to have been treated with palliative intent. 
The mean (s.d.) age was 58.2(9.5) years for younger patients and 77.8(5.4) years for older 
patients. Median duration of follow-up was 4.4 (i.q.r. 1.8–9.5) and 2.9 (1.2–6.6) months for 
younger and older patients respectively. The percentage of patients treated with palliative 
intent increased significantly over the years for both age groups (P<0.001) (Figure 1). 
Some 8108 patients (54 per cent) were aged at least 70 years, and 6903 (46 per cent) 
patients were less than 70 years of age. The two groups were comparable (Table 1), except 
for more younger patients presenting with signet-ring cell carcinomas (23.1 versus 13.2 per 
cent; P<0.001). Younger patients were significantly more often treated with chemotherapy 
compared with older patients (28.0 versus 7.9 per cent respectively; P<0.001). Older patients 
more often received supportive care alone (no surgery or chemotherapy) than younger 
patients (73.9 versus 52.5 per cent respectively; P<0.001). Surgery alone was performed in 
16.0 per cent of the younger patients and among 17.5 per cent of older patients (P=0.018). 
During the study interval, the proportion of patients undergoing palliative surgery 
decreased significantly in both younger and older patients, from 24.5 per cent in 1989–1993 
to 3.0 per cent in 2009–2013 (P<0.001), and from 26.2 per cent to 5.0 per cent, respectively 
(P<0.001). Postoperative 30-day mortality rates in 2005–2008 and 2009–2013 were 12.1 and 
11.3 per cent respectively (P=0.781) (7.5 and 8.0 per cent for younger patients (P=0.896) and 
16.6 and 15.2 per cent for older patients (P=0.129), respectively). 
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Table 1 Characteristics of younger and older patients diagnosed between 1989 and 2013 who received 
palliative treatment (cM1 and cT4(B)) 
 
 
Younger patients 
(age < 70 years) 
n = 6903 
Older patients 
(age ≥ 70 years) 
n = 8108 
Sex ratio (M : F) 4347 : 2556 4832 : 3276 
Period of diagnosis   
1989–1993 1589 (23.0) 1929 (23.8) 
1994–1998 1400 (20.3) 1669 (20.6) 
1999–2003 1393 (20.2) 1528 (18.8) 
2004–2008 1268 (18.4) 1526 (18.8) 
2009–2013 1253 (18.2) 1456 (18.0) 
cT status   
0–3 926 (13.4) 1021 (12.6) 
4 2515 (36.4) 2905 (35.8) 
Unknown 3462 (50.2) 4182 (51.6) 
cN status   
N0 703 (10.2) 897 (11.1) 
N+ 2757 (39.9) 2761 (34.1) 
Unknown 3443 (49.9) 4450 (54.9) 
cM status   
M0 973 (14.1) 1232 (15.2) 
M1 5602 (81.2) 6452 (79.6) 
Unknown 328 (4.8) 424 (5.2) 
Tumour location   
Proximal and middle 1972 (28.6) 2139 (26.4) 
Pyloric and antrum 1693 (24.5) 2444 (30.1) 
Overlapping or unspecified 3238 (46.9) 3525 (43.5) 
Tumour differentiation   
Well 111 (1.6) 148 (1.8) 
Moderate 936 (13.6) 1495 (18.4) 
Poor/undifferentiated 3524 (51.1) 3768 (46.5) 
Unknown 2332 (33.8) 2697 (33.3) 
Tumour morphology   
Adenocarcinoma 4274 (61.9) 6130 (75.6) 
Non-adenocarcinoma 405 (5.9) 421 (5.2) 
Linitis plastica 632 (9.2) 489 (6.0) 
Signet-ring cell carcinoma 1592 (23.1) 1068 (13.2) 
Hospital type   
Academic 571 (8.3) 460 (5.7) 
Teaching 4067 (58.9) 4778 (58.9) 
Non-teaching 2256 (32.7) 2867 (35.4) 
Unknown 9 (0.1) 3 (0.0) 
Table 1 continues on the next page 
Figure 1 Proportions of a younger (aged less than 70 years), b older (aged 70 years or more) and c all 
patients with potentially curable non-cardia gastric cancer and with palliative disease (cT4(B) or cM1) 
treated in the five periods of diagnosis 
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Continuation of table 1 
Treatment   
No resection or CT 3627 (52.5) 5995 (73.9) 
Chemotherapy 1935 (28.0) 640 (7.9) 
Resection 1106 (16.0) 1415 (17.5) 
Resection + CT 235 (3.4) 58 (0.7) 
Values in parentheses are percentages. 
 
There was a significant increase in the proportion of patients treated with chemotherapy 
alone over the study interval (Figure 2). In 1989–1993, 15.0 and 2.1 per cent of younger and 
older patients respectively received chemotherapy alone, compared with 51.3 and 20.8 per 
cent respectively in 2009–2013 (P≤0.001). 
 
Probability of surgery 
Multivariable logistic regression analyses showed that both younger and older patients with a 
more recent diagnosis had a significantly lower likelihood of having surgery: OR 0.42 (95 per 
cent c.i. 0.33 to 0.54) and 0.22 (0.17 to 0.28) respectively. Among younger patients, sex, period 
of diagnosis, tumour morphology, tumour differentiation, tumour location, cTNM status, 
chemotherapy, radiotherapy and type of diagnosing hospital were associated with a higher 
probability of undergoing surgery. In contrast, in older patients sex, tumour morphology 
and type of diagnosing hospital did not influence the probability of having surgery, but age 
did (Table 2). 
 
Table 2 Multivariable analysis of factors related to likelihood of having palliative surgery 
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Figure 2 Treatment modality according to period of diagnosis for a younger (aged less than 70 years) 
and b older (aged 70 years or more) patients with non-cardia gastric cancer who received palliative 
treatment. a,b P<0.001 (2test) 
 
Table 2 continues on the next page 
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Younger patients 
(age < 70 years) 
n = 6903 
  
Older patients 
(age ≥ 70 years) 
n = 8108 
 
 Odds ratio P value  Odds ratio P value 
Age 0.99 (0.99 - 1.00) 0.066  0.97 (0.90 - 0.98) < 0.001 
Sex      
M 1.00 (reference)   1.00 (reference)  
F 1.21 (1.05 - 1.40) 0.007  1.13 (0.99 - 1.29) 0.068 
Period of diagnosis      
1989–1993 1.00 (reference)   1.00 (reference)  
1994–1998 0.94 (0.78 - 1.14) 0.538  0.78 (0.65 - 0.92) 0.004 
1999–2003 0.66 (0.55 - 0.81) < 0.001  0.57 (0.47 - 0.69) < 0.001 
2004–2008 0.58 (0.47 - 0.73) < 0.001  0.40 (0.33 - 0.50) < 0.001 
2009–2013 0.42 (0.33 - 0.54) < 0.001  0.22 (0.17 - 0.28) < 0.001 
Tumour morphology      
Adenocarcinoma 1.00 (reference)   1.00 (reference)  
Non-adenocarcinoma 0.93 (0.67 - 1.29) 0.662  0.83 (0.59 - 1.18) 0.303 
Linitis plastica 1.51 (1.15 - 1.98) 0.003  1.16 (0.85 - 1.59) 0.343 
Signet ring cell carcinoma 1.52 (1.28 - 1.80) < 0.001  1.12 (0.93 - 1.36) 0.237 
Tumour differentiation      
Well 1.37 (0.87 - 2.16) 0.176  0.99 (0.65 - 1.49) 0.946 
Moderate 1.24 (1.02 - 1.49) 0.029  0.89 (0.76 - 1.05) 0.157 
Poor/undifferentiated 1.00 (reference)   1.00 (reference)  
Unknown 0.37 (0.31 - 0.44) < 0.001  0.23 (0.19 - 0.28) < 0.001 
Tumour location      
Proximal and middle 1.00 (reference)   1.00 (reference)  
Pylorus and antrum 1.49 (1.26 - 1.77) < 0.001  2.10 (1.78 - 2.47) < 0.001 
Overlapping/unspecified 0.59 (0.50 - 0.70) < 0.001  0.89 (0.75 - 1.05) 0.177 
cT status      
0–3 1.62 (1.24 - 2.11) < 0.001  1.77 (1.37 - 2.28) < 0.001 
4 1.00 (reference)   1.00 (reference)  
Unknown 1.32 (1.08 - 1.62) 0.008  1.16 (0.95 - 1.42) 0.152 
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Continuation of table 2  
Survival 
Survival analyses showed that both younger and older patients who underwent surgery had 
better 2-year overall survival than those who received chemotherapy alone (younger group: 
21.6 versus 6.3 per cent respectively, P<0.001; older group: 14.7 versus 4.6 per cent, P<0.001) 
(Figure 3). Overall survival at 2 years was lowest among patients who received only supportive 
care. Patients who had both surgery and chemotherapy had the most favourable survival. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Values in parentheses are 95 per cent confidence intervals. 
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Figure 3 Kaplan–Meier 2-year survival curves according to treatment method in a younger (aged less 
than 70 years) and b older (aged 70 years or more) patients with non-cardia gastric cancer who received 
palliative treatment. a,b P<0.001 (log rank test) 
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cN status     
N0 1.46 (1.18 - 1.81) 0.001 1.52 (1.24 - 1.86) < 0.001 
N+ 1.00 (reference)  1.00 (reference)  
Unknown 0.56 (0.48 - 0.65) < 0.001 0.44 (0.39 - 0.51) < 0.001 
cM status     
M0 6.58 (5.24 - 8.25) < 0.001 4.91 (3.95 - 6.10) < 0.001 
M1 1.00 (reference)  1.00 (reference)  
Unknown 2.91 (2.13 - 3.98) < 0.001 1.89 (1.40 - 2.56) < 0.001 
Chemotherapy     
No 1.00 (reference)  1.00 (reference)  
Yes 0.48 (0.41 - 0.57) < 0.001 0.58 (0.43 - 0.79) < 0.001 
Radiotherapy     
No 1.00 (reference)  1.00 (reference)  
Yes 0.53 (0.32 - 0.89) 0.017 0.18 (0.08 - 0.39) < 0.001 
Hospital type     
Academic 0.96 (0.74 - 1.23) 0.736 1.07 (0.81 - 1.41) 0.650 
Teaching 1.00 (reference)  1.00 (reference)  
Non-Teaching 0.86 (0.74 - 1.00) 0.045 1.08 (0.95 - 1.24) 0.256 
Unknown 1.59 (0.17 - 14.40) 0.681 4.27 (0.25 - 71.80) 0.313 
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Multivariable Cox regression analyses confirmed that younger and older patients who did 
not have chemotherapy or surgery had a worse overall survival than patients who had surgery 
alone (HR 2.77, 95 per cent c.i. 2.57 to 2.98, and 2.29, 2.15 to 2.45, respectively). Younger and 
Continuation of table 3 
 
 
Younger patients 
(age < 70 years) 
n = 6903 
 
 
Older patients 
(age ≥ 70 years) 
n = 8108 
older patients treated with chemotherapy had a worse overall survival than those treated 
with surgery (HR 1.22, 1.12 to 1.33, and 1.12, 1.01 to 1.24). Survival was best among patients 
who received both chemotherapy and surgery versus surgery only (younger group: HR 0.76, 
0.66 to 0.88; older group: HR 0.74, 0.57 to 0.97) (Table 3). 
Table 3 Multivariable Cox regression analysis of factors related to overall survival. 
 
 
  
   Hazard ratio P value Hazard ratio P value 
cM status 
M0 0.64 (0.59 - 0.70) < 0.001 0.65 (0.60 - 0.70) < 0.001 
M1 1.00 (reference) 1.00 (reference) 
Unknown 0.84 (0.74 - 0.95) 0.006 0.89 (0.79 - 0.99) 0.036 
Hospital type 
Younger patients 
(age < 70 years) 
n = 6903 
Older patients 
(age ≥ 70 years) 
n = 8108 
Academic 1.06 (0.97 - 1.16) 0.202 0.97 (0.88 - 1.07) 0.537 
Teaching 1.00 (reference) 1.00 (reference) 
 
  
   Hazard ratio  P value  Hazard ratio  P value  
Age 1.00 (1.00 - 1.01) 0.036 1.01 (1.01 - 1.02) < 0.001 
Sex 
M 1.00 (reference) 1.00 (reference) 
F 0.89 (0.84 - 0.93) < 0.001 0.91 (0.87 - 0.95) < 0.001 
Period of diagnosis 
Proximal and middle 1.00 (reference) 1.00 (reference) 
Pylorus and antrum 1.01 (0.95 - 1.08) 0.683 1.05 (0.99 - 1.12) 0.084 
Overlapping/unspecified 1.11 (1.05 - 1.18) < 0.001 1.14 (1.08 - 1.21) < 0.001 
Tumour morphology 
Adenocarcinoma 1.00 (reference) 1.00 (reference) 
Non-adenocarcinoma 1.05 (0.94 - 1.16) 0.384 1.33 (1.21 - 1.47) < 0.001 
Linitis plastica 1.03 (0.94 - 1.13) 0.483 1.07 (0.97 - 1.17) 0.205 
Signet-ring cell carcinoma 1.02 (0.96 - 1.08) 0.551 1.04 (0.97 - 1.11) 0.291 
Tumour differentiation 
Well 0.76 (0.62 - 0.92) 0.004 0.88 (0.74 - 1.04) 0.130 
Moderate 0.90 (0.84 - 0.97) 0.008 0.82 (0.78 - 0.88) < 0.001 
Poor/undifferentiated 1.00 (reference) 1.00 (reference) 
Unknown 0.98 (0.93 - 1.04) 0.563 0.89 (0.85 - 0.94) < 0.001 
cT status 
0–3 0.93 (0.85 - 1.02) 0.105 0.96 (0.88 - 1.04) 0.336 
4 1.00 (reference) 1.00 (reference) 
Unknown 1.11 (1.04 - 1.19) 0.002 1.11 (1.04 - 1.18) 0.001 
cN status 
N0 0.91 (0.83 - 0.99) 0.023 0.81 (0.75 - 0.88) < 0.001 
N+ 1.00 (reference) 1.00 (reference) 
Unknown 1.09 (1.04 - 1.15) 0.001 1.13 (1.08 - 1.19) < 0.001 
 
Table 3 continues on next page 
Non-teaching 1.07 (1.02 - 1.13) 0.011 1.04 (0.99 - 1.09) 0.117 
Unknown 0.93 (0.48 - 1.80) 0.830 0.57 (0.18 - 1.77) 0.328 
Treatment 
 
Resection 1.00 (reference)  1.00 (reference)  
Chemotherapy 1.22 (1.12 - 1.33) < 0.001 1.12 (1.01 - 1.24) 0.030 
Resection + CT 0.76 (0.66 - 0.88) < 0.001 0.74 (0.57 - 0.97) 0.027 
No resection or CT 2.77 (2.57 - 2.98) < 0.001 2.29 (2.15 - 2.45) < 0.001 
Values in parentheses are 95 per cent confidence intervals. CT= chemotherapy. 
 
Period of diagnosis was not associated with survival in older patients. Among younger 
patients, survival was better in 1994–1998 than in 1989–1993 (HR 0.92, 95 per cent c.i. 
0.85 to 0.98). For all other periods there was no statistically significant difference in survival 
(Table 3). A subgroup analysis, in which multivariable Cox regression analysis was performed 
in younger patients who did not receive surgery, found no significant survival difference over 
the years, whereas the same analysis in younger patients who did have surgery showed a 
significant survival improvement in 2009–2013 compared with 1989–1993 (HR 0.71, 0.54 
to 0.93) (Table 4). The same subgroup analysis in older patients treated with palliative intent 
who did or did not receive surgery showed no significant differences in survival over time. 
 
Table 4 Cox regression analysis of the influence of different clinicopathological factors on survival of 
younger and older patients who underwent palliative surgical resection 
 
 Younger patients   Older patients  
(age < 70 years)   ( ≥ 70 years) 
n=1341   n=1473 
Hazard ratio P value  Hazard ratio P value 
Period of diagnosis 
1989-1993 
 
1.00 (reference) 
   
1.00 (reference) 
 
1994-1998 0.81 (0.07, 0.94) 0.006  0.97 (0.85, 1.12) 0.710 
1999-2003 0.81 (0.69, 0.95) 0.010  0.90 (0.77, 1.05) 0.193 
2004-2008 0.81 (0.67, 0.97) 0.026  0.92 (0.78, 1.10) 0.353 
2009-2013 0.71 (0.54, 0.93) 0.013  0.86 (0.67, 1.11) 0.245 
* adjusted for: Age, sex, tumour location, tumour morphology, tumour grade, cTNM-stage and type of diagnosing 
hospital 
1989–1993 1.00 (reference)  1.00 (reference)  
1994–1998 0.92 (0.85 - 0.98) 0.018 1.05 (0.98 - 1.12) 0.173 
1999–2003 0.93 (0.86 - 1.00) 0.054 0.98 (0.92 - 1.05) 0.632 
2004–2008 0.99 (0.91 - 1.07) 0.756 0.96 (0.89 - 1.03) 0.224 
2009–2013 1.03 (0.95 - 1.12) 0.459 1.00 (0.93 - 1.08) 0.981 
Tumour location     
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Discussion 
 
In this population-based nationwide study, 45.2 per cent of younger patients and 35.7 per cent 
of older patients presented with locally advanced or metastasized gastric cancer at diagnosis. 
During the study interval, the proportion undergoing palliative surgery reduced significantly. 
However, both younger and older patients who underwent gastrectomy had a significantly 
better survival compared with patients treated with chemotherapy or supportive care alone. 
An increased incidence of stage IV disease and decreased resection rates have been 
shown for other gastrointestinal cancers in the Netherlands.17–19 This decrease in palliative 
resection suggests a better selection of patients as a result of improved diagnostic accuracy 
and preoperative staging, and the availability of systemic treatment options.18 The latter was 
also demonstrated in the present study, by a significant increase in use of chemotherapy, 
especially from 2005 onwards. In addition, the Dutch clinical guideline9 on treatment of gastric 
cancer, implemented in 2009, advises that palliative gastrectomy should be performed only 
in patients under 70 years of age, who have no more than one item of incurability – either 
distant metastasis (M+ disease) or tumour infiltrating the surrounding organs (cT4 disease). 
This could also have led to a decrease in palliative gastrectomy. Finally, better understanding 
of postoperative morbidity and mortality in patients with stage IV gastric cancer may have 
led physicians to refrain from a surgical approach5,6. In the present study, especially in older 
patients, 30-day postoperative mortality rates were high, despite a substantial improvement 
in postoperative mortality compared with that in previous Dutch studies.5,6 A Dutch study5 
of palliative gastrectomy reported a 30-day postoperative mortality rate of 20 per cent in 
1989–1993, considerably higher than the 15.2 per cent found in the present study. 
Despite increased use of chemotherapy, survival of all patients receiving palliative care 
for gastric cancer did not improve after adjustment for clinicopathological factors. However, 
in multivariable analysis overall survival increased between 2010 and 2013 for younger 
patients treated with gastrectomy, which may be due to centralization of gastric cancer 
surgery as of 2012 in the Netherlands. An additional explanation may be better selection of 
younger patients with cancer, who are relatively fit for palliative surgery. The present study 
also showed that younger patients diagnosed in teaching hospitals had a significantly better 
overall survival than those diagnosed in non-teaching hospitals. 
Previous studies from Germany20,21 have suggested that tumour resection should be part of 
palliative therapy in gastric cancer, with prolongation of median survival up to 5 months, and 
acceptable perioperative morbidity and mortality rates of 47.7 and 11.6 per cent respectively. 
Other studies have shown a positive effect of palliative gastrectomy on overall survival in 
smaller groups and in a meta-analysis.22 In line with this, the present study showed that 
survival of patients who had a palliative resection was higher than that in those receiving 
chemotherapy alone. The 2-year survival rate was 21.6 and 14.7 per cent in younger and older 
patients who underwent palliative surgery, compared with 6.3 and 4.6 per cent in patients 
who received chemotherapy alone. A positive effect of palliative resection on survival has 
been reported for various malignancies, although there has been no explanation as to why 
palliative resection is associated with improved overall survival.23–28 
 
There are studies that have suggested a more positive or equal effect on survival 
compared with palliative surgery in patients with gastric cancer treated with palliative 
chemotherapy.7,29,30 Recently an RCT comparing palliative gastrectomy and chemotherapy 
with chemotherapy alone (REGATTA trial)29 showed no benefit for palliative gastrectomy. 
However, this trial involved an Asian population and, because of well-known differences 
between Asian and European patients with gastric cancer, this finding should be treated with 
care.31–33 Furthermore, the REGATTA trial included only patients with liver, peritoneal or para- 
aortic lymph node metastases, and thus the effect of palliative surgery on survival of patients 
with gastric cancer and a locally advanced (T4b) tumour remains unclear. The difference in 
survival between patients treated with chemotherapy alone and those who had surgery and 
chemotherapy in the present study is, however, noteworthy, and not in line with the findings 
of the REGATTA trial. A European RCT evaluating the effect of palliative gastrectomy versus 
palliative chemotherapy on overall survival is thus needed. 
The present study has some limitations. This was a retrospective cohort study in which 
there is a likelihood of selection bias. The survival difference between various treatment 
groups may be caused by selecting fitter patients for palliative gastrectomy. The absence of 
information on clinical symptoms, co-morbidity, hospital resection volume, ASA fitness grade 
and therapeutic complication rates is another limitation. These data have only recently been 
included entirely in the Netherlands Cancer Registry, and could therefore not be included 
in the present study. Furthermore, information regarding adherence to multidisciplinary 
team meetings, intention of treatment and therapeutic plans was not available. There was 
also a relatively large proportion of unknown characteristics (for instance cTNM status, 
tumour location and differentiation). This was because in the earlier periods clinical staging 
was not always available and a high proportion of patients did not undergo surgery. Finally, 
no adjustment was made for immortal time bias – the period during follow-up in which 
death cannot occur. For example, in the present study, patients who had been treated with 
chemotherapy and resection could not die within the first few weeks after diagnosis as 
otherwise they would not have been able to receive these treatments. However, taking into 
account immortal time bias would have implicated excluding patients who had died in the first 
months after diagnosis. This would have mainly resulted in the exclusion of patients treated 
with neither chemotherapy nor resection, because these patients generally have the worst 
prognosis. Finally this would have created skewness in the study population. 
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Abstract 
 
Background: 
Survival rates for gastric cancer patients remain dismal over the past decade. One of the 
important reasons for the generally poor prognosis of this disease is that a considerable 
amount (45 per cent) of patients is diagnosed with metastatic disease. General practice in 
the Netherlands for metastatic gastric cancer patients is palliative chemotherapy which 
may improve median survival of stage IV up to 11 months. The use of palliative surgery has 
significantly decreased throughout the years. Although it can be performed to improve Health 
Related Quality of Life (HRQL) and/or survival. Until today, no consistent data exist on the 
effect of palliative gastrectomy on survival duration and quality of life. We designed a single- 
arm phase 2 study to obtain high quality, prospectively collected data on overall survival and 
quality of life of a well-defined group of patients undergoing palliative chemotherapy and 
subsequent surgery. 
 
Methods: 
The COSTA-trail is designed as a Dutch national, multi-centre, single-arm phase 2 trial. 
Patients with histologically proven primary gastric adenocarcinoma with distant metastases 
are included. Patients need to be relatively fit (ECOG PS ≤ 2) and need to have an adequate 
organ function. 
Patients will receive peri-operative CAPOX (capecitabine and oxalipatin) or FOLFOX (folinic 
acid, fluorouracil and oxaliplatin) chemotherapy. If the tumour is HER2 positive, trastuzumab 
is added to the treatment regimen. Patients undergo partial or subtotal gastrectomy without 
aiming to resect (intra-abdominal) metastases. A macroscopic complete gastric resection will 
be performed and followed by a Roux-and-Y reconstruction. Primary endpoint of the study is 
overall survival, defined as the time from the start of chemotherapy to death from any cause. 
Secondary study endpoints are progression-free survival, health related quality of life and 
safety of both chemotherapy and surgery. Exploratory translational tissue- and blood-based 
analyses will also be performed. 
 
Discussion: 
We hypothesize that the COSTA-trial will show that palliative gastric cancer patients treated 
with surgery and chemotherapy do have a relatively good overall survival, with acceptable 
treatment related morbidity and improving health-related quality of life. 
Background 
 
Survival rates for gastric cancer patients remain dismal over the past decade. One of the 
important reasons for the generally poor prognosis of this disease is that a considerable 
amount (45 per cent) of patients is diagnosed with metastatic disease (stage IV). 1, 2 With less 
than 4 months median overall survival in stage IV gastric cancer in population based studies, 
the survival duration in these patients is among the poorest in gastro-intestinal oncology.3, 4 
General practice in the Netherlands for advanced gastric cancer patients is palliative 
chemotherapy aiming to prolong disease control.5 Palliative chemotherapy may improve 
median survival from 4.3 to 11 months.6 Several authors as well as the Dutch Clinical practice 
guideline have suggested that (additional) palliative gastrectomy may improve survival 
and quality of life.7-9 In clinical practice, however, surgery is most often only performed in 
case of resistant bleeding or obstruction, with palliative radiotherapy or bypass surgery as 
feasible alternatives.10 In fact, the use of palliative surgery has significantly decreased.5 In 
1989 over 25 per cent of all gastric cancer patients treated with palliative intent (N=3,518) 
received palliative surgery in the Netherlands, which decreased to less than 5 per cent in 
2013(N=2,709).5 
This phase 2 feasibility study is designed to investigate the role of surgical resection of 
the primary tumour in addition to conventional palliative chemotherapy in metastatic gastric 
cancer patients. 
 
Surgery in palliative patients 
Until today, no consistent data exist on the effect of palliative gastrectomy on survival duration 
and quality of life. Recently, increasing attention is being paid to surgery in metastatic 
cancer patients in order to improve survival.5, 11-16 Several small and retrospective studies 
have suggested an improved survival rate in those patients with metastatic gastric cancer 
having undergone palliative gastrectomy.7-9 Based on a retrospective analysis Hartgrink et. 
al. concluded that overall survival improved after a palliative gastrectomy (8.1 versus 5.4 
months; P< 0.001).7 Also Bonenkamp et. al. concluded after a retrospective analysis of data 
from a randomized controlled trial on lymphadenectomy in gastric cancer, that after palliative 
gastric resection median survival increased from 5.6 months to 8.3 months compared to 
nonresective treatment regimens (P= 0,002).9 
Recently, a randomized controlled trial was published, comparing palliative gastrectomy 
followed by chemotherapy with S-1 and cisplatinum to chemotherapy alone in patients with 
single-organ metastatic gastric cancer.17 This phase 3 REGATTA-trial was powered to include 
330 patients in order to show an increase in 2-year overall survival from 10 per cent to 30 
per cent. Unfortunately, this study was closed early due to futility; at interim-analysis the 
predicted probability of overall survival being significantly higher in the gastrectomy plus 
chemotherapy group than in the chemotherapy alone group was too low to continue the study 
protocol. Furthermore, in this study, due to slow accrual only 175 patients were enrolled. 
In the REGATTA-trial median overall survival was 16,6 months for patients assigned to the 
chemotherapy alone group and 14,3 months for those assigned to surgery and chemotherapy 
group (P=0,70). The incidence of chemotherapy-associated morbidity was higher in patients 
8 8 
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assigned to gastrectomy plus chemotherapy group. A major limitation of the REGATTA- 
trial was that no quality of life data were recorded, which in our opinion is essential in the 
evaluation of a palliative treatment. 
The AIO-FLOT3 trial, a German phase II study evaluated the efficacy of induction 
chemotherapy (FLOT: fluorouracil, leucovorin, oxaliplatin and docetaxel) followed by 
surgery for patients with limited metastatic gastric cancer (subtotal or total gastrectomy) or 
gastroesophageal junction cancer (transthoracic oesophagectomy with resection proximal 
cardia or transhiatal distal oesophagectomy with gastrectomy).18 Limited metastatic gastric 
cancer was defined as abdominal or retroperitoneal lymph node metastases only or 1 
incurable organ site metastasis. At least a macroscopic complete resection of the metastatic 
lesions was performed. In this study the surgery group showed a median overall survival of 
31.3 months versus 15.9 months in patients treated with chemotherapy only.18 An important 
remark should be made to the AIO-FLOT3 study design, i.e. the surgery group is a very 
heterogeneous group because the prognosis and surgical treatment of metastatic gastric 
cancer and gastro-oesophageal junction cancer knows substantial differences.19 Results of 
this trial are however promising. 
Our study group recently published a retrospective cohort study on 15.011 palliatively 
treated gastric cancer patients (UICC cT4 (b) and/or cM1 patients).5 In this study we showed 
that patients who underwent chemotherapy only had a significantly worse survival compared 
to patients treated with surgery only (HR 1.22, 95 per cent c.i. 1.12 to 1.33 P<0.01). Moreover, 
patients who underwent both resection and chemotherapy had the best survival (HR 0.76, 
95 per cent c.i. 0.65 to 0.87 P<0.01). Clearly, these data should be interpreted with caution 
given the numerous known and unknown confounders and selection bias which is inevitable 
in a retrospective study design. 
The abovementioned retrospective series and the lack of an adequately powered 
prospective trial urged us to design a single-arm phase II study to obtain prospectively 
collected solid data on overall survival, safety, feasibility and health related quality of life of 
a well-defined group of patients undergoing palliative chemotherapy and palliative gastric 
resection. 
 
Methods/Design 
 
Aim, design and endpoints 
The COSTA-trial is a prospective single arm phase II study. This design is chosen in order to 
evaluate the overall survival of a well-defined cohort of Dutch gastric cancer patients. Besides, 
we want to relate this to previously done population based and international data.17, 18, 20 This 
design was also chosen to evaluate the exact safety of surgery and chemotherapy in this group 
of palliative patients, prior to randomizing patients in a larger phase III trial. 
Primary objective will be to evaluate the overall survival of patients with synchronous 
metastatic gastric cancer, treated with palliative chemotherapy, followed by palliative 
partial or subtotal gastrectomy. Overall survival will be defined as the time from start of the 
chemotherapy to death from any cause. 
 
Secondary study objectives are progression-free survival, safety of chemotherapy and 
surgery and health-related quality of life. Progression-free survival is defined as time from 
start of the chemotherapy to disease progression or death from any cause. Safety of both 
chemotherapy and gastrectomy will be assessed according to the Common Terminology 
Criteria for Adverse Events (version 4.0).21 Health-related quality of life (HRQL) is defined 
as the individual’s perception of their position in life in the context of the culture and the 
value systems in which they live and in relation to their goals, expectations, standards and 
concerns.22 The HRQL will be measured in collaboration with the POCOP-initiative: the 
Prospective Observational Cohort Study of Oesophageal-gastric cancer Patients (POCOP).23 
The POCOP study is a prospective nationwide study of the Dutch Upper GI Cancer Group 
(DUCG) to investigate HRQL in oesophagogastric cancer patients of all stages. Among others 
POCOP registers patient reported quality of life outcome, by measuring cancer-specific HRQL 
(EORTC QLQ-C30)24 and the tumour-specific HRQL (EORTC QLQ-OG25).25 
In addition, exploratory tissue or blood-based, molecular analyses will be performed for 
identification of putative biomarkers that may or may not predict patient outcome in this 
setting. 
 
Study procedures and interventions 
Written informed consent to participate in the COSTA-study is obtained from those patients 
fulfilling the inclusion criteria after which patients are enrolled (Figure 1). All patients start 
with 3 cycles of chemotherapy (CAPOX) consisting of capecitabine 1000mg/m2 orally twice 
daily on day 1-14 and oxaliplatin 130mg/m2 administered intravenously on day 1 of a 21 
day cycle. Alternatively patients receive 4 cycles of chemotherapy (FOLFOX) consisting of 
folinic acid 400mg/m2, 5-fluorouracil 400mg/m2 and oxaliplatin 85mg/m2 all administered 
intravenously on day 1 of a 14 day cycle, , followed by 5-fluorouracil administered in a 22 
hours infusion. If the tumour is HER2 positive, trastuzumab is added to the treatment regimen 
(8mg/kg first cycle and thereafter 6 mg/kg per cycle given intravenously on day one of a cycle 
until progression). 
After 3 (CAPOX) or 4 (FOLFOX) cycles of chemotherapy, treatment response is evaluated 
on computed tomography and assessed according to RECIST version 1.1.26 If there is no 
evidence of progressive disease, patients will receive 1 additional cycle of CAPOX or 2 
additional cycles of FOLFOX. Patients will be directed to a participating hospital in which 
gastric cancer surgery is performed. All participating hospitals are ‘high volume hospitals’ 
performing at least 20 gastrectomies per year. Subsequently, patients undergo a diagnostic 
laparoscopy or laparotomy. In the absence of extensive peritoneal metastases, partial or 
subtotal gastrectomy will be performed. Except for perigastric lymph node metastases, other 
more distant metastatic lymph node lesions remain untouched. A macroscopically complete 
resection will be performed followed by a Roux-and-Y reconstruction. Resection of adjacent 
structures will be done when needed and deemed feasible by (local) gastric cancer surgeon, 
however no resection of additional (intra-abdominal) metastases will be performed. 
After surgery, patients will resume chemotherapy with CAPOX or FOLFOX at the last dose 
administered before surgery. After 6 cycles of CAPOX or FOLFOX in total, treatment with 
oxaliplatin is terminated. Systemic treatment with capecitabine or fluoruoracil is continued 
8 8 
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until disease progression or unacceptable toxicity. Response evaluation will be performed 
every 8 weeks (if FOLFOX is given) or 9 weeks (in case of CAPOX) using a CT scan and will 
be assessed according to RECIST version 1.1.26 Any post-progression treatment is allowed 
according to the physicians’ choice. 
After inclusion and staging, patients will be enrolled in the POCOP-study. The HRQL 
forms are to be filled in at baseline, after three months (prior to surgery), after surgery and 
subsequently every 3 months in the first year, every 6 months in the second year and then 
yearly until study withdrawal or death. For translational study purposes, 10 mL blood will 
be collected at multiple time points: at baseline, at time of restaging (in COSTA centres only), 
after three months (prior to surgery), after surgery, and at time of disease progression (in 
COSTA centres only). Complete trial protocol is shown in figure 1. 
 
Inclusion/exclusion 
Patients with a histologically proven primary gastric adenocarcinoma and synchronous distant 
metastases will be included after informed written consent, if they are suitable for partial or 
near total gastrectomy. Limited peritoneal carcinomatosis (peritoneal carcinomatosis index 
(PCI) ≤ 7) is allowed if patients are no candidate for the PERISCOPE II-trial.27 Patients need 
to be relatively fit (i.e. WHO-ECOG performance state ≤ 2) and they need to have an adequate 
organ function. Patients should have an adequate enteral (oral and/or tube) feeding. 
Patients will be excluded if they have other malignancies that interfere with the prognosis 
of the gastric tumour. Also patients that have a gastric tumour which is actively bleeding 
with hemodynamic consequences will be excluded (palliative radiotherapy pre-operatively 
is allowed). Any previous treatment for gastric cancer and/or gastrectomy is not allowed 
(except for submucosal excision or radiotherapy). Pregnant or breastfeeding patients will 
be excluded, as well as patients with unstable hypertension or evidence of coronary heart 
disease (not revascularized) within 12 months before enrolment. Any condition preventing 
the safety or feasibility of resection of the primary tumour or administration of chemotherapy 
will not be allowed, e.g. massive ascites, extensive peritonitis carcinomatosa, organ failure or 
active bacterial infection. Patients should also have a sufficient knowledge of Dutch language 
in order to conduct a questionnaire and written informed consent. 
 
Power calculation 
In order to be able to make an assumption of the overall survival difference in patients treated 
with chemotherapy only or chemotherapy combined with surgery, we analysed non-published 
data of the Netherlands Cancer Registry (NCR). The NCR is a nationwide population-based 
cancer registry, which includes all newly diagnosed cancer cases in the Netherlands. For power 
calculation purposes we selected patients with non-cardia gastric cancer who presented with 
synchronous metastasis and were treated with chemotherapy and/or surgery between 2008 
and 2015. This study showed that patients treated with surgery and chemotherapy had a 
median survival of 16.8 months. However, patients treated with chemotherapy only had a 
median overall survival of 7.7 months. 
Previous  literature  has  shown  that  12-18  per  cent  of  all  patients  show  peritoneal 
metastasis despite negative CT findings.28, 29 In the COSTA-trial, patients with a peritoneal 
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index higher than 7 will be excluded (figure 1), and we assume this will be approximately 15 
per cent of all COSTA-patients. Literature has also shown that up to 30 per cent of all patients 
have progressive disease under chemotherapy.30 
Based on the abovementioned analysis of data from the NCR, the COSTA-trial aims to show 
that the median survival will be significantly longer than 7.7 months (the median survival 
for this patient group given the present treatment regime, i.e. chemotherapy). We used a 
simulation study to obtain a sample size determination. We assumed a median overall survival 
of 16.8 months in the estimated 70-85 per cent of patients actually proceeding to surgery, and 
7.7 months in the remaining 15-30 per cent of patients for whom surgery is not feasible (e.g. 
due to disease progression or peritoneal metastases). The simulation showed that when we 
include 71 patients, there is an 80 per cent power to show that the median overall survival 
is longer than 7.7 months using a two sided test with an alpha of 0.05. 
Data of the NCR show that yearly 110 patients were diagnosed with the abovementioned 
selection criteria between 2008-2015. Assuming that approximately 15 per cent of all patients 
will participate in this study, there will be a 52 months accrual period. With 3-year follow-up, 
the total duration of this study will be approximately 7 years and 4 months. 
 
Liquid biopsies 
In addition to the COSTA-trial protocol, translational research will be performed. This 
exploratory study will evaluate whether circulating tumour DNA (ctDNA) analysis can be 
used for the identification of subgroups of patients within the COSTA study that benefit from 
resection of the primary tumour after induction chemotherapy. Although data are still limited, 
in metastatic gastrointestinal carcinomas circulating tumour DNA has been shown to be 
detectable in almost all cases.31 ctDNA analyses are regarded a valuable diagnostic and disease 
monitoring tool in cancer patients, and might help in clinical decision making. 
 
Statistical analysis 
For overall and disease-free survival, survival curves will be calculated by means of the 
Kaplan-Meier techniques. Complications of both chemotherapy and surgery will be registered 
as categorical variables. HRQL will be registered as a continuous or categorical variable, 
sum- and total scores of the questionnaires will be transformed to a standardized scale from 
0-100, as recommended by the EORTC.32 We identified the most important HRQL endpoints 
before study onset in a multidisciplinary team (medical and surgical oncologists). These 
HRQL endpoints will be EORTC QLQ-C30: Global Health Status/quality of life, physical and 
emotional functioning. EORTC QLQ-OG25: dysphagia and eating restrictions. Patients will 
be classified as improved or worsened if change from baseline will be 10 points or more (on 
the basis of a standardized 100 point scale). Changes of less than 10 points will be regarded 
as stable. Handling of missing data or questionnaires will be done according to the EORTC 
guidelines.32 Calculation will be performed in case half of the items from the scale have been 
answered. Variation in quality of life during complete treatment (i.e. chemotherapy and 
surgery) will be displayed with bar graphs. Mean change from baseline and time to definite 
deterioration of 10 per cent in Global Health Status, physical functioning, fatigue (QLQ-C30), 
eating restrictions and dysphagia (QLQ-OG25) will be calculated. 
Discussion 
 
In this study, we hypothesize that overall survival for patients with metastatic gastric cancer 
treated with resection of the primary tumour can be at least 16.8 months, as reported in our 
previous retrospective analysis, and in previous international literature.5, 7-9 We assume that 
palliative gastrectomy can be done to improve HRQL compared to pre-operative quality of 
life status8, 33-35 and that safety of gastrectomy and chemotherapy will be equal to previously 
performed studies in palliative gastric cancer patients. After gastrectomy we expect a 7-9 per 
cent risk of post-operative complications needing intervention and 6 per cent post-operative 
mortality.17, 18 
This study also evaluates the feasibility of a subsequent randomized controlled trial. 
Evaluating the overall survival of this well-defined group of palliative treated patients and 
relating it to previously collected retrospective data on patients treated with chemotherapy 
only gives an impression of the expected benefit of a palliative gastrectomy. Furthermore 
this trial will show how many and in which time frame patients can be included to fulfil the 
treatment protocol. This information combined will show the feasibility of a phase III trial. 
The abovementioned hypotheses on morbidity and mortality in the COSTA-trial are not 
in line with the recent REGATTA-trial, there are however some dissimilarities in study design 
and population that could explain these difference.  Possible explanations are the extent   
of surgery; 64 per cent of all REGATTA patients underwent total gastrectomy, which is not 
allowed in the COSTA study protocol. Recent literature showed an increased risk of post- 
operative morbidity and mortality after total gastrectomy compared to partial gastrectomy.36 
The REGATTA-trial also included over 70 per cent of patients with peritoneal metastases, 
which is a generally accepted complicating factor in gastrointestinal surgery.9, 37 Since the 
COSTA-trial only includes patients with limited peritoneal metastases, survival of surgical 
treated patients will be better compared to the REGATTA-trial. Also, the REGATTA-trial 
included Asian gastric cancer patients, with different patient and tumour characteristics 
compared to Caucasian patients.38-40 Due to all these reasons we expect the COSTA-trial to 
show that palliative gastric cancer patients treated with surgery and chemotherapy have a 
relatively good overall survival, with acceptable treatment related morbidity and improving 
health-related quality of life compared to the quality of life before treatment. 
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Summary 
 
The vast majority of studies in this thesis have been performed with data from nationwide 
registries (Netherlands Cancer Registry (NCR) and the Dutch Upper gastrointestinal Cancer 
Audit (DUCA)). Both nationwide registries contain an invaluable amount of information on 
tumour-, patient- and treatment specific items. Main difference between both registries is 
that the DUCA database contains information on all patients who are intentionally treated 
surgically, while the NCR database contains information on all newly diagnosed patients. 
In part I we focused on the centralization of gastric cancer surgery in the Netherlands. 
Centralization of gastric cancer surgery is believed to improve both short term and long term 
outcome. Performing more gastrectomies per year in a single centre should lead to better 
surgical training and more specialized oncological, peri-operative care. Centralization of 
gastric surgery has been introduced in the Netherlands in 2012, mandating a minimum of 
10 gastrectomies per hospital per year. In 2013 this minimum amount of gastrectomies was 
raised to 20 gastrectomies per hospital per year. The expected benefit of centralization of 
gastric cancer surgery was however, not yet proven beyond doubt. 
In Chapter 2 we evaluated the centralization of gastric cancer surgery on a regional 
level. We compared two cohorts of surgically treated gastric cancer patients without distant 
metastasis in the Eastern part of the Netherlands. The first group consisted of patients treated 
before centralization in one of the 6 participating hospitals. The second group were patients 
treated after centralization in only a single hospital. We found that more patients underwent 
adequate lymph node harvesting (21 per cent vs. 93 per cent P<0.01) and fewer patients had 
to suffer from cardiac complications (16 per cent vs. 7.5 per cent P<0.05). Also a successful 
introduction of laparoscopic gastrectomy was seen during the second time period (6 per 
cent vs. 40 per cent P<0.01). Multivariable analysis showed only a trend towards better 
survival after centralization, (HR 0.6 95 per cent c.i. 0.4-1.1; P=0.08) which might be due to 
the relatively small study population (N=250 patients). 
The difficulties with the small study population, urged us to perform a larger study on the 
effects of centralizing gastric cancer surgery. This nationwide study is described in Chapter 3. 
Again, two groups were selected consisting of patients before (2009-2011) and after (2013- 
2015) centralization and mortality and survival was compared. We found that significantly 
more patients underwent total gastrectomy and more often received peri-operative 
chemotherapy after centralization. Most importantly 90-day mortality after centralization 
decreased from 11 per cent towards 7 per cent (P<0.01). Moreover, patients more often 
underwent a complete resection (R0) (77 per cent vs. 81 per cent P<0.01). Multivariable 
analysis confirmed the improved survival after centralization (HR 0.88; 95 per cent c.i. 0.79- 
0.98). To exclude a possible effect of selective patient referral for surgery, we also evaluated 
survival for the complete group of gastric cancer patients, both surgically and non-surgically 
treated patients. 2-year overall survival curves showed an increase of 2-year overall survival 
from 27 per cent towards 30 per cent (P=0.01). Yet median survival for non-surgically treated 
patients did not increase significantly (17 vs. 18 weeks). We therefore concluded that the 
improved overall survival after centralization could not only be caused by selective patient 
referral. 
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In Part II the emphasis was put on prognostic factors and age-related differences in 
gastric cancer patients. In Chapter 4 we analysed postoperative complication and mortality 
differences between young (<70 years of age) and elderly (≥70 years of age) patients who 
underwent surgical treatment. We found that young patients more often had a poor tumour 
grade and a diffuse type of tumour which has a poorer prognosis compared to intestinal type 
of gastric cancer. Young patients more often underwent a total gastrectomy and more often 
received peri-operative chemotherapy (48 per cent vs. 18 per cent P<0.01). Elderly patients 
more often underwent an incomplete resection with an inadequate lymphadenectomy. 
Moreover, elderly patients had the highest rates of post-operative morbidity (41 per cent vs. 
33 per cent, P<0.01) and mortality (8.0 per cent vs. 3.2 per cent P<0.01). On the other hand, in 
multivariable analysis, we identified that not age but American Society of Anaesthesiologists 
score (ASA-score), having received neo-adjuvant chemotherapy and the type of resection 
(i.e. partial or total gastrectomy) were the best predictors for morbidity and mortality after 
gastric cancer surgery. 
The long term trends and survival in gastric cancer treatment and especially the differences 
between young and elderly patients were described in Chapter 5. This was the first study to 
describe a significantly improved overall survival for patients with potentially curable (cT1-3, 
cM0) non-cardia gastric cancer in the Netherlands. Median overall survival for young patients 
increased from 30.3 months between 1989-1993 towards 40.5 months between 2009-2013 
(P<0.01). For elderly patients median overall survival increased from 10.7 months to 13.1 
months (P<0.01). Because of the stronger improvement of overall survival in young patients, 
an increasing survival gap between young and elderly patients was observed. In terms of 
treatment outcome, we concluded that patients who underwent surgery and chemotherapy 
had the best five-year overall survival rates of 47 per cent and 39 per cent for young and 
elderly patients, respectively. An increasing number of young and elderly patients were treated 
with chemotherapy and surgery during the last 24 years, nonetheless there was a significant 
increase in elderly patients undergoing neither surgery nor chemotherapy between 1989 and 
2013 (35 per cent vs. 42 per cent P<0.01). In part, the dissimilarity in treatment between 
young and elderly patients could be the reason for the difference in overall survival. 
Gastric cancer staging is based on Tumour Node Metastasis (TNM)-staging of preferably 
15 or more lymph nodes harvested during surgery and pathology. Unfortunately, only 15 per 
cent of all patients who underwent surgery between 2000-2009 had more than 15 lymph 
nodes harvested. Harvesting insufficient lymph nodes can result in unreliable TNM-staging. 
Performing an adequate TNM-staging is relevant, not only because patient prognosis is 
based on this staging, but also because treatment is tailored according to TNM-stage. In 
Chapter 6, we proposed an alternative staging system called lymph node ratio (LNR), which 
could substitute the original N-stage which is the absolute number of positive lymph nodes. 
The lymph node ratio is the percentage of metastatic lymph nodes within the total amount 
of lymph nodes harvested. We showed that the LNR had the best homogenous spread of 
overall five-year survival rate and hazard ratios in multivariable analysis. In addition, the LNR 
correlated the least with the total amount of lymph nodes examined (correlation coefficient 
= 0.11; P<0.01) making it less vulnerable for stage migration. Furthermore, the LNR was able 
 
to identify certain subgroups within TNM N1 stage with a significant difference in 5-year 
overall survival. 
In the last part of this thesis, we studied patients who are beyond curative treatment 
options. In Part III we defined all patients with distant metastasis (stage IV disease) and/or 
a tumour infiltrating surrounding organs (pT4) as palliatively treated patients. In accordance 
with part II we also studied age related differences. In Chapter 7 we assessed trends in 
treatment and survival of palliatively treated gastric cancer patients between 1989-2013. We 
concluded that the proportion of patients undergoing palliative surgery decreased significantly 
in both younger and older patients. 24.5 per cent of all younger patients underwent palliative 
surgery between 1989-1993, this decreased to 3.0 per cent between 2009-2013 (P<0.01). 
For elderly patients this went from 26.2 per cent to 5.0 per cent (P<0.01). The proportion 
of patients treated with chemotherapy alone, increased from 15.0 per cent and 2.1 per cent 
towards 51.3 per cent and 20.8 per cent for respectively young and elderly patients. Patients 
who underwent palliative surgery had better 2-year overall survival than those who received 
chemotherapy alone (young: 21.6 per cent vs. 6.3 per cent P<0.01 elderly: 14.7 per cent vs. 
4.6 per cent P<0.01). In multivariable analysis, patients who underwent both surgery and 
chemotherapy had the most favourable survival (young: HR 0.76 95 per cent c.i. 1.12-1.33, 
elderly: 0.74 95 per cent c.i. 0.57-0.97). Moreover, a subgroup analysis in this study, in which 
multivariable Cox regression analysis was performed in younger patients who did not receive 
surgery, found no significant survival difference over the years. The same analysis in younger 
patients who underwent surgery showed a significant survival improvement in 2009-2013 
compared with 1989-1993 (HR 0.71 95 per cent c.i. 0.54-0.93). Despite the fact that the 
abovementioned favourable outcome for palliative surgery might be due to selection bias, 
the difference in survival between patients treated with chemotherapy alone and those who 
had surgery and chemotherapy is noteworthy. 
The significant survival difference between the two types of treatment for palliative gastric 
cancer patients, urged us to propose a trial to evaluate the survival of gastric surgery in palliative 
gastric cancer patients. The COSTA-trial (ChemOtherapy and Surgery in the Treatment of 
Advanced gastric cancer) is described in Chapter 8. In this trial relatively fit patients (i.e. 
ECOG ≤2, adequate organ function) will be included with synchronous metastasized gastric 
cancer and will be treated with peri-operative chemotherapy (Capecitabine and Oxaliplatin or 
Folinic Acid, Fluorouracil and Oxaliplatin) and resection of the primary tumour. In this single 
arm phase 2 trial we aim to evaluate overall and disease free survival, safety of chemotherapy 
and surgery and health related quality of life. The complete study protocol will be performed 
in order to obtain solid, prospectively collected data on overall survival of a well-defined 
group of patients undergoing palliative chemotherapy and palliative surgery. At the same 
time investigating the feasibility of a subsequent randomized phase 3 study. 
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Future Perspectives 
 
Centralisation                                                             of                                                              care 
Since it was shown in this thesis that centralizing gastric cancer surgery had a positive influence 
on post-operative mortality and survival, the question arises if further centralization is deemed 
necessary. Future studies should aim at identifying the optimal number of gastrectomies per 
year to keep post-operative morbidity and mortality as low as possible. Increasing the yearly 
volume would lead to a more experienced group of surgeons and could possibly result in a 
faster implementation of new techniques. Innovation of operation techniques could cause 
a further improvement in post-operative morbidity, mortality and health related quality of 
life. Furthermore, it is unclear if centralization should be defined as a surgeon volume or a 
hospital volume. Mamidanna et. al. tried to define the optimal surgeon volume and evaluated 
over 12,000 gastrectomies performed in England.1 The surgeon volume varied between 1 and 
14 gastrectomies per year. Unfortunately, the study could not identify the optimal surgeon 
volume because as long as surgeon volume increased, mortality rate continued to improve. 
Centralizing surgical gastric treatment resulted in a decreasing morbidity and mortality in 
the Netherlands.2, 3 This may also apply for chemotherapy treatment in gastric cancer. A study 
by Haj Mohammad et. al. showed no improved survival for metastatic gastric cancer patients 
treated chemotherapeutically in a high-volume centre (i.e. 6 chemotherapeutical treatments 
per year) compared to patients not treated in a high-volume centre.4 However, 6 could still be 
considered a fairly low number. Moreover, the impact of adjuvant chemotherapy treatment 
on morbidity and mortality in high-volume centres is unknown and should be studied.    
For other tumours, such as ovarian cancer studies suggest a positive relationship between 
the number of patients and overall survival after chemotherapy.5 Also in non-surgically 
(lymphoma, testicular cancer) treated cancers a positive effect has been demonstrated of 
patients numbers and treatment related and long-term mortality.6, 7 Taking this into account as 
well as the proven importance of centralization of gastric cancer surgery, it can be argued that 
centralization of peri-operative treatment could potentially further improve gastric cancer 
outcome and should be explored in future studies. 
 
Staging 
Only 15 per cent of all gastric cancer patients in the Netherlands underwent adequate 
lymphadenectomy between 2000-2009.8 Still up to one third of all surgically treated gastric 
cancer patients undergo insufficient lymph node harvesting in recent years (2011-2015).9 
Although lymph node harvesting has significantly improved during the past two decades, it 
can be advocated to also implement the lymph node ratio into the next TNM classification. 
By implementing the lymph node ratio, physicians could better predict long term survival, 
which would improve patient information. 
Other research opportunities can also be found in tests to ensure earlier diagnosis. Despite 
the fact that gastric cancer is a disease with low, and still declining, incidence rates, it is mostly 
diagnosed at an advanced stage of disease.10 Earlier detection of gastric cancer would therefore 
have an important impact on improving overall survival. However, endoscopic screening in our 
10 
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low-risk Dutch population is not cost effective.11 Various non-invasive screening approaches 
are being studied and might eventually result in a possible screening tool.11 
 
Neo-adjuvant and adjuvant treatment 
So far surgery is the only curative treatment option in gastric cancer patients, but the poor 
survival with surgery alone has led to a multimodal approach of gastric cancer.12 Nowadays, 
Dutch multimodal treatment consists of peri-operative epirubicin based chemotherapy which 
has shown to improve overall survival in the MAGIC-trial.13 Nevertheless, only 42 per cent of 
all patients within the MAGIC-trial were able to complete protocol treatment postoperatively. 
This dilemma is especially seen in elderly gastric cancer patients, who receive peri-operative 
chemotherapy in only 16-18 per cent and up to 60 per cent of all elderly patients receive no 
chemotherapy at all. This is probably due to the expected morbidity following surgery and/ 
or chemotherapy, but also due to the often limited functional reserve in elderly patients. 
Various international randomized trials are studying other possible (neo-) adjuvant treatment 
options.12 Recently the FLOT4-AIO trial was performed, in which peri-operative chemotherapy 
according to the MAGIC-trial was compared to peri-operative chemotherapy with docetaxel, 
oxaliplatin and fluoracil/leucovorin (FLOT). 14 Compared to epirubicin, cisplatin and fluoracil 
(ECF), FLOT improved median overall survival from 35 months to 50 months (p=0.012).14 
Whether this new chemotherapy regimen or others will be implemented in the Netherlands 
is to be decided. Also, the role of immunotherapy in gastric cancer treatment in daily clinical 
practice needs to be established. Immunotherapy induces potentially limited morbidity, but 
improved outcome for gastric cancer patients is yet to be demonstrated.15 
 
Elderly and palliative patients 
Various (inter)national trials are currently performed to further improve outcome in patient 
groups with a notoriously worse prognosis, such as elderly patients and patients with advanced 
stage disease. The proposed COSTA-trial, will evaluate the effect of resection of the primary 
tumour on survival in patients who present with incurable disease. The German FLOT5-trial 
(NCT02578368), is a phase 3 trial comparing chemotherapy alone with chemotherapy and 
surgical resection in patients with limited-metastatic adenocarcinoma of the stomach or 
oesophagogastric junction. In contrast to the COSTA-trial, the FLOT5 study will use peri- 
operative fluorouracil, leucovorin, oxaliplatin and docetaxel. 
Not only the effect of surgery of the primary in patients with advanced disease is            
a promising treatment option to further improve survival. Also, the effect of resection of 
metastases could potentially have an impact on survival. For instance, the LIME-study assesses 
the safety and feasibility of a multimodal treatment regimen with a curable intent for patients 
with synchronous hepatic metastases of oesophagogastric cancer. Also, the PERISCOPE-2 
(NCT03348150), treatment of PERItoneal dissemination in Stomach Cancer patients with 
cytOreductive surgery and hyperthermic intraPEritoneal chemotherapy (HIPEC), will evaluate 
the added value of HIPEC in peritoneal metastasized patients. PERISCOPE 2 is a multicentre 
randomized controlled two-armed phase 3 study. Presumably these and other studies will 
further increase the currently low number (3-5 per cent) of all patients receiving palliative 
surgery with a positive effect on overall survival. 
 
These studies on (neo)-adjuvant treatment will also potentially generate an optimal 
multimodal treatment option for elderly patients; one with high tolerability and improved 
overall survival compared to surgery alone. Unfortunately, since elderly patients are often 
not included in randomized trials, creating an optimal multimodal treatment regimen in 
elderly patients might be difficult.16 By including all patients in nationwide registration 
programs (POCOP) valuable information can be obtained especially in elderly patients. This 
is important since there is a growing prevalence of elderly patients with gastric cancer treated 
with neither surgery nor chemotherapy. In 2013, 42 per cent of elderly patients were not 
treated and it remains unclear whether this was due to good clinical judgment or because 
of the clinicians’ assumption that chronological age makes elderly patients unfit for therapy. 
Future research should therefore also aim at identifying reasons for not treating patients. 
Recently a project funded by the Dutch cancer society (KWF) was started to analyse which 
amendable factors (e.g. behavioural and organizational) affect variation in treatment with 
curative intent of patients with potentially curable oesophageal and gastric cancer. In this 
project both quantitative and qualitative methods will be used to analyse the factors related 
to treatment decisions. This should result in more insight into these factors for both patients 
and physicians, which would aid them in their treatment decision. 
In conclusion, in this thesis it has been shown that the lymph node ratio could be a valuable 
addition to the TNM-classification and that survival of palliatively treated gastric cancer 
did not improve during the last decades. This was despite a change in treatment regimen 
from surgical towards chemotherapeutical. However, survival of curatively treated patients 
significantly improved, whereas the survival difference between young and elderly patients 
is increasing. In terms of short term outcome, the best predictors of post-operative morbidity 
and mortality are: ASA-score, neo-adjuvant chemotherapy and type of resection. Importantly, 
recent centralization of gastric cancer surgery has been a successful improvement of Dutch 
gastric cancer treatment. Still improvement of overall survival in all gastric cancer patients 
is still necessary and including patients in future trials is of paramount importance. 
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Het overgrote deel van de studies in dit proefschrift is gedaan met gegevens uit landelijke 
databases (Nederlandse Kankerregistratie (NKR) en de Dutch Upper gastrointestinal Cancer 
Audit (DUCA)). Beide databases hebben een onschatbare hoeveelheid informatie over patiënten 
met maagkanker, de bijbehorende tumor eigenschappen en behandelkarakteristieken. Het 
grote verschil tussen beide databases is dat de DUCA database informatie bevat over alle 
patiënten die in opzet chirurgisch behandeld worden, terwijl de NKR informatie heeft over 
alle nieuwe en histologisch bewezen tumoren. 
In deel I van dit proefschrift richtten we ons op de centralisatie van de chirurgische 
zorg voor patiënten met maagkanker in  Nederland.  Men  neemt  aan  dat  centralisatie  
van maagkanker chirurgie de lange en korte termijn overleving gunstig beïnvloedt. Het 
uitvoeren van meer maagresecties per jaar in één ziekenhuis zou moeten leiden tot een 
betere chirurgische training en meer gespecialiseerde oncologische en peri-operatieve zorg. 
Sinds 2012 is de centralisatie van maagkanker chirurgie geëffectueerd en sindsdien moeten 
ziekenhuizen minimaal 10 maagresecties per jaar verrichten. In 2013 is dit aantal verhoogd 
naar 20 maagresecties per ziekenhuis per jaar. Het te verwachten voordeel van de centralisatie 
van maagkanker chirurgie is echter nooit onomstotelijk bewezen. 
In hoofdstuk 2 hebben we de bovengenoemde centralisatie van chirurgie op een 
regionaal niveau geëvalueerd. We hebben twee cohorten van chirurgisch behandelde en 
niet gemetastaseerde patiënten met maagkanker in de regio Oost-Nederland vergeleken. 
Het eerste cohort bestond uit patiënten die behandeld waren vóór de centralisatie van zorg 
in een van de 6 regionale ziekenhuizen. De tweede groep patiënten was behandeld na de 
centralisatie in het Rijnstate Ziekenhuis te Arnhem. Na analyse vonden we dat meer patiënten 
een adequate lymfeklier resectie ondergingen (21 procent vs. 93 procent P<0.01) en minder 
patiënten kregen cardiale complicaties post-operatief (16 procent vs. 7.5 procent P<0.05). 
Ook zagen we dat meer patiënten succesvol laparoscopisch werden behandeld (6 procent 
vs. 40 procent P<0.01). In de multivariabele analyse was er vóór patiënten die behandeld 
werden ná de centralisatie een trend naar een betere overleving zichtbaar. (HR 0.6, 95 procent 
betrouwbaarheidsinterval (bi.) 0.4 tot 1.1; P=0.08). Het feit dat dit slechts een trend is, zou 
kunnen komen door de relatief kleine studiepopulatie (N= 250 patiënten). 
Het bezwaar van de kleine studiepopulatie heeft er toe geleid om een grotere studie op te 
zetten naar het effect van centralisatie van maagkanker chirurgie in Nederland. Deze landelijke 
studie werd beschreven in hoofdstuk 3. Opnieuw hebben we twee groepen gemaakt, die 
bestonden uit chirurgisch behandelde patiënten met maagkanker voor (2009-2011) en na 
(2013-2015) de centralisatie van zorg. De behandeling, mortaliteit en overleving werden 
vergeleken, waarna we vonden dat na de centralisatie significant meer patiënten een totale 
maagresectie ondergingen en meer patiënten kregen peri-operatieve chemotherapie. De 
belangrijkste bevinding van deze studie was de daling in 90 dagen mortaliteit na centralisatie, 
van 11 procent naar 7 procent (P<0.01). Multivariabele analyse bevestigde de verbeterde 
overleving na centralisatie (HR 0.88; 95 procent bi. 0.79 tot 0.98). Om het mogelijke effect 
van positieve verwijzing uit te sluiten, hebben we ook de overleving van alle patiënten   
met maagkanker vergeleken; chirurgisch en niet-chirurgisch behandelde patiënten. Het is 
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immers voor te stellen dat na de centralisatie relatief fittere patiënten werden verwezen 
voor chirurgische behandeling, hetgeen de overleving gunstig beïnvloedt. Hoewel de 
tweejaarsoverleving in de totale groep van 27 procent naar 30 procent steeg, was de mediane 
overleving voor niet-chirurgisch behandelde patiënten niet significant toegenomen (17 vs. 
18 weken). Hierdoor hebben we geconcludeerd dat de verbeterde overleving niet alleen het 
resultaat kan zijn van selectieve patiënt verwijzingen. 
In deel 2 wordt de nadruk gelegd op prognostische factoren en leeftijdsgebonden 
verschillen. In hoofdstuk 4 analyseerden we verschillen in de behandeling, de post-operatieve 
complicaties en de mortaliteit tussen jonge (<70 jaar) en oudere (≥ 70 jaar) patiënten die 
een chirurgische behandeling voor maagkanker ondergingen. We vonden dat jonge patiënten 
vaker een slecht gedifferentieerd type tumor hebben. Tevens bleek dat jonge patiënten vaker 
een diffuus type tumor hebben, hetgeen een slechtere prognose kent dan het intestinale 
tumor type. Jonge patiënten ondergingen vaker een totale maagresectie en kregen vaker 
peri-operatieve chemotherapie (48 procent vs. 18 procent P<0.01). Daarentegen ondergingen 
oudere patiënten vaker een incomplete tumor resectie met een inadequate lymfeklier 
resectie. Oudere patiënten hadden ook vaker te kampen met post-operatieve complicaties 
(41 procent vs. 33 procent, P<0.01) en sterfte (8.0 procent vs. 3.2 procent P<0.01). Daar staat 
tegenover dat uit multivariabele analyse blijkt dat leeftijd an sich niet de beste voorspeller 
was voor morbiditeit en mortaliteit na maagkanker chirurgie. De beste voorspellers waren: 
American Society of Anesthesiologists score (ASA-score), het ondergaan van neo-adjuvante 
chemotherapie en het type resectie (partieel of totaal). 
De trends en lange termijn overleving na de behandeling voor maagkanker en met name 
de leeftijdsgebonden verschillen tussen jonge en oudere patiënten werd beschreven in 
hoofdstuk 5. Dit is de eerste gepubliceerde studie ooit die een significante toename liet zien 
in de overleving van patiënten met een in opzet curatieve vorm van non-cardia maagkanker 
(cT1-3, cM0) in Nederland. Mediane overleving van jonge patiënten nam toe van 30.3 
maanden tussen 1989-1993, naar 40.5 maanden tussen 2009-2013 (P<0.01). Voor oudere 
patiënten nam dit toe van 10.7 naar 13.1 maand (P<0.01). Door de sterkere toename van 
de overleving in de jongere patiënten populatie werd een toenemend verschil in overleving 
gezien tussen jonge en oude patiënten. Qua behandeling constateerden we dat patiënten die 
zowel chemotherapeutisch als chirurgisch werden behandeld, de beste vijfjaarsoverleving 
hadden; namelijk 47 procent en 39 procent voor respectievelijk jonge en oudere patiënten. 
Steeds meer patiënten worden behandeld met chemotherapie én chirurgie in de afgelopen 
24 jaar. Desalniettemin was er een significante toename van het aantal oudere patiënten 
dat geen chirurgie noch chemotherapie onderging tussen 1989 en 2013 (35 procent vs. 42 
procent P<0.01). Het verschil in de algehele overleving tussen jonge en oudere patiënten zal 
gedeeltelijk verklaard kunnen worden door het verschil in behandeling. 
De stadiëring van maagkanker gebeurt op basis van de Tumor Node Metastasis (TNM)- 
classificatie. Voor het verkrijgen van een betrouwbaar N-stadium moeten er minstens 15 
lymfeklieren worden verkregen middels chirurgische resectie en pathologisch onderzoek. 
Helaas werd slechts bij 15 procent van de patiënten tussen 2000-2009 voldoende lymfeklieren 
verkregen. Desalniettemin is het oogsten van voldoende lymfeklieren van groot belang voor 
het verkrijgen van een betrouwbaar TNM-stadium. Een betrouwbaar TNM-stadium is niet 
 
alleen relevant omdat de prognose van de patiënten hierop gebaseerd is, maar ook omdat 
een deel van de behandeling hierop wordt aangepast. In hoofdstuk 6 wordt een alternatief 
stagering systeem voorgesteld. Deze lymfeklierratio kan het huidige N-stadium, het absolute 
aantal positieve lymfeklieren, vervangen. De lymfeklierratio is het percentage positieve 
lymfklieren ten opzichte van het totaal aantal verkregen lymfeklieren. We hebben laten zien 
dat de lymfeklierenratio de meest homogene verdeling van vijfjaarsoverlevingscurven en 
hazard ratio’s in de multivariabele analyse heeft. Ook toonden we aan dat de lymfeklierenratio 
het minst correleerde met het totaal aantal verkregen lymfeklieren (correlatie coëfficiënt 
= 0.11; P<0.01), dit maakt de lymfeklierenratio minder gevoelig voor potentiele stadium 
migratie. Tot slot was de lymfeklierratio in staat om specifieke subgroepen te identificeren 
in de TNM N1 groep, die een significant betere vijfjaarsoverleving hebben. 
In het laatste deel van dit proefschrift hebben we ons gericht op patiënten die niet meer 
curatief te behandelen zijn. In deel 3 hebben we alle patiënten met afstandsmetastase 
(stadium IV) en/of een tumor die ingroeit in de aangrenzende organen (pT4) beschouwd 
als palliatieve patiënten. In overeenstemming met deel 2 hebben we ook leeftijdsgebonden 
verschillen onderzocht. In hoofdstuk 7 onderzochten we bij palliatieve patiënten de trends 
in overleving en behandeling van 1989 tot 2013. We concludeerden dat het aantal patiënten 
dat een palliatieve vorm van chirurgie onderging, significant gedaald is. Dit gold voor zowel 
jonge als oudere patiënten. 24.5 procent van alle jonge patiënten onderging een palliatieve 
vorm van chirurgie tussen 1989-1993. Dit percentage daalde naar maar liefst 3.0 procent 
tussen 2009-2013 (P<0.01). Bij oudere patiënten daalde dit van 26.2 procent naar 5.0 
procent (P<0.01). Het aantal patiënten dat alleen chemotherapie onderging, nam toe van 
15.0 procent en 2.1 procent naar 51.3 procent en 20.8 procent voor respectievelijk jonge 
en oudere patiënten. Palliatieve patiënten die een chirurgische behandeling ondergingen 
hadden een betere tweejaarsoverleving dan de patiënten die enkel met chemotherapie 
werden behandeld (jong: 21.6 procent vs. 6.3 procent P<0.01 oudere: 14.7 procent vs. 
4.6 procent P<0.01). In de multivariabele analyse zagen we dat patiënten die behandeld 
werden met zowel chemotherapie als chirurgie de beste overleving hadden (jong: HR 0.76 
95 procent bi. 1.12 tot 1.33, oudere: 0.74 95 procent bi. 0.57 tot 0.97). Verder hebben we een 
subgroep analyse verricht bij jongere patiënten. Uit deze multivariabele Cox regressie analyse 
kwam naar voren dat jonge patiënten die geen chirurgische behandeling ondergingen geen 
significante verbetering in de overleving hebben doorgemaakt. Eenzelfde analyse voor jonge 
patiënten die wel chirurgisch behandeld werden, liet wel een significante verbetering van de 
overleving zien tussen 1989 en 2013 (HR 0.71 95 procent bi. 0.54 tot 0.93). Aangezien dit een 
retrospectieve studie betreft kan de beschreven overlevingswinst worden veroorzaakt door 
selectie. Desalniettemin is het verschil in overleving na enkel chemotherapie in vergelijking 
met chirurgie en chemotherapie opvallend. 
Het significante verschil in overleving tussen beide vormen van behandeling voor 
palliatieve patiënten met maagkanker heeft ons ertoe gebracht een vervolg studie op te 
zetten. Deze studie evalueert de overleving van palliatieve maagkanker patiënten die zowel 
chirurgisch als chemotherapeutisch behandeld worden. De COSTA-trial (ChemOtherapy 
and additional Surgery in the Treatment of Advanced gastric cancer) werd beschreven in 
hoofdstuk 8. In deze studie worden relatief fitte patiënten geïncludeerd (ECOG ≤2, adequate 
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orgaanfunctie), die een synchroon gemetastaseerde vorm van maagkanker hebben. Zij worden 
behandeld met peri-operatieve chemotherapie (capecitabine en oxaliplatin of folinezuur, 
fluorouracil en oxaliplatin) en een partiële of sub-totale maagresectie. Het doel van deze single 
arm fase 2 studie is om de algehele en ziektevrije overleving, de veiligheid van behandeling en 
de kwaliteit van leven te analyseren. Het volledige studieprotocol moet ertoe leiden dat er van 
een vooraf goed omschreven groep patiënten prospectieve data wordt verzameld aangaande 
de overleving na een behandeling met chemotherapie en chirurgie en tegelijkertijd wordt de 
haalbaarheid van een fase 3 studie geëvalueerd. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Chapter 12 
Curriculum Vitae 
 Curriculum Vitae |169 
 
Curriculum Vitae 
 
Stijn Nelen was born on the 16th of June 1986 in 
Nijmegen. He grew up in  Drunen  in  the  southern  
part of the Netherlands. After graduating from high 
school in ‘s-Hertogenbosch, he started medical school 
in 2005 at the Radboud University Nijmegen, where   
he graduated in 2012. While studying medicine he 
worked as a teaching-assistant training fellow students 
on acute care principles, and was a member of the 
fraternity, “Kroegdispuut de Tempeliers.” He completed 
an important part of his clinical rotations at the Jeroen 
Bosch Hospital in ‘s-Hertogenbosch. With the help of dr. 
K. Bosscha he went to the Memorial Sloan Kettering Cancer Center in New York which resulted 
in his interest in gastric cancer surgery and in the present doctoral thesis. 
 
After finishing medical school he worked for a year as a resident (not in training) at the 
Canisius-Wilhelmina Hospital in Nijmegen. In 2013 he started his surgical training at St. 
Elisabeth Hospital, Tilburg (dr. P.W.H.E. Vriens and dr. J.Heisterkamp). In 2014 his training 
continued at the Radboud University Medical Center (dr. B. Verhoeven and Prof. dr. C.J.H.M. 
van Laarhoven). In 2016 he returned to Tilburg (Elisabeth Tweesteden Hospital) under the 
supervision of dr. P.W.H.E. Vriens and dr. M.S. Ibelings. At present, he is continuing his training 
to become a trauma surgeon (drs. M. Bemelman). He is also a board member of the Dutch 
Society of Surgical Residents (VAGH). 
 
Stijn Nelen lives together with Laura Korsten, their daughter Diede, and son Pepijn. 
12 
 Chapter 13 
Acknowledgements 
Acknowledgements |173 
 
 
 
 
Acknowledgements 
 
Met het schrijven van dit hoofdstuk komt er een einde aan enkele bewogen chirurgisch 
wetenschappelijke jaren. Van statussen doorpluizen in een kamertje achteraf, naar een 
opleidingsplek heelkunde en uiteindelijk de vormgeving van mijn proefschrift. Allemaal zaken 
die zo nu en dan erg zwaar op de maag kunnen liggen en ik zeker niet had kunnen bereiken 
zonder de hulp van velen. Tijd om die mensen te bedanken in misschien wel het meest (of 
enige) gelezen hoofdstuk van dit boekwerk. 
 
Prof. dr. De Wilt, beste Hans, dank dat je me aan de hand nam en mij wees op de mogelijkheden. 
Complimenten voor de manier waarop je onuitputbaar alle stukken van kritiek voorzag, hoe 
je de stukken naar een hoger niveau tilde en hoe je mij de drive gaf om telkens weer verder 
te gaan. Ik heb diep respect voor de manier waarop je alle ballen in de lucht weet te houden. 
Je hebt beloofd mij ‘af te maken’ en het is je gelukt! 
Jammer dat ik op de piste niet net zo veel van je kon leren als in de kliniek. Het is daarom 
maar goed dat Prof. Van Goor (Fügen, 2015) als onafhankelijk expert voor eens en voor altijd 
de boeken heeft gesloten aangaande dit onderwerp… 
 
Prof. dr. Lemmens, beste Valery, betrokken vanaf het allereerste moment en mede dankzij 
jou ben ik op wetenschappelijk vlak nooit iets tekort gekomen. Goede onderzoeksvragen, de 
juiste ondersteuning en in record tijd stukken reviseren waarbij je de vinger vaak precies op 
de zere plek wist te leggen. 
 
Dr. Bosscha, beste Koop, dank voor het vertrouwen dat je vanaf het begin in mij hebt gesteld. 
Door jou heb ik aardig wat plekken op de aarde gezien en zonder jou was dit alles nooit van 
de grond gekomen. Waar er geen co-schap voor mij beschikbaar was heb je het gemaakt, toen 
ik naar het buitenland wilde regelde je New York en als ik te veel mailde met vragen werd er 
steevast gedineerd. Hoe ik van co-assistentje in het Groot Ziekengasthuis nu met je aan tafel 
mag zitten voor de Nederlandse Vereniging van Heelkunde is voor mij erg bijzonder. Stuk voor 
stuk ontwikkelingen waar jij een belangrijke rol in hebt gespeeld. Dank daarvoor. 
 
Dr. Verhoeven, beste Rob, daar waar de digitale media te kort schoten heb jij mij op de 
vrijdagen de nodige epidemiologische kennis bijgebracht. Het is grappig om te ervaren 
hoeveel ik in de afgelopen jaren van je heb mogen leren; hoe ik van zwijgzaam in het hoekje 
ineens mee kon praten over epidemiologische gespreksonderwerpen. Mooi om te zien hoe we 
op veel vlakken op een lijn zaten, minder mooi waren de 4 uur Rob-o-Soup momenten. Hoe je 
met één enkele vraag een dag lang noeste arbeid als sneeuw voor de zon kon laten verdwijnen. 
Al met al jammer dat die vrijdagen erop zitten Rob, ik heb het goed naar mijn zin gehad daar. 
Of zoals je zelf in Krakau wist te zeggen: “niet gek hè, voor een stelletje epidemiologen.” 
 
Geachte leden van de manuscriptcommissie en leden van de promotiecommissie, veel 
dank voor de beoordeling van mijn manuscript en de bereidheid om zitting te nemen in de 
corona. Ik kijk uit naar de vruchtbare discussies tijdens de verdediging. 13 
174| Chapter 13 Acknowledgements |175 
 
 
 
 
Mede auteurs, hartelijk dank voor jullie waardevolle bijdrage aan de verschillende 
hoofdstukken in dit boek. In het bijzonder wil ik een aantal mensen bedanken voor hun 
inbreng. Lianne Heuthorst, je speelde een belangrijke rol in meerdere hoofdstukken en ik 
heb je ervaren als een buitengewoon nauwkeurige, hardwerkende en enthousiaste collega 
onderzoekster. Ik hoop van harte dat het lukt om ‘onze’ COSTA-studie van de grond te krijgen. 
Ik wens je heel veel succes met je verdere (chirurgische) toekomst. Maak je vooral niet ál te 
druk dan komt het echt allemaal goed! Margreet van Putten, ook al weet ik waarschijnlijk 
voor de rest van mijn leven niet meer of het multivariable of multivariabel is, jouw rustige 
en herhaaldelijke uitleg over epidemiologische vraagstukken heeft altijd zeer verhelderend 
voor mij gewerkt. Het was goed om met jou samen te mogen werken en mooi om te zien hoe 
je onze hoofdstukken met verve hebt verdedigd in Rotterdam. 
 
De Dutch Upper-GI Cancer Group en in het bijzonder alle leden van de COSTA-studiegroep. 
Ik ben erg trots op wat we tot nu toe hebben gerealiseerd voor de COSTA-studie. Ik hoop van 
harte dat de studie dat krijgt wat het nodig heeft om het tot een nationaal succes te maken. 
 
Alle medewerkers van het Integraal Kankercentrum Nederland en de Dutch Upper-GI 
Cancer Audit. Jullie werk is cruciaal geweest voor het onderzoek dat beschreven wordt in 
mijn proefschrift. 
 
(Oud-)collega’s in het Canisius Wilhelmina Ziekenhuis, Radboudumc en Elisabeth- 
Tweesteden ziekenhuis, dank voor alle belangstelling, collegialiteit en samenwerking. 
Mijn huidige collega’s in het ETZ wil ik met name ook danken voor jullie oplettendheid; de 
assistentenkamer voelt nog altijd als een baken van rust voor mijn USB-stick. Bijzonder veel 
waardering gaat ook uit naar dr. Boll. Beste Bart, de heelkunde begon voor mij toch echt bij jou. 
Mijn carotis-onderzoek heeft helaas niet heel veel indruk gemaakt op de wetenschappelijke 
wereld. Jou een heupfractuur zien opereren heeft daarentegen wel veel indruk gemaakt op 
mij als middelbaar scholier. Dank voor al je hulp en dat je me enthousiast hebt gemaakt voor 
dit prachtige vak. 
 
Hans van de Noort, het was altijd prettig om de vrijdag op jouw kamer te beginnen met een 
kop koffie. Even de nodige en onnodige zaken doornemen en het weekend alvast een beetje 
inluiden. De academie kan soms een doolhof zijn, maar met jou erbij is het een eitje! 
 
Ook wil ik graag de stille krachten achter mijn proefschrift danken voor hun inzet en 
toewijding. Zonder de barista’s van de koffiecorner in het Radboudumc, Youtube.com en de 
playlist ‘rustige pianomuziek’ op Spotify was het schrijven van dit boekje onbegonnen werk 
geweest. 
 
Dr. Vriens, beste Patrick, ik voel me bevoorrecht om tot Tilburgs chirurg opgeleid te worden. 
Hiervoor wil ik jou als opleider in het bijzonder, maar ook alle andere chirurgen in de vakgroep 
heel hartelijk danken. De rozenkrans heeft me al veel gebracht in de afgelopen jaren. 
 
Drs. Bemelman, beste Mike, ik ben nog meer vereerd nu ik tot Tilburgs traumachirurg word 
opgeleid in een van Nederlands grootste traumacentra. Met veel plezier ga ik dagelijks naar 
mijn werk en opleiding en dat is mede dankzij jou en de rest van de traumachirurgen (Lansink, 
Van Egmond, Van der Heijden, Van der Niet, Van Zutphen, Theeuwes, Kleinveld, Van Stigt en 
Ten Brinke). 
 
Rob, Roy en Max, wat is het prettig om te ervaren dat sommige dingen door de jaren heen 
veranderen; van streethockey in de Mozartlaan en dansen om een metershoge papier-maché 
pot, naar oe-de-loe-de-lé op een zeilboot en uiteindelijk praten op niveau in de duikboot. Maar 
nog prettiger is het om te zien dat heel veel zaken gewoon hetzelfde blijven en ik vandaag 
met jullie deze dag mag vieren. 
 
Eibert, Jan, Bob, samen met Jan en Tom een mooie club vrienden vanuit de studententijd. 
Inmiddels is de onwelriekende Swinkelder vervangen voor een hoop burgerlijke 
aangelegenheden, maar de gedeelde liefde voor slap geouwehoer en een drankje op zijn tijd 
is gebleven. Laat het afronden van dit hoofdstuk het begin zijn van een hoofdstuk met meer 
van die momenten. 
 
Wat fantastisch is het om Jan en Tom vandaag als paranimfen aan mijn zijde te hebben. 
Inmiddels heel wat jaartjes lief en leed gedeeld en dat maakt een dag als vandaag extra 
bijzonder. Tom, als 9 november 2018 maar een heel klein beetje lijkt op 17 juni 2016 ben ik 
een meer dan gelukkig man. Onwijs knap hoe je dat allemaal hebt weten klaar te spelen. Jan, 
bijzonder is het om te zien hoe je met zoveel toewijding onderzoek kan doen. Ik weet niet 
hoeveel hoofdstukken je nu uiteindelijk in je boekwerk gaat stoppen, maar ik kijk uit naar 
jouw spektakelstuk. In ogenschouw genomen dat je de ballen hebt gehad om het roer volledig 
om te gooien, maakt die prestatie extra uitzonderlijk en knap. 
 
Jakelijn, Jak, zoals je zelf graag tegen mij zegt: “vrienden heb je voor het uitkiezen, familie 
helaas niet.” Alle gekheid op een stokje: ik vind het ontzettend mooi dat je vandaag samen 
met Arief vooraan zit om deze dag met me mee te maken. Met alle drukke agenda’s schiet het 
er nog wel eens bij in, nu dit boekje af is scheelt dat weer een excuus! En laat me raden: nu 
heb ik zeker naast mijn opleiding ook mijn proefschrift aan jou te danken? Onze familiaire 
voorkeur voor de licht cynische humor wordt slechts door enkelen gewaardeerd, goed dat 
we er in ieder geval samen om kunnen lachen en dat dat maar voor altijd zo mag blijven! 
 
Lieve Pap en Mam, jullie vormden de basis waarvandaan ik dit boekje heb geschreven. Zonder 
een beetje doorzettingsvermogen en de ‘niet zeuren, maar poetsen’-mentaliteit was mijn 
proefschrift er nooit gekomen. Ik zeg het waarschijnlijk te weinig, maar ik ben jullie intens 
dankbaar voor alle interesse en ondersteuning door de jaren heen. Onvoorwaardelijke steun 
was er voor de goede, maar zeker ook de slechte ideeën in mijn leven en dat is fantastisch. 
Had ik nu maar beter opgelet bij het denkt aleer gij doende zijt, dat had in retrospect wat 
slechte ideeën gescheeld. 
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Lieve Diede en Pepijn, als je na een dag wetenschappelijke inspanningen te horen krijgt dat 
het allemaal nét even anders moet is er niks lekkerder dan samen met jullie achtjes te rennen 
door de woonkamer, schreeuwend blokjes te smijten of bellen blazend naar het plafond te 
staren. Dank dat jullie dan in staat waren een lach op mijn gezicht te toveren. 
 
Lieve Laura, Lau het zit erop! Wat een opluchting, want ik weet dat ik niet de enige was 
die dit proefschrift de afgelopen jaren zo nu en dan eens heeft vervloekt. Gek genoeg heb je 
mij er altijd in gesteund en me de ruimte geboden om dit boekje te kunnen realiseren. Het 
is een cliché, maar zonder jou was me dit nooit gelukt: je nuchtere relativeringsvermogen, 
opbeurende woorden en adviezen hebben immens veel voor mij betekend. Excuus voor de 
ontelbare keren dat jij mij voorzag van dat advies, ik alles weer eens beter wist, maar jij tóch 
gewoon gelijk had. Samen met jou zit het leven vol met hoogtepunten, hoogtepunten waarin 
ik la reyna en el mafioso zeker niet onbenoemd wil laten. Hoogtepunten met zo nu en dan een 
verwaarloosbaar dieptepuntje; ik hoop dat dit boekwerk iets herstelt van het vertrouwen in 
mijn medische vakbekwaamheid na Marokko-gate. Lau, we hebben het onwijs goed samen 
en ik prijs me gelukkig met iemand naast me die mij af en toe weer even uitlegt wat écht 
belangrijk is in het leven. 
 
Mijzelf kennende vergeet ik ongetwijfeld nog mensen, weet dat ik jullie diep van binnen extra 
dankbaar ben voor alles. 
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 Year(s) ECTS 
TRAINING ACTIVITIES   
a) Courses & Workshops 
University of Tilburg, Brabant Medical School. Statistiek I 
University of Tilburg, Brabant Medical School. Statistiek II 
University of Tilburg, Brabant Medical School. Statistiek III 
 
2010 
2010 
2010 
 
0.5 
0.5 
0.5 
b) Seminars & lectures 
Participation in Dutch UpperGI Cancer Group meetings 
 
2017-2018 
 
0.5 
c) Symposia & congresses 
Poster presentation United European Gastroenterology Week, 
Amsterdam 
Chirurgendagen, Veldhoven 
Oral Presentation, European Society of Surgical Oncology, Krakow 
Oral Presentation, European Society of Surgical Oncology, Krakow 
Poster Presentation, Society of Surgical Oncology, Chicago 
 
 
2012 
2013-2018 
2017 
2017 
2018 
 
 
0.5 
1.5 
0.75 
0.75 
0.25 
d) Other 
Reviewing scientific publication 
 
2018 
 
0.2 
TEACHING ACTIVITIES   
e) Supervision of internships / other 
Student internship coaching 
 
2016-2017 
 
1 
TOTAL  6.95 
 
A 
Name PhD student: 
Department: 
Graduate School: 
S.D. Nelen 
Surgical Oncology 
Radboud Institute for 
Health Sciences 
PhD period: 
Promotor(s): 
 
Co-promotor(s): 
01-11-2012 –09-11-2018 
Prof. dr. J.H.W. de Wilt, 
Prof. dr. V.E.P.P. Lemmens 
dr. K.Bosscha, 
dr. R.H.A. Verhoeven 
 
